US20220023198A1 - Oral soluble film containing sildenafil citrate - Google Patents
Oral soluble film containing sildenafil citrate Download PDFInfo
- Publication number
- US20220023198A1 US20220023198A1 US17/488,610 US202117488610A US2022023198A1 US 20220023198 A1 US20220023198 A1 US 20220023198A1 US 202117488610 A US202117488610 A US 202117488610A US 2022023198 A1 US2022023198 A1 US 2022023198A1
- Authority
- US
- United States
- Prior art keywords
- soluble film
- specific embodiments
- oral soluble
- oral
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 229960002639 sildenafil citrate Drugs 0.000 title claims abstract description 168
- 239000011230 binding agent Substances 0.000 claims abstract description 101
- 239000000796 flavoring agent Substances 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 85
- 239000003765 sweetening agent Substances 0.000 claims abstract description 83
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 82
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 74
- 239000004014 plasticizer Substances 0.000 claims abstract description 64
- 239000000945 filler Substances 0.000 claims abstract description 62
- 239000003086 colorant Substances 0.000 claims abstract description 54
- 239000002904 solvent Substances 0.000 claims abstract description 50
- 239000003755 preservative agent Substances 0.000 claims abstract description 47
- 230000002335 preservative effect Effects 0.000 claims abstract description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 143
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 113
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 100
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 99
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 99
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 98
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 74
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 74
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 74
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 74
- 229920001223 polyethylene glycol Polymers 0.000 claims description 71
- 239000002202 Polyethylene glycol Substances 0.000 claims description 70
- 235000011187 glycerol Nutrition 0.000 claims description 69
- 244000246386 Mentha pulegium Species 0.000 claims description 66
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 66
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 66
- 235000001050 hortel pimenta Nutrition 0.000 claims description 66
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 63
- 229960003310 sildenafil Drugs 0.000 claims description 54
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 50
- 239000004376 Sucralose Substances 0.000 claims description 49
- 235000019408 sucralose Nutrition 0.000 claims description 49
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 45
- 239000000619 acesulfame-K Substances 0.000 claims description 45
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 44
- 229960004998 acesulfame potassium Drugs 0.000 claims description 44
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 44
- 235000010234 sodium benzoate Nutrition 0.000 claims description 42
- 239000004299 sodium benzoate Substances 0.000 claims description 42
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 40
- 230000006870 function Effects 0.000 claims description 40
- 201000001881 impotence Diseases 0.000 claims description 38
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 229920000578 graft copolymer Polymers 0.000 claims description 27
- 239000000377 silicon dioxide Substances 0.000 claims description 27
- 235000012239 silicon dioxide Nutrition 0.000 claims description 24
- 238000004090 dissolution Methods 0.000 claims description 19
- 239000006068 taste-masking agent Substances 0.000 claims description 19
- 239000012458 free base Substances 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 230000001568 sexual effect Effects 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 10
- 239000003906 humectant Substances 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- 238000005070 sampling Methods 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 5
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 55
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 46
- 238000004519 manufacturing process Methods 0.000 abstract description 28
- 239000010408 film Substances 0.000 description 1187
- 239000002002 slurry Substances 0.000 description 306
- 239000000126 substance Substances 0.000 description 106
- 239000003814 drug Substances 0.000 description 79
- 229940079593 drug Drugs 0.000 description 77
- 229960005150 glycerol Drugs 0.000 description 67
- 239000008186 active pharmaceutical agent Substances 0.000 description 61
- 239000012602 primary packaging material Substances 0.000 description 52
- -1 Viagra®) Chemical compound 0.000 description 44
- 239000000825 pharmaceutical preparation Substances 0.000 description 40
- 239000002245 particle Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 239000002552 dosage form Substances 0.000 description 30
- 238000001035 drying Methods 0.000 description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 238000009826 distribution Methods 0.000 description 21
- 229940126534 drug product Drugs 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 235000019634 flavors Nutrition 0.000 description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 229940088679 drug related substance Drugs 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000007935 oral tablet Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 11
- 239000001913 cellulose Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000008184 oral solid dosage form Substances 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 10
- 229920001983 poloxamer Polymers 0.000 description 10
- 210000003296 saliva Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 229940094720 viagra Drugs 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 239000006172 buffering agent Substances 0.000 description 8
- 239000004359 castor oil Substances 0.000 description 8
- 235000019438 castor oil Nutrition 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 239000003002 pH adjusting agent Substances 0.000 description 8
- 239000007967 peppermint flavor Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 235000010447 xylitol Nutrition 0.000 description 8
- 239000000811 xylitol Substances 0.000 description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 8
- 229960002675 xylitol Drugs 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 239000002269 analeptic agent Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- 229960003943 hypromellose Drugs 0.000 description 7
- 239000005414 inactive ingredient Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000011140 metalized polyester Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 235000014749 Mentha crispa Nutrition 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 235000009499 Vanilla fragrans Nutrition 0.000 description 6
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000005266 casting Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 235000019325 ethyl cellulose Nutrition 0.000 description 6
- 229920001249 ethyl cellulose Polymers 0.000 description 6
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 229960002900 methylcellulose Drugs 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 229940096978 oral tablet Drugs 0.000 description 6
- 235000019477 peppermint oil Nutrition 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 229920001100 Polydextrose Polymers 0.000 description 5
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000007961 artificial flavoring substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000012745 brilliant blue FCF Nutrition 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 5
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000010579 first pass effect Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000012633 leachable Substances 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 235000013856 polydextrose Nutrition 0.000 description 5
- 239000001259 polydextrose Substances 0.000 description 5
- 229940035035 polydextrose Drugs 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920002907 Guar gum Polymers 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 244000078639 Mentha spicata Species 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000004161 brilliant blue FCF Substances 0.000 description 4
- 229940002226 buccal film Drugs 0.000 description 4
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 4
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000007908 nanoemulsion Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 229940067631 phospholipid Drugs 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 229920000148 Polycarbophil calcium Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 244000290333 Vanilla fragrans Species 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 229960005164 acesulfame Drugs 0.000 description 3
- 229940081735 acetylcellulose Drugs 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 229960004667 ethyl cellulose Drugs 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 235000010439 isomalt Nutrition 0.000 description 3
- 239000000905 isomalt Substances 0.000 description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229940099690 malic acid Drugs 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 239000007960 nature-identical flavoring substance Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007415 particle size distribution analysis Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 229950005134 polycarbophil Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229960002668 sodium chloride Drugs 0.000 description 3
- 235000011088 sodium lactate Nutrition 0.000 description 3
- 239000001540 sodium lactate Substances 0.000 description 3
- 229940005581 sodium lactate Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 229940074410 trehalose Drugs 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 2
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 239000004716 Ethylene/acrylic acid copolymer Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000014435 Mentha Nutrition 0.000 description 2
- 241001072983 Mentha Species 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000012629 Mentha aquatica Nutrition 0.000 description 2
- 244000173610 Mentha aquatica Species 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000019886 MethocelTM Nutrition 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 241001409321 Siraitia grosvenorii Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229920005605 branched copolymer Polymers 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229960001777 castor oil Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229920000554 ionomer Polymers 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920000092 linear low density polyethylene Polymers 0.000 description 2
- 239000004707 linear low-density polyethylene Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930007503 menthone Natural products 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229960005250 naloxone hydrochloride Drugs 0.000 description 2
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 2
- 239000007959 natural flavoring substance Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940098695 palmitic acid Drugs 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- YGWKXXYGDYYFJU-SSDOTTSWSA-N (+)-menthofuran Chemical compound C1[C@H](C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-SSDOTTSWSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- YTKBWWKAVMSYHE-OALUTQOASA-N (3s)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NCCCC=1C=C(O)C(OC)=CC=1)C1=CC=CC=C1 YTKBWWKAVMSYHE-OALUTQOASA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- 239000001745 (6R)-3,6-dimethyl-4,5,6,7-tetrahydro-1-benzofuran Substances 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WIBJWDHQQRFQQO-KVVVOXFISA-N (z)-octadec-9-enoic acid;octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O WIBJWDHQQRFQQO-KVVVOXFISA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004394 Advantame Substances 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019492 Cashew oil Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- FKJNCBGJYUAKQQ-MBVMSADQSA-N Eriocarpin Chemical compound C1([C@@H]2[C@@]3(C)C(=O)[C@@H](O)[C@H]4[C@@]5([C@]3(CC2)O)O[C@H]5C[C@@H]2[C@]4(C)C[C@H]3O[C@@]4(O)[C@H](O)C[C@H](O[C@H]4O[C@@H]3C2)C)=CC(=O)OC1 FKJNCBGJYUAKQQ-MBVMSADQSA-N 0.000 description 1
- 229930183282 Eriocarpin Natural products 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000004049 Mentha X gracilis Nutrition 0.000 description 1
- 244000155567 Mentha x cardiaca Species 0.000 description 1
- YGWKXXYGDYYFJU-UHFFFAOYSA-N Menthofuran Natural products C1C(C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 235000019494 Mongongo nut oil Nutrition 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 108010093901 N-(N-(3-(3-hydroxy-4-methoxyphenyl) propyl)-alpha-aspartyl)-L-phenylalanine 1-methyl ester Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019495 Pecan oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 235000019496 Pine nut oil Nutrition 0.000 description 1
- 235000019497 Pistachio oil Nutrition 0.000 description 1
- 241000223503 Platysma Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920003078 Povidone K 12 Polymers 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 240000003935 Sclerocarya birrea Species 0.000 description 1
- 235000001836 Sclerocarya caffra Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000019453 advantame Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940075534 amino methacrylate copolymer Drugs 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019632 basic taste sensations Nutrition 0.000 description 1
- 229940096447 belbuca Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000011213 bioburden testing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000038 blue colorant Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- HRBZRZSCMANEHQ-UHFFFAOYSA-L calcium;hexadecanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O HRBZRZSCMANEHQ-UHFFFAOYSA-L 0.000 description 1
- 235000021093 calorie-free sugar substitutes Nutrition 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 239000010467 cashew oil Substances 0.000 description 1
- 229940059459 cashew oil Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- VJTAZCKMHINUKO-UHFFFAOYSA-M chloro(2-methoxyethyl)mercury Chemical compound [Cl-].COCC[Hg+] VJTAZCKMHINUKO-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FKJNCBGJYUAKQQ-UHFFFAOYSA-N desglucosyrioside Natural products C1C2OC3OC(C)CC(O)C3(O)OC2CC2(C)C1CC1OC1(C1(CC3)O)C2C(O)C(=O)C1(C)C3C1=CC(=O)OC1 FKJNCBGJYUAKQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000013016 formulated drug substance Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940031726 laureth-10 Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940017144 n-butyl lactate Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229940127242 parasympathomimetic drug Drugs 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010470 pecan oil Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 239000010490 pine nut oil Substances 0.000 description 1
- 239000010471 pistachio oil Substances 0.000 description 1
- 229940082415 pistachio oil Drugs 0.000 description 1
- 239000008104 plant cellulose Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003135 prenol lipids Chemical class 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960005359 propylparaben sodium Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003313 saccharo lipids Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- KVMUSGMZFRRCAS-UHFFFAOYSA-N sodium;5-oxo-1-(4-sulfophenyl)-4-[(4-sulfophenyl)diazenyl]-4h-pyrazole-3-carboxylic acid Chemical compound [Na+].OC(=O)C1=NN(C=2C=CC(=CC=2)S(O)(=O)=O)C(=O)C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KVMUSGMZFRRCAS-UHFFFAOYSA-N 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940053209 suboxone Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940005741 sunflower lecithin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 239000001003 triarylmethane dye Substances 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
- 239000010508 watermelon seed oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940052751 zuplenz Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Definitions
- Sildenafil sold under the brand name Viagra® among others, is a medication used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It is taken by mouth, or injection into a vein. Sildenafil acts by blocking phosphodiesterase 5 (PDES), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis. It requires sexual arousal, however, to work for ED. It also results in dilation of the blood vessels in the lungs.
- PDES phosphodiesterase 5
- sildenafil The primary indication of sildenafil is the treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete sexual intercourse). Its use is now one of the standard treatments for erectile dysfunction, including for men with diabetes mellitus.
- oral soluble films may be used to deliver active ingredients.
- the films can be formulated to disintegrate upon oral administration to rapidly (e.g., on the order of seconds) release the active ingredient.
- rapidly disintegrating films include films based on hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.
- BELBUCA® (buprenorphine hydrochloride) buccal film
- BUNAVAILTM (buprenorphine hydrochloride; naloxone hydrochloride) buccal film
- SUB OXONE® (buprenorphine hydrochloride; naloxone hydrochloride) sublingual buccal film
- SYMPAZAN® (clobazam) oral film
- ZUPLENZ® ondansetron
- EXSERVANTM riluzole
- KYNMOBITM apomorphine hydrochloride
- the simplest method includes mixing and co-processing of a bitter tasting API with excipient(s) having a good or pleasant taste (the method is referred to as the obscuration technique, and the excipient can include, e.g., a flavoring agent and/or taste masking agent). Selection of the appropriate flavoring agent or taste masking agent is challenging, as it is not readily apparent which ones will be effective, given a desired (bitter tasting) API and the corresponding remaining excipients. Additionally, the flavoring agent or taste masking agent can inadvertently alter the physical and/or performance characteristics of the OSF, which can regrettably lead to the need to reformulate.
- OSFs containing sildenafil citrate are currently known, and several are commercially available. However, it is currently believed that no OSF containing sildenafil citrate has received approval from the United States Food and Drug Administration (FDA), to be marketed and sold in the United States, for the safe and effective treatment of ED or PAH.
- FDA United States Food and Drug Administration
- An aspect of the present invention relates to an oral soluble film for releasing the active ingredient sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) into the oral cavity and delivering, e.g., enterally via ingestion.
- Another aspect of the present invention relates to an oral soluble film that can be used to administer the active ingredient, at an amount sufficient and effective to (1) obtain a desired result, such as the treatment of the subject, and to (2) obtain a desired level of the active ingredient in the subject (as evidenced by, e.g., plasma levels of the active ingredient).
- composition of the oral soluble film includes the active ingredient, in combination with multiple excipients (e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent), present in an amount effective to achieve desired physical and performance characteristics of the oral soluble film, both in vitro and in vivo.
- excipients e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent
- the OSF described herein can independently possess one or more advantages relative to other OSFs and/or traditional dosage forms (e.g., tablets and capsules).
- the one or more advantages can relate to, e.g., physical characteristics and/or performance characteristics of the oral soluble film.
- the OSF can be in the form of a unit dose having a requisite drug load, while having acceptable physical dimensions (e.g., length, width, and thickness), mass, and water content; and while also exhibiting a desired disintegration time and pharmacokinetic (PK) profile.
- PK pharmacokinetic
- the variation of active ingredient between two equally sized unit dosages is relatively small.
- accuracy in the administered dose can be assured from every strip or film.
- the unit dose has a suitable breaking strength, elongation strength, loss on drying (LOD), surface area, and/or density.
- the OSF is flexible, compliant, and not brittle.
- the OSF does not have an unpleasant taste (e.g., the bitter taste of the active ingredient is effectively masked).
- the OSF does not have an unpleasant mouth feel.
- the oral soluble film upon administration to the subject, exhibits a suitable pharmacokinetic (PK) profile that includes, e.g., AUC, C max , t max , and/or t 1/2 .
- a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material.
- a single dose of strip can be individually packaged without requiring a secondary container.
- Individually packaged OSFs are typically more difficult to tamper with, compared to traditional packages for tablets and capsules, such as bottles or foil blister packs. Additionally, many consumers may prefer the convenience to carry individually packaged OSFs. In specific embodiments, the individually packaged OSF can be easily handled, stored, and transported.
- the primary packaging material forms a primary package that protects the oral soluble film from light, protects the oral soluble film from microbial contamination, is child resistant, is a barrier to moisture and vapor, is airtight, and/or mitigates leachable(s) into the oral soluble film.
- the OSF can easily be titrated.
- the OSF can be discretely administered.
- the OSF can be administered in the absence of water or beverage. This makes the dosage form acceptable among pediatric and geriatric patients, as well as patients with a fear of choking (e.g., those suffering from dysphagia).
- the present invention provides for an oral soluble film that includes: (a) sildenafil citrate, (b) binder, (c) filler, (d) flavoring agent, (e) plasticizer, (f) sweetening agent, (g) preservative, (h) solvent, and (i) optionally coloring agent.
- the present invention provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (i) coloring agent.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent; (e) plasticizer that includes glycerin; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (g) optionally coloring agent.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (i) coloring agent.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer that includes glycerin; (f) sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) preservative that includes sodium benzoate; (h) solvent that includes water; and (i) optionally coloring agent.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- graft copolymer graft copolymer
- silicon dioxide silicon dioxide
- filler that includes microcrystalline cellulose
- flavoring agent that includes peppermint flavoring
- plasticizer
- the present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer that includes glycerin; (f) sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) coloring agent that includes FD&C Blue 1; (h) preservative that includes sodium benzoate; and (i) solvent that includes water.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- graft copolymer graft copolymer
- silicon dioxide silicon dioxide
- filler that includes microcrystalline cellulose
- flavoring agent that includes peppermint
- the present invention also provides for an oral soluble film that includes: (a) 36 ⁇ 7 wt. % sildenafil citrate; (b) 30 ⁇ 6 wt. % binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) 5.45 ⁇ 1 wt. % filler that includes microcrystalline cellulose; (d) 6.44 ⁇ 1.25 wt. % flavoring agent that includes peppermint flavoring; (e) 12 ⁇ 2.5 wt. % plasticizer that includes glycerin; (f) 10 ⁇ 2 wt.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- % sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) 0.01 ⁇ 0.002 wt. % coloring agent that includes FD&C Blue 1; and (h) 0.10 ⁇ 0.02 wt. % preservative that includes sodium benzoate.
- ACE-K sucralose and acesulfame potassium
- the present invention also provides for an oral soluble film configured as a unit dose, wherein the unit dose of the oral soluble film includes: (a) 70.24 ⁇ 7 mg sildenafil citrate; (b) 58.53 ⁇ 12 mg binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) 10.63 ⁇ 2 mg filler that includes microcrystalline cellulose; (d) 12.56 ⁇ 2.5 mg flavoring agent that includes peppermint flavoring; (e) 23.41 ⁇ 5 mg plasticizer that includes glycerin; (f) 19.5 ⁇ 4 mg sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) 0.02 ⁇ 0.004 mg coloring agent that includes FD&C Blue 1; (h) 0.20 ⁇ 0.04 mg preservative that includes sodium benzoate; and (i) 9.76 ⁇ 2.25 mg solvent that includes water
- the present invention also provides for an oral soluble film that includes: sildenafil citrate, polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, silicon dioxide, microcrystalline cellulose, peppermint flavoring, glycerin, sucralose, acesulfame potassium (ACE-K), FD&C Blue 1, sodium benzoate, and water.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for an oral soluble film that includes: 36 ⁇ 7 wt. % sildenafil citrate; 30 ⁇ 6 wt. % in the aggregate of polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and silicon dioxide; 5.45 ⁇ 1 wt. % microcrystalline cellulose; 6.44 ⁇ 1.25 wt. % peppermint flavoring; 12 ⁇ 2.5 wt. % glycerin; 10 ⁇ 2 wt. % in the aggregate sucralose and acesulfame potassium (ACE-K); 0.01 ⁇ 0.002 wt. % FD&C Blue 1; and 0.10 ⁇ 0.02 wt. % sodium benzoate.
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for an oral soluble film that includes (based on an anhydrous oral soluble film):
- the present invention also provides for an oral soluble film configured as a unit dose, wherein each unit dose of the oral soluble film includes (based on an anhydrous oral soluble film):
- the present invention also provides for a slurry, suitable for forming an oral soluble film.
- the slurry includes: 16.8 ⁇ 2 wt. % sildenafil citrate; 14.1 ⁇ 3 wt. % in the aggregate of polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and silicon dioxide; 2.5 ⁇ 0.5 wt. % microcrystalline cellulose; 3.0 ⁇ 0.75 wt. % peppermint flavoring; 5.6 ⁇ 1.25 wt. % glycerin; 4.66 ⁇ 1 wt. % in the aggregate sucralose and acesulfame potassium (ACE-K); 0.005 ⁇ 0.001 wt. % FD&C Blue 1; 0.05 ⁇ 0.01 wt. % sodium benzoate; and 53.3 ⁇ 10 wt. % water.
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the present invention also provides for a single dose of the oral soluble film described herein, that is individually packaged and sealed with a primary packaging material.
- the primary packaging material includes multiple layers, wherein at least one layer is manufactured from metalized polyester.
- the primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) is airtight, (vi) mitigates leachable(s) into the oral soluble film, (vii) identifies a logo and/or includes printed indicia, or (viii) any combination thereof.
- the present invention also provides for a kit that includes an enclosure that contains (a) multiple doses of the oral soluble film described herein, each individually packaged and sealed with a primary packaging material, and (b) prescribing information.
- the primary packaging material includes multiple layers, wherein at least one layer is manufactured from metalized polyester.
- the primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) is airtight, (vi) mitigates leachable(s) into the oral soluble film, (vii) identifies a logo and/or includes printed indicia, or (viii) any combination thereof.
- the present invention also provides for a method of medical treatment that includes orally administering to a subject in need thereof, the oral soluble film described herein.
- the present invention also provides for a method of treating a disease or disorder ameliorated by sildenafil citrate, the method includes orally administering to a subject in need thereof, the oral soluble film described herein.
- the present invention also provides for a method of treating erectile dysfunction (ED) in a male subject, the method includes orally administering to the male subject in need thereof an oral soluble film described herein.
- ED erectile dysfunction
- the present invention also provides for a method of treating antidepressant-induced erectile dysfunction in a male subject, the method includes orally administering to the male subject in need thereof an oral soluble film described herein.
- the present invention also provides for a method of treating pulmonary arterial hypertension (PAH) in a subject, the method includes orally administering to the subject in need thereof an oral soluble film described herein.
- PAH pulmonary arterial hypertension
- An aspect of the present invention relates to an oral soluble film for releasing the active ingredient sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) into the oral cavity and delivering, e.g., enterally via ingestion.
- Another aspect of the present invention relates to an oral soluble film that can be used to administer the active ingredient, at an amount sufficient and effective to (1) obtain a desired result, such as the treatment of the subject, and/or to (2) obtain a desired level of the active ingredient in the subject (as evidenced by, e.g., plasma levels of the active ingredient).
- the composition of the oral soluble film includes the active ingredient, in combination with multiple excipients (e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent), present in an amount effective to achieve the desired physical and performance characteristics of the oral soluble film, both in vitro and in vivo.
- excipients e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent
- This includes, e.g., effectively masking the taste of the active ingredient, which is highly bitter.
- This is accomplished while employing only those excipients (in amounts) that will be permitted by FDA.
- This may be further accomplished by obtaining an oral soluble film that is suitable for regulatory approval, as well as improving medication adherence and compliance by the subject. Likewise, this in turn may be accomplished by providing for an oral soluble film having the requisite physical and performance characteristics.
- These characteristics can include, e.g., the desired and targeted: in vitro disintegration time, in vitro dissolution time, loss on drying (LOD), breaking strength, minimal foreign body sensation, elongation strength, PK parameters (e.g., C max , T max , t 1/2 , AUC), mass/weight, thickness, moisture content, density, pH, drug load (content of API), elongation, and/or drug content uniformity (CU).
- in vitro disintegration time in vitro dissolution time
- LOD loss on drying
- breaking strength minimal foreign body sensation
- elongation strength PK parameters (e.g., C max , T max , t 1/2 , AUC), mass/weight, thickness, moisture content, density, pH, drug load (content of API), elongation, and/or drug content uniformity (CU).
- excipient refers to a pharmacologically inactive substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film).
- An excipient is a substance formulated alongside the active pharmaceutical ingredient (API), and can include agents for stabilizing, bulking/filling, disintegrating, dissolving, flavoring, facilitating drug absorption, reducing viscosity, and/or enhancing solubility.
- Excipients can also be useful in the manufacturing process, to aid in the handling of the API, such as by facilitating powder flowability or non-stick properties, and/or aiding in vitro stability such as prevention or mitigation of degradation of the API over the expected shelf life.
- excipients also depends upon the route of administration and the dosage form, as well as the API and other factors. Pharmaceutical regulations and standards require that all ingredients in drug products, as well as their chemical decomposition products, be identified and shown to be safe. The Federation of International Pharmaceutical Excipients Council (IPEC), a pharmaceutical regulatory non-profit, develops, implements, and promotes global use of appropriate quality, safety, and functionality standards for pharmaceutical excipients and excipient delivery systems.
- IPEC International Pharmaceutical Excipients Council
- Excipients useful in the formulations described herein include, e.g., binder, filler, preservative, sweetening agent, solvent, co-solvent, plasticizer, flavoring agent, taste masking agent, colorant, anti-caking agent, coating agent, emulsifier, solubilizing agent, lipid, humectant, thickening agent, lubricant, adsorbent, suspending agent, disintegrating agent, permeation enhancer, saliva stimulating agent, release modifier, adjuvant, fragrance, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant.
- binder filler, preservative, sweetening agent, solvent, co-solvent, plasticizer, flavoring agent, taste masking agent, colorant, anti-caking agent, coating agent, emulsifier, solubilizing agent, lipid, humectant, thickening agent, lubricant, adsorbent, suspending agent, disintegrating agent, permeation enhancer, saliva stimulating agent, release modifier,
- Excipients that can be used in the formulation of oral soluble films are described in, e.g., Lachman, et al., “The Theory and Practice of Industrial Pharmacy,” 4 th Edition (2013); Sheskey et al., “Handbook of Pharmaceutical Excipients,” 9th Edition (2020); and Remington, “The Science and Practice of Pharmacy,” 22nd Edition (2015). All excipients used in the formulation of the oral soluble film described herein, in the desired amounts, should preferably be approved by the FDA for use in oral pharmaceutical dosage forms. See, e.g., the FDA Inactive Ingredient Database (IID), https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (accessed Apr. 15, 2021). Additionally, the excipients will preferably be commercially available in acceptable grade, physiologically inert, and physically and chemically stable by themselves, as well as in combination with the desired API.
- IID FDA Inactive Ingredient Database
- Sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) functions as an active ingredient in the oral soluble film described herein.
- the sildenafil functions as the sole active ingredient.
- one or more excipients used in the pharmaceutical preparation of the oral soluble films described herein can possess a single use or function.
- each of sucralose and acesulfame potassium (ACE-K) function as a sweetener.
- FD&C Blue 1 functions as a colorant.
- sodium benzoate when present in the oral soluble film described herein, sodium benzoate functions as a preservative. Without being limited or bound to any particular theory, it is believed that across multiple specific embodiments, these substances provide little or no additional function(s) than those ascribed above.
- one or more excipients employed in the oral soluble film described herein can have multiple uses or functions.
- Kollicoat® Protect is employed as a binder, but in specific embodiments can further function as an anti-caking agent, disintegrating agent, coating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF, to increase elongation of the OSF, or any combination thereof.
- natural peppermint flavor is employed as a flavoring agent, but in specific embodiments can further function as a taste masking agent, permeation enhancer, or combination thereof.
- glycerin is employed as a plasticizer, but in specific embodiments can further function as a sweetener, humectant, co-solvent, thickening agent, lubricant, or any combination thereof.
- microcrystalline cellulose is employed as a filler, but in specific embodiments can further function as an anti-caking agent, emulsifier, bulking agent, binder, viscosity increasing agent, or any combination thereof.
- the present invention provides for an oral soluble film that includes (i) sildenafil citrate, (ii) binder, (iii) filler, (iv) flavoring agent, (v) plasticizer, (vi) sweetener, (vii) coloring agent, and (viii) preservative. It is contemplated that in specific embodiments, one or more excipients can be employed in the oral soluble film, each to effectively serve multiple functions.
- a single excipient e.g., Kollicoat® Protect
- a single excipient can function as a binder, as well as an anti-caking agent, disintegrating agent, coating agent, taste masking agent, binder, emulsifier, to increase tensile strength of the OSF, and/or to increase elongation of the OSF.
- a single excipient e.g., Peppermint Flavor
- a single excipient e.g., glycerin
- a plasticizer as well as a sweetener, humectant, co-solvent, thickening agent, and/or lubricant.
- Excipients useful in the oral soluble film described herein, having multiple functions, are described, e.g., in Handbook of Pharmaceutical Excipients, Sheskey et al., Eds., 9th Edition, Pharmaceutical Press (2020).
- the OSF may be prepared by first forming a slurry.
- any one or more of the ingredients (including the API) employed can effectively be dissolved or dispersed therein (e.g., in the solvent).
- salts such as sodium benzoate and acesulfame potassium.
- the salt can dissociate into the respective anion and cation; and would therefore no longer necessarily exist in the salt form-benzoic acid, acesulfame free base, and sildenafil free base.
- reference to the slurry (and resulting oral soluble film) as containing substances in the salt form is otherwise acceptable and appropriate.
- the inactive ingredient microcrystalline cellulose can be employed in the manufacture of the drug product, oral soluble film.
- the microcrystalline cellulose present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the cellulose would therefore no longer necessarily retain the microcrystalline form.
- reference to the slurry (and resulting oral soluble film) as containing microcrystalline cellulose is otherwise acceptable and appropriate.
- the drug substance sildenafil citrate having a specified bulk density or particle size distribution (PSD)
- PSD particle size distribution
- the sildenafil citrate present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the sildenafil citrate would therefore no longer necessarily retain the drug substance PSD or bulk density.
- reference to the slurry (and resulting oral soluble film) as containing the sildenafil citrate having a specified bulk density or PSD is otherwise acceptable and appropriate.
- the inactive ingredient microcrystalline cellulose having a specified bulk density or particle size distribution (PSD)
- PSD bulk density or particle size distribution
- the MCC present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the MCC would therefore no longer necessarily retain the PSD.
- reference to the slurry (and resulting oral soluble film) as containing the MCC having a specified PSD (based on the MCC employed) is otherwise acceptable and appropriate.
- the active ingredient e.g., sildenafil citrate
- excipients e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and/or solvent.
- the slurry (and the resulting oral soluble film) as being manufactured from (or as being formed from) the active ingredient and excipients, as specifically indicated. It is appreciated that those of skill in the art understand and agree that each of the above characterizations of the slurry (and the resulting oral soluble film) are acceptable and appropriate.
- inactive ingredient refers to a substance that is pharmacologically and biologically inactive.
- the inactive ingredients are usually called excipients in pharmaceutical contexts.
- slurry refers to a mixture of solids that is dispersed, suspended, solubilized, and/or dissolved in liquid. Together, the solids and liquid will include those substances used to manufacture the oral soluble film.
- the solid substances employed in the manufacture of the oral soluble film can essentially be dissolved in the liquid, can essentially be suspended in the liquid, can essentially be dispersed in the liquid, can essentially be solubilized in the liquid, or a combination thereof.
- An oral soluble film can be formed by curing a cast slurry. The curing can be carried out, e.g., at an elevated temperature, for a period of time. In doing so, a significant amount of the solvent (e.g., water) will be removed. The remaining water will contribute to the moisture content in the oral soluble film (in addition to any moisture from the surrounding environment that is picked up by any hygroscopic polymers employed).
- binder refers to a substance, typically a polymer, used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to hold the ingredients together. Binders ensure that the oral soluble films can be formed with the requisite mechanical strength. The binders also provide the requisite volume to low amount of active present in soluble films. The presence of the binder can also facilitate the formation of the cured film. As such, the binder includes those substances, which when present in the cast slurry and upon curing, will effectively provide for a cured film. In designing of an oral soluble film formulation, consideration should be given to the target product and drug release profile.
- a primary component of an oral film is the binder, which may be a polymer blend. Selection of the binder may be guided by the desired strength and stability of the oral soluble film, as well as mucoadhesiveness, pliability, dissolution rate, and moisture content.
- the binder may also be referred to as a “film forming agent,” or more specifically a “film forming polymer” (or equivalent terms, such as “strip-forming polymer” and “mucoadhesive polymer”) when it is a polymer.
- Polymeric binders (film forming agents) can be natural or a synthetic. Employing a binder can allow for, and promote, the formation of a “film matrix” (also referred to as a polymeric matrix).
- a film matrix is typically obtained by curing the cast slurry, which contains the binder(s).
- binders for use in an OSF described herein include polyacrylic acid (PAA) (alternatively referred to as poly(acrylic acid) or Carbomer®); 1-polyacrylic acid; methyl methacrylate copolymer; carboxyvinyl polymer; polyethylene glycol (PEG) (alternatively referred to as polyethylene oxide or PEO); acacia; agar; alginic acid (alternatively referred to as algin); sodium alginate (Na alginate); calcium carbonate; calcium lactate; carboxymethyl cellulose (CMC) (alternatively referred to as cellulose gum or carboxy methylcellulose or carboxymethylcellulose); carrageenan; cellulose acetate; chitosan; copovidone; starch (e.g., corn starch or pregelatinized starch); cottonseed oil; dextrates; dextrin; de
- filler refers to substances used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to add bulk to the pharmaceutical dosage form, improving the consistency in dose metering and/or making the active ingredient easier for consumer to take. Fillers can also help with the manufacturing and stabilization of these products. Fillers can also bind and stabilize the dosage form. They are employed in the manufacture of an OSF to increase weight/mass and/or to improve content uniformity. Fillers can provide properties such as improved cohesion and/or to promote flow.
- fillers for use in an OSF described herein include anhydrous lactose, calcium carbonate, calcium lactate, calcium phosphate (dibasic anhydrous, dibasic dihydrate, or tribasic), calcium silicate, calcium sulfate, cellulose (powdered or silicified microcrystalline), cellulose acetate, corn starch and pregelatinized starch, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glucose, glyceryl palmitostearate, glycine, hydrolyzed starch, lactose, lactose monohydrate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, medium-chain triglycerides, microcrystalline cellulose (MCC), partially pregelatinized starches, plant cellulose, polydextrose, polymethacrylates, si
- preservative refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to prevent or mitigate microbial growth or by undesirable chemical changes. In general, preservation is implemented in two modes, chemical and physical. Examples of preservatives for use in an OSF described herein include ethanol, benzoic acid, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), butylparaben, calcium acetate, calcium chloride, calcium lactate, cetylpyridinium chloride, chlorhexidine, chlorobutanol, citric acid monohydrate, ethylparaben, glycerin, lactic acid, methylparaben, parabens, potassium benzoate, potassium sorbate, propyl gallate, propylene glycol, propylparaben, propylparaben sodium, sodium acetate, sodium benzoate, sodium lactate, sodium propionate, sorb
- sweetening agent refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to impart a sweet taste like that of sugar.
- the sweetener can be artificial or naturally occurring.
- sweetening agents for use in an OSF described herein include sugar, acesulfame salts (e.g., acesulfame potassium (ACE-K)), alitame, aspartame, dextrose, erythritol, fructose, glycerin, isomalt, lactitol, advantame, monk fruit extract (mogrosides), glucose, galactose, maltitol, maltose, mannitol, monk fruit extract, neohesperidin dihydrochalcone, neotame, saccharin, saccharin salts (e.g., saccharin sodium), sodium cyclamate, sorbitol, stevia, stevioside, rebaudioside A, sucralose, sucrose, tagatose, thaumatin, trehalose, licorice extract, and xylitol.
- solvent refers to a substance that is used in the pharmaceutical preparation of an oral soluble film, to dissolve the active pharmaceutical ingredient (API) and/or excipients.
- a solvent can be employed to form a slurry.
- solvents improve solubility of the active ingredient within the film forming matrix.
- Solvents may be chosen based on the active ingredient's solubility therein.
- Preferred solvents include volatile class 3 residual solvents such as ethanol and acetone and non-volatile solvents such as water.
- the solvent is at least one of ethanol and water.
- co-solvent refers to a substance that is used in the pharmaceutical preparation of an oral soluble film, to assist the solvent in dissolving the active pharmaceutical ingredient (API) and/or excipients, to form a slurry.
- co-solvents for use in an OSF described herein include almond oil, castor oil, corn oil, cottonseed oil, ethanol, glycerin, olive oil, polyethylene glycol, polyoxy 35 castor oil, propylene glycol, safflower oil, sesame oil, soybean oil, sunflower oil, and ethanol.
- plasticizer refers to a substance that, when added to polymer(s), makes the polymer more pliable and softer, enhancing the flexibility and plasticity of the films. They can be added to reduce the glass transition temperature to reduce the risk of thermally destabilizing the active ingredient and/or excipients. The plasticizer is believed to permeate the polymer structure, disrupting intermolecular hydrogen bonding, and permanently lowers intermolecular attractions. Plasticizers can be used to allow initial film forming, to reduce the brittleness, and improve the processability and flexibility of the resulting film, thereby avoiding cracking, e.g., during the curing process. Plasticizers can be used to improve elasticity of the oral soluble film which can be important for manufacturing scale-up.
- Plasticizers can also play a role when combined with certain polymers in the overall dissolution rate of the film.
- plasticizers for use in an OSF described herein include castor oil, glycerin, glycerol monostearate, D, hypromellose phthalate, mannitol, mineral oil and, palmitic acid, polyethylene glycol, polyvinyl acetate phthalate, propylene glycol, pyrrolidone, sorbitol, stearic acid, triacetin, tributyl citrate, triethyl citrate, water, glycerin fatty acid esters, sucrose fatty acid esters, lecithin, enzyme modified lecithin, polysorbates, sorbitan fatty acid esters, maltitol, xylitol, polyethylene glycol (PEG), hydrogenated starch syrup, starch syrup, and glycerol oleate.
- PEG polyethylene glycol
- flavoring agent refers to a substance used in the pharmaceutical preparation of an oral soluble film, to impart a flavor, e.g., to improve the attractiveness and acceptance by the subject.
- the basic taste sensations are salty, sweet, bitter, sour, and umami.
- Flavors may be chosen from natural and synthetic flavorings. An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
- the flavoring agent can be available as a solid (e.g., powder), as a liquid (e.g., oil), or a combination thereof. Additionally, the flavoring agent for use in the OSF can include any one or more of a natural flavoring substance, a nature-identical flavoring substance, and an artificial flavoring substance.
- flavoring agents for use in an OSF described herein include allspice, anise, n-butyl lactate, cardamom, cherry, confectioner's sugar, cinnamon, clove, ethyl vanillin, ethylcellulose, eugenol, ginger, gingermint, lemon, lemongrass, levomenthol, lime, malic acid, maltol, menthol, mint, nutmeg, orange, peppermint, phosphoric acid, propionic acid, sodium acetate, sodium lactate, spearmint, tangerine, tartaric acid, thymol, triethyl citrate, vanillin, vanilla cream, watermint, wintergreen, mountain berry, and grape.
- the peppermint flavoring agent can include Natural Peppermint Oil, commercially available from A. M. Todd; Natural Peppermint Flavor 501500 TPK504, commercially available from Firmenich (Anaheim, Calif.); or Natural and Artificial Peppermint, commercially available from Firmenich (Anaheim, Calif.).
- the spearmint flavoring agent can include Spearmint Flavor, Nat & Art, commercially available from FONA (Geneva, Ill.); or Natural Spearmint Flavor, commercially available from Virginia Dare (Brooklyn, N.Y.).
- the orange flavoring agent can include Nat Orange Durarome 860205 TD 1091, commercially available from Firmenich (Anaheim, Calif.); Orange Flavor Nat WONF, commercially available from FONA (Geneva, Ill.); Orange Flavor, Nat & Art, commercially available from FONA (Geneva, Ill.); or Superflex Natural Orange, commercially available from Virginia Dare (Brooklyn, N.Y.).
- the vanilla cream flavoring agent can include Natural Flavor for Cream (NFF Vanilla), commercially available from Virginia Dare (Brooklyn, N.Y.).
- natural flavoring substance refers to a flavoring substance obtained from plant or animal raw materials, by physical, microbiological, or enzymatic processes. They can be either used in their natural state or processed for human consumption, but cannot contain any nature-identical or artificial flavoring substances.
- the term “nature-identical flavoring substance” refers to a flavoring substance obtained by synthesis or isolated through chemical processes, which is chemically and organoleptically identical to flavoring substances naturally present in products intended for human consumption. They cannot contain any artificial flavoring substances.
- artificial flavoring substance refers to a flavoring substance that is not identified in a natural product intended for human consumption, whether or not the product is processed. These are typically produced by fractional distillation and additional chemical manipulation of naturally sourced chemicals, crude oil, or coal tar. Although they are chemically different, in sensory characteristics they are the same as natural ones. Most artificial flavors are specific and often complex mixtures of singular naturally occurring flavor compounds combined together to either imitate or enhance a natural flavor. These mixtures are formulated by flavorists to give a food product a unique flavor and to maintain flavor consistency between different product batches or after recipe changes.
- the list of known artificial flavoring agents includes thousands of molecular compounds, and the flavor chemist (flavorist) can often mix these together to produce many of the common flavors. Many of these artificial flavorants consist of esters, which are often described as being “sweet” or “fruity”.
- taste masking agent refers to a substance used in the pharmaceutical preparation of an oral soluble film, to mask the unpleasant taste of a substance present in the formulation, to improve the attractiveness and acceptance by the subject.
- the taste masking agent can specifically refer to a substance used to mask the bitter or unpleasant taste of the active ingredient.
- Examples of taste masking agents for use in an OSF described herein include alginic acid, erythritol, and glyceryl palmitostearate, and monoammonium glycyrrhizinate (MAG).
- the taste masking agent in addition to masking the taste of any unpleasant or bitter tasting substances (e.g., the active ingredient) present in the oral soluble film, can optionally also impart a pleasant flavor.
- the same substance can serve as both a flavoring agent and as a taste masking agent.
- colorant refers to substance used in the pharmaceutical preparation of an oral soluble film, to change the color of the slurry and/or oral soluble film.
- the colorant is a dye, pigment, or substance that imparts color when it is added to a slurry. Colorants work by absorbing varying amounts of light at different wavelengths (or frequencies) of its spectrum, transmitting (if translucent) or reflecting the remaining light in straight lines or scattered. Color consistency can be significant, as it allows easy identification of a medication to the subject. Furthermore, colors often improve the aesthetic look and feel of medications. By increasing these organoleptic properties, a subject is more likely to adhere to their schedule and therapeutic objectives will also have a better outcome for the subject.
- the colorant can include, e.g., FD&C colors (e.g., FD&C red, FD&C yellow, FD&C blue, FD&C green), D&C colors, or a combination thereof.
- FD&C colors e.g., FD&C red, FD&C yellow, FD&C blue, FD&C green
- D&C colors or a combination thereof.
- Examples of colorants for use in an OSF described herein include FD&C Red No. 3, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, FD&C Green No. 3, FD&C Blue No. 1, and FD&C Blue No. 2.
- anti-caking agent refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to prevent or mitigate the occurrence of the formation of lumps (caking) of powdered or granulated materials.
- Use of the anti-tacking agent can result in the ease of flowability of the solid powders used to form the slurry. Crystalline solids often cake by formation of liquid bridge and subsequent fusion of microcrystals. Amorphous materials can cake by glass transitions and changes in viscosity.
- anti-caking agents for use in an OSF described herein include calcium silicate, tribasic calcium phosphate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate, and talc, mannitol, and starch.
- coating agent refers to a substance that is applied to a solid or powder particle, to sufficiently coat the particle.
- the thickness of such a coating is usually less than 100 ⁇ m.
- the motivation for coating a particle ranges from improving the stability (light protection, moisture and gas barrier) to increasing the flowability to thereby make it easier to process.
- coating agents for use in an OSF described herein include calcium carbonate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carnauba wax, cellulose acetate, (CAP), chitosan, ethylcellulose, fructose, gelatin, glycerin, glyceryl behenate, glyceryl palmitostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, isomalt, glucose, maltitol, maltodextrin, methylcellulose, microcrystalline wax, poloxamer, polydextrose, polyethylene glycol, poly-DL-(lactic acid), polyvinyl acetate phthalate, polyvinyl alcohol, povidone, sucrose, titanium oxide, tributyl citrate, triethyl citrate, vanillin, xylitol, and zein.
- emulsifier refers to a substance capable of forming or promoting an emulsion.
- the emulsifier can promote the separation of phases (e.g., aqueous and lipids), while allowing them to be mixed.
- emulsifiers for use in an OSF described herein include acacia, cholesterol, glycerin, glyceryl monostearate, hydroxypropyl cellulose, lecithin, methylcellulose, mineral oil and, monobasic sodium phosphate, monoethanolamine, oleic acid, polyethylene glycol, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polysorbate (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, etc.), propylene glycol, propylene glycol alginate, sodium lauryl sulfate, sorbitan esters, and stearic acid.
- acacia cholesterol, glycerin, glyceryl monostearate, hydroxypropyl cellulose, lecithin, methylcellulose, mineral oil and, monobasic sodium phosphate, monoethanol
- solubilizing agent refers to a substance used in the pharmaceutical preparation of an oral soluble film, to increase the solubility and/or bioavailability of the API.
- a solubilizing agent can act as a surfactant and increases the solubility of one agent in another.
- a substance that would not normally dissolve in a particular solution may be able to dissolve with the use of a solubilizing agent.
- solubilizing agents for use in an OSF described herein include cyclodextrins, glycerin monostearate, hydroxpropyl betadex, hypromellose, inulin, lecithin, meglumine, phospholipids, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, povidone, pyrrolidone, sorbitan esters, starch, stearic acid, sulfobutylether ⁇ -cyclodextrin, tricaprylin, triolein, and vitamin E polyethylene glycol succinate, N-acetylated amino-acid derivative, ethoxylated sorbitan, mono and diglycerides.
- emulsion refers to a mixture of two or more liquids that are normally immiscible (unmixable or unblendable) owing to liquid-liquid phase separation.
- Two liquids can form different types of emulsions.
- oil and water can form, first, an oil-in-water emulsion, in which the oil is the dispersed phase, and water is the continuous phase.
- Multiple emulsions are also possible, including a “water-in-oil-in-water” emulsion and an “oil-in-water-in-oil” emulsion.
- Emulsions, being liquids do not exhibit a static internal structure.
- the droplets dispersed in the continuous phase are usually assumed to be statistically distributed to produce roughly spherical droplets.
- molecules are ordered during liquid-liquid phase separation, they form liquid crystals rather than emulsions.
- Lipids used by all living organisms, are one example of molecules able to form either emulsions (e.g.: spherical micelles; Lipoproteins) or liquid crystals (lipid bilayer membranes).
- the droplets may be amorphous, liquid-crystalline, or any mixture thereof.
- the diameters of the droplets constituting the dispersed phase usually range from approximately 10 nm to 100 ⁇ m; i.e., the droplets may exceed the usual size limits for colloidal particles.
- An emulsion is termed an oil/water (o/w) emulsion if the dispersed phase is an organic material, and the continuous phase is water or an aqueous solution and is termed water/oil (w/o) if the dispersed phase is water or an aqueous solution and the continuous phase is an organic liquid (an “oil”).
- microemulsions and nanoemulsions Two special classes of emulsions—microemulsions and nanoemulsions, with droplet sizes below 100 nm—appear translucent. This property is due to the fact that light waves are scattered by the droplets only if their sizes exceed about one-quarter of the wavelength of the incident light. Since the visible spectrum of light is composed of wavelengths between 390 and 750 nanometers (nm), if the droplet sizes in the emulsion are below about 100 nm, the light can penetrate through the emulsion without being scattered. Due to their similarity in appearance, translucent nanoemulsions and microemulsions are frequently confused.
- microemulsions may be spontaneously formed by “solubilizing” oil molecules with a mixture of surfactants, co-surfactants, and co-solvents.
- the required surfactant concentration in a microemulsion is, however, several times higher than that in a translucent nanoemulsion, and significantly exceeds the concentration of the dispersed phase. Because of many undesirable side-effects caused by surfactants, their presence is often considered disadvantageous or prohibitive in many applications.
- the stability of a microemulsion may be compromised by dilution, by heating, or by changing pH levels.
- lipid refers to a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, phospholipids, and others. “Lipid” may also refer to ethoxylated fatty alcohols such as oleth-10 and laureth-10 and mixtures of ethoxylated mono and diglycerides such as PEG-16 macadamia glycerides and PEG-10 sunflower glycerides. The compounds are hydrophobic or amphiphilic small molecules.
- lipids originate entirely or in part from two distinct types of biochemical subunits or “building-blocks”: ketoacyl and isoprene groups.
- lipids may be divided into eight categories: fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, and polyketides (derived from condensation of ketoacyl subunits); and sterol lipids and prenol lipids (derived from condensation of isoprene subunits).
- lipid is sometimes used as a synonym for fats, fats are a subgroup of lipids called triglycerides. Lipids also encompass molecules such as fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), as well as other sterol-containing metabolites such as cholesterol.
- lipids for use in an OSF described herein include almond oil, argan oil, avocado oil, canola oil, cashew oil, castor oil, cocoa butter, coconut oil, colza oil, corn oil, cottonseed oil, grape seed oil, hazelnut oil, hemp oil, hydroxylated lecithin, lecithin, linseed oil, macadamia oil, mango butter, marula oil, mongongo nut oil, olive oil, palm kernel oil, palm oil, peanut oil, pecan oil, perilla oil, pine nut oil, pistachio oil, poppy seed oil, pumpkin seed oil, rice bran oil, safflower oil, sesame oil, Shea butter, soybean oil, sunflower oil, sunflower lecithin, walnut oil, and watermelon seed oil, vitamin E, mono and diglycerides, propylene glycol, polyethylene glycol, Kolliphor® RH, and Kolliphor® EL.
- humectant refers to a substance used in the pharmaceutical preparation of an oral soluble film, to keep the slurry and/or oral soluble film moist.
- a humectant attracts and retains the moisture in the air nearby via absorption, drawing the water vapor into or beneath the oral soluble film's surface. This is the opposite use of a hygroscopic material where it is used as a desiccant used to draw moisture away.
- Humectants can be used in oral soluble films to help solubilize active ingredients, increasing the active ingredients' ability to penetrate a mucosal surface, or its activity time.
- humectants for use in an OSF described herein include glycerin, polydextrose, propylene glycol, sodium lactate, sorbitol, trehalose, triacetin, xylitol, sodium chloride, and polyvinylpyrrolidone.
- thickening agent refers to substances used in the pharmaceutical preparation of oral soluble films, to improve the viscosity and consistency of the slurry before casting. Active ingredient content uniformity is often a requirement for dosage forms, particularly those containing low dose highly potent active ingredients. To uniquely meet this requirement, oral soluble film formulations can contain uniform dispersions of active ingredient throughout the whole manufacturing process.
- thickening agents for use in an OSF described herein include acacia, agar, alginic acid, calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, chitosan, cyclomethicone, ethylcellulose, gelatin, glycerin, guar gum, hydrogenated vegetable oil, hydroxyethy cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, locust bean gum, maltodextrin, methylcellulose, pectin, polydextrose, polyethylene glycol, polyvinyl alcohol, potassium chloride, potassium alginate, povidone, propylene glycol alginate, sodium alginate, sodium chloride, starch, sucrose, sulfobutylether ⁇ -cyclodextrin, and xanthan gum.
- lubricant refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to improve processing characteristics.
- the lubricant can enhance flow of the slurry by reducing interparticulate friction.
- the lubricant is typically added to a powder to improve its flowability.
- a lubricant will typically only work at a certain range of concentrations. Above a certain concentration, the lubricant will function to inhibit flowability.
- lubricants for use in an OSF described herein include ascorbyl palmitate, calcium palmitate, castor oil, fumed silica (colloidal silicon dioxide), glycerin monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil (e.g., Sterotex®, Lubritab®, and Cutina®), light mineral oil, magnesium stearate, medium-chain triglycerides, mineral oil, palmitic acid, partial fatty acid esters of sugars, polyethylene glycol fatty acid esters, polyethylene glycol fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, 2-ethoxy ethanol, ethyl alcohol, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, starch, sucrose esters, and talc.
- ascorbyl palmitate calcium palmitate, castor oil, fumed silica (colloidal silicon dioxide), glycerin monostearate, gly
- adsorbent refers to a substance used to prevent or mitigate the occurrence of another substance from undergoing sorption (process in which one substance takes up or holds another, by either absorption or adsorption). Typically, the adsorbent is used to prevent or mitigate another substance from taking up water or moisture.
- adsorbents for use in an OSF described herein include aluminum hydroxide, aluminum oxide, aluminum phosphate, attapulgite, bentonite, powdered cellulose, colloidal silicon dioxide, magnesium aluminum silicate, microcrystalline cellulose, pectin, polycarbophil, and talc.
- suspending agent refers to a substance that helps another substance (e.g., active pharmaceutical ingredient) to stay suspended in the formulation (e.g., slurry) and to prevent or mitigate the occurrence of caking at the bottom of the container.
- a well-formulated suspension is that it can be easily re-suspended by the use of moderate agitation or blending.
- the suspending agent will help other substances to stay suspended in the slurry, prior to the curing. In doing so, the substances are held in the slurry by the suspending agent, and do not settle at the bottom to any appreciable degree.
- suspending agents for use in an OSF described herein include acacia, agar, alginic acid, bentonite, calcium stearate, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, powdered cellulose, cellulose (microcrystalline and carboxymethylcellulose sodium), colloidal silicon dioxide, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, kaolin, magnesium aluminum silicate, maltitol solution, medium-chain triglycerides, methylcellulose, microcrystalline cellulose, phospholipids, polycarbophil, polyethylene glycol, polyoxyethylene sorbitan fatty acid esters, potassium alginate, povidone, propylene glycol alginate, sesame oil, sodium alginate, sodium starch glycolate, sorbitan esters, sucrose, tragacanth, vitamin E polyethylene glycol succinate, and xanthan gum.
- disintegrating agent refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film or orally disintegrating tablet), that helps the dosage form to disintegrate and release the active ingredient on contact with moisture.
- the disintegrant is employed in the manufacture of an OSF to promote its rapid disintegration or break down into small particles after administration for facilitating rapid dissolution into bodily fluid.
- disintegrating agents for use in an OSF described herein include alginic acid, AmberliteTM calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, colloidal silicon dioxide, corn starch and pregelatinized starch, croscarmellose sodium, crospovidone, glycine, guar gum, hydroxypropyl cellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium starch glycolate, pregelatinized starch, and low substituted HPMC.
- alginic acid AmberliteTM calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, colloidal silicon dioxide, corn starch and pregelatinized starch, croscarmellose sodium, crospovidone, glycine, guar gum, hydroxypropyl cellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium starch glycolate, pregelatinized starch, and
- permeation enhancer refers to a substance used in the pharmaceutical preparation of an oral soluble film, to increase the delivery of the active ingredient, when administered in vivo (e.g., orally), resulting in an increased absorption of the active ingredient.
- the active ingredient can be delivered across the desired body surface, e.g., oral mucosa, such as buccal, sublingual, mucosa, or gingival; or an intestinal surface.
- permeation enhancers for use in an OSF described herein include anionic surfactants (e.g., sodium lauryl sulfate, sodium laurate, Laureth-9, sodium dodecyl sulfate (SDS), dioctyl sodium sulfosuccinate), nonionic surfactants (polyoxyethylene-9-lauryl ethe (PLE), Tween® 80, nonylphenoxypolyoxyethylene (NPPOE), polysorbate, sodium glycocholate), cationic surfactants (e.g., cetylpyridinium chloride, chitosan, trimethyl chitosan, poly-L-arginine, L-lysine), fatty acids or derivatives thereof (e.g., oleic acid caprylic acid, mono(di)glycerides, lauric acid, linoleic acid, acylcholines, acylcarnitine, sodium caprate, and oleic acid), and polyol
- active pharmaceutical ingredient refers to the substance sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate).
- the active pharmaceutical ingredient is pharmacologically and biologically active.
- saliva stimulating agent refers to a substance used to increase the production of saliva, thereby increasing salivary flow rate.
- saliva stimulating agents for use in an OSF described herein include organic acids (e.g., ascorbic acid, citric acid, fumaric acid, tartaric acid, and malic acid), parasympathomimetic drugs (e.g., choline esters such as pilocarpine hydrochloride and cholinesterase inhibitors), physostigmine, and other substances (e.g., xylitol, xylitol/sorbitol, and nicotinamide).
- organic acids e.g., ascorbic acid, citric acid, fumaric acid, tartaric acid, and malic acid
- parasympathomimetic drugs e.g., choline esters such as pilocarpine hydrochloride and cholinesterase inhibitors
- physostigmine e.g., xylitol, x
- release modifier refers to a substance used to modify the release of the active ingredient from an oral solid dosage form (e.g., OSF) and/or is used to modify the absorption of the active ingredient when the oral solid dosage form is orally administered to the subject.
- the drug release can be contrasted to an immediate release (IR), and includes, e.g., an extended release (XR), sustained release (SR), or delayed release (DR).
- IR immediate release
- XR extended release
- SR sustained release
- DR delayed release
- adjuvant refers to a substance used to modify (e.g., increase) the effect or efficacy of the active ingredient present in an oral solid dosage form (e.g., OSF).
- the adjuvant can be, e.g., a pharmacological agent or immunological agent.
- fragment refers to a substance used to impart a desired smell, scent, or odor to a formulation (e.g., slurry or OSF).
- surfactant refers to a substance used to lower the surface tension (or interfacial tension) between two liquids, between a gas and a liquid, or between a liquid and a solid. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, or dispersants.
- the surfactant can be anionic, cationic, zwitterionic, or non-ionic.
- pH adjusting agent refers to a substance used to change the pH of an aqueous solution (e.g., slurry).
- the pH adjusting agent can be an acid, such that when added to an aqueous solution (e.g., slurry), it will decrease the pH.
- the pH adjusting agent can be a base, such that when added to an aqueous solution (e.g., slurry), it will increase the pH.
- the base can be an organic base (e.g., sodium bicarbonate), an inorganic base (e.g., sodium hydroxide), or combination thereof.
- the acid can be an inorganic acid (e.g., hydrochloric acid), an organic acid (e.g., citric acid, malic acid, tartaric acid, etc.), or a combination thereof.
- buffering agent refers to a weak acid or weak base used to maintain the pH (e.g., acidity or basicity) of a solution (e.g., slurry) near a chosen value after the addition of another acid or base. That is, the function of a buffering agent is to prevent or mitigate the occurrence of a rapid change in pH when acids or bases are added to the solution (e.g., slurry). Buffering agents have variable properties—some are more soluble than others; some are acidic while others are basic.
- the acid can be an organic acid, mineral acid, or combination thereof.
- the base can be an organic base, inorganic base, or combination thereof.
- stabilizer refers to a substance used to prevent or mitigate the occurrence of degradation of any one of more substances present in a formulation (e.g., the slurry and/or oral soluble film). This would include preventing or mitigating degradation of the active ingredient, as well as any of the inactive ingredients or excipients.
- antioxidant refers to a substance used to inhibit, prevent, or mitigate the occurrence of oxidation of any one of more substances present in a formulation (e.g., the slurry and/or oral soluble film). This would include inhibiting, preventing, or mitigating oxidation of the active ingredient, as well as any of the inactive ingredients or excipients.
- examples of antioxidants for use in an OSF described herein include ascorbic acid (vitamin C), vitamin A, ⁇ -tocopherol (vitamin E), beta-carotene, glutathione, ubiquinol (coenzyme Q), and selenium.
- microcrystalline refers to a crystallized substance containing small crystals, wherein the crystalline lattice is visible only through microscopic examination.
- Microcrystalline cellulose or “MCC” is a term used for refined wood pulp. A naturally occurring polymer, it is composed of glucose units connected by a 1-4 beta glycosidic bond. These linear cellulose chains are bundled together as microfibril spiraled together in the walls of plant cell.
- the term “silicified microcrystalline cellulose” refers to MCC which is silicified. Silicification is the process in which organic matter becomes saturated with silica.
- the microcrystalline cellulose can function as a filler.
- the microcrystalline cellulose can optionally further function as an anti-caking agent, emulsifier, bulking agent, viscosity increasing agent, binder, or any combination thereof.
- the term “glycerin” refers to the substance having the IUPAC name propane-1,2,3-triol; CAS Number 56-81-5, 8043-29-6, 25618-55-7, 8013-25-0; chemical formula C 3 H 8 O 3 or CH 2 OH—CHOH—CH 2 OH; and molar mass 92.09 g/mol.
- the glycerin can be glycerin, 99% natural. The “99%” is a designation of purity and the “natural” is a designation that the substance is not synthetically prepared.
- the glycerin can function as a plasticizer.
- the glycerin can optionally further function as a sweetener, humectant, solvent, thickening agent, lubricant, or any combination thereof.
- copolymer refers to a polymer derived from more than one species of monomer.
- the polymerization of monomers into copolymers is called copolymerization.
- Copolymers obtained by copolymerization of two monomer species are sometimes called bipolymers. Since a copolymer consists of at least two types of constituent units (also structural units), copolymers can be classified based on how these units are arranged along the chain.
- Linear copolymers consist of a single main chain, and include alternating copolymers, statistical copolymers, and block copolymers.
- Branched copolymers consist of a single main chain with one or more polymeric side chains, and can be grafted, star shaped or have other architectures.
- Graft copolymers are a special type of branched copolymer in which the side chains are structurally distinct from the main chain.
- the main chain is formed from one type of monomer (A) and branches are formed from another monomer (B), or else the side-chains have constitutional or configurational features that differ from those in the main chain.
- the individual chains of a graft copolymer may be homopolymers or copolymers.
- the copolymer can be a graft copolymer.
- the graft copolymer can be polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer. Polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer is present in the product Kollicoat® Protect.
- polyvinyl alcohol refers to a water-soluble synthetic polymer. It has the chemical formula (C 2 H 4 O) x , idealized formula [CH 2 CH(OH)] n , and CAS No. 9002-89-5. PVA is present in the product Kollicoat® Protect.
- PEG polyethylene glycol
- PEG polyether compound
- PEO polyethylene oxide
- POE polyoxyethylene
- PEG has the CAS No. 25322-68-3.
- silicon dioxide refers to an oxide of silicon with the chemical formula SiO 2 , molar mass 60.08 g/mol, and CAS No. 7631-86-9. Silicon dioxide is present in the product Kollicoat® Protect.
- Kollicoat® Protect refers to the commercial product containing (i) polyvinyl alcohol (PVA), (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and (iii) silicon dioxide.
- Kollicoat® Protect is a combination of water-soluble Kollicoat® IR and polyvinyl alcohol, wherein the Kollicoat® IR is a polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer.
- the PEG portion of Kollicoat® IR is PEG 6000.
- the Kollicoat® products are commercially available from BASF (Florham Park, N.J.).
- Kollicoat® Protect has the chemical name polyvinyl alcohol-polyethylene glycol copolymer and polyvinyl alcohol (PVA).
- Kollicoat® Protect has the CAS-Nos: Kollicoat® IR 96734-39-3, Polyvinyl alcohol 9002-89-5, and silicon dioxide 7631-86-9.
- the Kollicoat® Protect can function as a binder (e.g., rapidly dissolving binder).
- the Kollicoat® Protect can optionally further function as a film-coating agent, disintegrating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF and/or elongation, anti-caking agent, or any combination thereof.
- peppermint refers to a hybrid mint, a cross between watermint and spearmint.
- Peppermint has a relatively high menthol content.
- the oil also contains menthone and carboxyl esters, particularly menthyl acetate.
- Dried peppermint typically has 0.3-0.4 wt. % of volatile oil containing menthol (7-48 wt. %), menthone (20-46 wt. %), menthyl acetate (3-10 wt. %), menthofuran (1-17 wt. %) and 1,8-cineol (3-6 wt. %).
- Peppermint oil can contain small amounts of many additional compounds including limonene, pulegone, caryophyllene and pinene. Peppermint can also contain terpenoids and flavonoids, such as eriocarpin, hesperidin, and kaempferol 7-O-rutinoside.
- the peppermint can be available as dried peppermint (e.g., spray dried peppermint powder) or as a liquid (e.g., peppermint oil). When present as a spray dried powder, the peppermint can include a combination of peppermint oil and carrier (e.g., 25 wt. % peppermint oil and 75 wt. % carrier).
- the peppermint can include, e.g., the product Natural Peppermint Flavor, which is commercially available as Product No. 501500 TPK0504 from Firmenich Inc. (Anaheim, Calif.); the product Natural Peppermint Oil, commercially available from A. M. Todd; or the product Natural and Artificial Peppermint, commercially available from Firmenich (Anaheim, Calif.).
- the peppermint can function as a flavoring agent.
- the peppermint can optionally further function as a taste masking agent, permeation enhancer, or a combination thereof.
- silicafil refers to the compound having the name 5- ⁇ 2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl ⁇ -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; CAS No. 139755-83-2, molecular formula C 22 H 30 N 6 O 4 S, and molar mass 474.5764 g/mol. The structural formula is provided below.
- sildenafil is described in standard references such as, e.g., The Physician's Desk Reference, 2018 Edition; The Merck Index, 15th Edition (2013); and United States Pharmacopeia (USP) (2016). Together with a pharmaceutically acceptable counter-ion, sildenafil is also available as a pharmaceutically acceptable salt, e.g., the citrate salt (CAS No. 171599-83-0, molecular formula .C 6 H 8 O 7 ).
- the sildenafil citrate present in the oral soluble film described herein functions as an active ingredient (e.g., the sole active ingredient).
- the oral soluble film (drug product) can be manufactured from sildenafil citrate (drug substance) having a desired bulk density and/or particle size distribution (PSD).
- the oral soluble film (drug product) can be manufactured from sildenafil citrate (drug substance) having a desired physical form (e.g., amorphous, or crystalline), hydrate, or solvate thereof.
- Sildenafil citrate is commercially available from, e.g., MSN Organics Private Ltd. (Telangana, India); Amoli Organics Pvt. Ltd. (Milan, Italy); Azico Biophore India Pvt. Ltd. (Hyderabad, India); Raks Pharma Pvt. Ltd. (Andhra Pradesh, India); and SMS Pharmaceuticals Ltd. (Hyderabad, India).
- sodium benzoate refers to the substance which has the chemical formula C 6 H 5 COONa; CAS No. 532-32-1; and molar mass 144.105 g/mol. When present in the oral soluble film described herein, the sodium benzoate can function as a preservative.
- FD&C Blue 1 refers to a synthetic organic compound used primarily as a blue colorant for processed foods, medications, dietary supplements, and cosmetics. It has the IUPAC name disodium; 2-[[4-[ethyl-[(3-sulfonatophenyl)methyl]amino]phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]benzenesulfonate. It is classified as a triarylmethane dye and is known under various names, such as FD&C Blue No. 1 or Acid Blue 9.
- E133 has a color index of 42090. It has the appearance of a blue powder and is soluble in water and glycerol, with a maximum absorption at about 628 nanometers. It is one of the oldest FDA-approved color additives and is generally considered nontoxic and safe. When present in the oral soluble film described herein, the FD&C Blue 1 can function as a colorant.
- acesulfame potassium or “ACE-K” refers to a calorie-free sugar substitute (artificial sweetener) having the IUPAC name potassium 6-methyl-2,2-dioxo-2H-1,2 ⁇ 6 ,3-oxathiazin-4-olate. In the European Union, it is known under the E number (additive code) E950. In chemical structure, acesulfame potassium is the potassium salt of 6-methyl-1,2,3-oxathiazine-4(3H)-one 2,2-dioxide. It is a white crystalline powder with molecular formula C 4 H 4 KNO 4 S and a molecular weight of 201.24 g/mol. When present in the oral soluble film described herein, the ACE-K can function as a sweetener.
- sucralose refers to an artificial sweetener and sugar substitute. In the European Union, it is also known under the E number E955. Sucralose has the IUPAC name 1,6-dichloro-1,6-dideoxy- ⁇ -D-fructofuranosyl-4-chloro-4-deoxy- ⁇ -D-galactopyranoside; CAS No. 56038-13-2; chemical formula C 12 H 19 Cl 3 O 8 ; and molar mass 397.64 g/mol. When present in the oral soluble film described herein, the sucralose can function as a sweetener.
- oral soluble film or “OSF” (and the equivalent terms such as “soluble film,” “orodispersible film,” “oral thin film,” “OTF,” “oral film,” “edible film,” “mucoadhesive film,” “mucoadhesive oral film,” “MOF,” “oral disintegrating film,” “oral dissolvable film,” “ODF,” etc.) refers to a soluble film specifically configured for oral administration.
- the term also includes “buccal film” (oral soluble film intended to be placed in the buccal space) and “sublingual film” (oral soluble film intended to be placed under the tongue).
- the oral soluble film is self-supporting, or in other words, is able to maintain its integrity and structure in the absence of a separate support.
- Oral soluble films are composed of pharmaceutically acceptable ingredients that are edible or ingestible.
- the oral soluble film can be configured for multi- or unidirectional release.
- OSFs can be similar in size and shape to a postage stamp, and are designed for oral administration, with the user placing the strip on the tongue (enteric), under the tongue (sublingual), through the oral mucosa (mucosal), against the inside of the cheek (buccal), or on the gums (gingival). Aside from the enteric route, these drug delivery options allow the medication to bypass the first pass metabolism thereby making the medication more bioavailable. As the film dissolves, the drug can enter the blood stream enterically, mucosally, buccally, gingivally, and/or sublingually.
- the oral soluble film is prepared using hydrophilic polymers that can dissolve on the tongue or buccal cavity, delivering the drug to the systemic circulation via dissolution when contact with liquid is made.
- Oral film drug delivery accordingly uses a dissolving film to administer drugs via absorption in the mouth (buccally, sublingually, or gingivally) and/or via the small intestines (enterically).
- oral films described herein can provide a faster-acting and better absorption profile.
- the oral soluble film can be shaped as being circular, round, oval, elliptical, or polygonal (e.g., triangular, square, or rectangular).
- the OSF can optionally include a logo and/or indicia located thereon.
- the logo and/or indicia can identify, e.g., the marketing company name, manufacturing company name, drug substance name, drug product name, strength, dosage form, route of administration, and/or product serialization.
- Such logo and/or indicia can be printed thereon, e.g., with pharmaceutically acceptable ink, or can be embossed.
- anhydrous film refers to an oral soluble film containing no significant or appreciable amount of water.
- reference to the weight percentage amount of water (moisture) present in an anhydrous film is essentially zero.
- an oral soluble film will likely include at least trace amounts of water—as the complete removal of the water during the curing phase is unlikely.
- the oral soluble film may pick up moisture during the packaging, shipment, and/or storage.
- substances e.g., excipients and API
- present in the orally soluble film described herein can be characterized by the weight percentage amount, based on an anhydrous film.
- hydrated film refers to an oral soluble film containing a significant and appreciable amount of water.
- the amount of water present in a hydrated film can be measured (e.g., loss on drying).
- unit dosage refers to an oral soluble film sized to the appropriate dimension, such that the individual film contains a desired amount of active ingredient to be administered to a subject for an intended use.
- the soluble film Prior to sizing to the appropriate dimension (thereby providing the unit dosage form), the soluble film can exist, e.g., in either the unwound form (e.g., sheet) or in the wound form (e.g., bulk roll).
- drug substance refers to the unformulated API (active pharmaceutical ingredient).
- the API has the therapeutic effect in the body as opposed to the excipients, which assist with the delivery of the API.
- the chemical purity and physical state can influence the quality and performance of a drug substance. This is especially important for water insoluble drugs.
- drug product refers to the formulated drug substance with excipients.
- the drug product is typically the final marketed dosage form of the drug substance, for example a tablet, capsule, or oral soluble film (OSF).
- a drug substance because of multiple factors (sensitivity, stability, etc.) is often mixed with other components before being released for use in the market.
- the drug substance together with the added ingredients (excipients) is known as drug product.
- the drug substance together with these added agents is called the drug product and within its packaging is called the “finished product.”
- drug load refers to the amount of active pharmaceutical ingredient present in the oral soluble film.
- the oral soluble film can have a high drug load, such that the active pharmaceutical ingredient is present in a relatively high amount (e.g., above 30 wt. %) of the oral soluble film.
- the drug load is expressed as
- binder load refers to the amount of binder (e.g., Kollicoat® Protect and MCC) present in the oral soluble film.
- the oral soluble film can have a high binder load, such that the binders are present, in the aggregate, in a relatively high amount (e.g., at least 25 wt. % of the oral soluble film).
- the oral soluble film can have a high binder load, such that the Kollicoat® binders are present, in the aggregate, in a relatively high amount (e.g., at least 30 wt. % of the oral soluble film).
- weight ratio refers to the weight ratio of two items.
- weight ratio of binder to API can be expressed as
- the weight ratio of binder to API is 83 ⁇ 10%. In further specific embodiments, the weight ratio of binder to API is 83 ⁇ 5%.
- CL/F refers to the apparent total clearance of drug from plasma after oral administration. It is measured in units of volume/time (mL/min) or in units of volume/time/kg (mL/min/kg).
- T max refers to time of maximum plasma concentration and is the time to reach maximum (peak) plasma concentration following drug administration. It is measured in units of time (hours).
- t 1/2 refers to elimination half-life and is time to reach elimination half-life (to be used in one or non-compartmental model). It is measured in units of time (hours).
- treating includes the administration of an active pharmaceutical ingredient (API), or a unit dosage form containing the same (e.g., oral soluble film), to a subject with the purpose of preventing, mitigating, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of the disease or disorder.
- the disease or disorder can be, e.g., erectile dysfunction (ED), antidepressant-induced erectile dysfunction (ED), or pulmonary arterial hypertension (PAH).
- ED erectile dysfunction
- impotence refers to the type of sexual dysfunction in which the penis fails to become or stay erect during sexual activity. It is the most common sexual problem in men. Through its connection to self-image and to problems in sexual relationships, erectile dysfunction can cause psychological harm. ED is characterized by the regular or repeated inability to achieve or maintain an erection of sufficient rigidity to accomplish sexual activity. ED often has an impact on the emotional well-being of both men and their partner(s). Many men do not seek treatment due to feelings of embarrassment. It is believed that about 75% of diagnosed cases of ED go untreated.
- kit refers to a system for delivering an oral soluble film as described herein, from one location to another.
- delivery systems can include enclosures that allow for the storage, transport, and/or delivery of an oral soluble film as described herein and any accompanying materials.
- the enclosure can be, e.g., a box or a bag.
- the accompanying materials can include, e.g., label, reference material, prescribing information, supporting material, or a combination thereof.
- the kit can include a single dose of the oral soluble film described herein, that is individually packaged and sealed with a primary packaging material.
- the kit can include multiple doses of the oral soluble film described herein, each of which is individually packaged and sealed with a primary packaging material.
- the kit can include an enclosure containing (i) multiple doses of the oral soluble film described herein, each individually packaged and sealed with a primary packaging material, and (ii) prescribing information.
- the primary packaging material can include at least one of metalized polyester, cellophane, polypropylene, nylon, polyester, vinylidene chloride, vinyl chloride, polycarbonate, low-density polyethylene, high-density polyethylene, linear low-density polyethylene, ionomer, polyvinyl alcohol, ethylene/vinyl acetate copolymer, ethylene/acrylic acid copolymer, ethylene/ethyl acrylate copolymer, polystyrene, and aluminum foil.
- the primary packaging material can include a single layer of material, or can include multiple layers of material (wherein each layer can independently include the same or different material as the other layers).
- the primary packaging material forms a primary package that can (i) protect the oral soluble film from light, (ii) protect the oral soluble film from microbial contamination, (iii) be child resistant, (iv) be a barrier to moisture and vapor, (v) mitigate leachable into the oral soluble film, (vi) identifies a logo and/or includes printed indicia, or (vii) any combination thereof.
- the logo and/or printed indicia can identify, e.g., the marketing company name, manufacturing company name, drug substance name, drug product name, strength, dosage form, route of administration, and/or product serialization.
- Prescribing information refers to information relevant to the drug product, that is generally drafted by the drug company and such information is approved by the FDA. It includes the details and directions healthcare providers need to prescribe the drug product properly. It is also the basis for how the drug company can advertise its drug product.
- the prescribing information includes such details about the drug product as: its chemical description; how it works; how it interacts with other drugs, supplements, foods, and beverages; what condition(s) or disease(s) it treats; who should not use the drug product; serious side effects, even if they occur rarely; commonly occurring side effects, even if they are not serious; and effects on specific groups of patients, such as children, pregnant women, or older adults and how to use it in these populations.
- the drug company drafts prescription drug information designed for patients that the FDA approves. These are often called “Patient Package Inserts,” “Patient Product Information,” or “PPIs.”
- drug company refers to the one or more companies that (i) markets the drug product (or retains ownership rights to the same), (ii) manufactures the drug product (or retains ownership rights to the same), and/or (iii) is the NDA applicant holder.
- the drug company can be a single company or can include separate, multiple companies.
- subject refers to living organisms such as humans, dogs, cats, and other mammals.
- Administration of the active ingredient included in the oral soluble film described herein can be carried out at dosages and for periods of time effective for the treatment of the subject.
- the subject is a human.
- the human subject can be a male or female, and can further be an adult, adolescent, child, toddler, or infant.
- the human subject can be a post-pubescent male, typically at least 18 years old.
- transmucosal refers to any route of administration via a mucosal membrane or mucosal surface. Examples include, but are not limited to, buccal, sublingual, nasal, vaginal, and rectal.
- buccal administration refers to a topical route of administration by which a drug held or applied in the buccal area (in the cheek) diffuses through the oral mucosa (tissues which line the mouth) and enters directly into the bloodstream.
- buccal administration may provide better bioavailability of some drugs and a more rapid onset of action compared to oral administration because the medication does not pass through the digestive system and thereby avoids first pass metabolism. In multiple instances, buccal administration has been found to avoid liver and GI toxicities.
- fascial space also termed the buccinator space
- fascial space refers to a fascial space of the head and neck (sometimes also termed fascial tissue spaces or tissue spaces). It is a potential space in the cheek, and is paired on each side.
- the buccal space is superficial to the buccinator muscle and deep to the platysma muscle and the skin.
- the buccal space is part of the subcutaneous space, which is continuous from head to toe.
- oral mucosa refers to the mucous membrane lining the inside of the mouth and consists of stratified squamous epithelium termed oral epithelium and an underlying connective tissue termed lamina intestinal.
- Oral mucosa can be divided into three main categories based on function and histology: (1) Masticatory mucosa, keratinized stratified squamous epithelium, found on the dorsum of the tongue, hard palate and attached gingiva; (2) Lining mucosa, nonkeratinized stratified squamous epithelium, found almost everywhere else in the oral cavity, including the: (a) Buccal mucosa refers to the inside lining of the cheeks and floor of the mouth and is part of the lining mucosa; (b) Labial mucosa refers to the inside lining of the lips and is part of the lining mucosa; and (c) Alveolar mucosa refers to the lining between the buccal and labi
- sublingual administration refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue. When a drug comes in contact with the mucous membrane beneath the tongue, it is absorbed. Because the connective tissue beneath the epithelium contains a profusion of capillaries, the substance then diffuses into them and enters the venous circulation. In contrast, substances absorbed in the intestines are subject to first-pass metabolism in the liver before entering the general circulation. Sublingual administration has certain advantages over oral administration.
- gingival administration refers to the pharmacological route of administration by which substances diffuse into the blood through tissues in the gums.
- the gums or gingiva consist of the mucosal tissue that lies over the mandible and maxilla inside the mouth.
- enteral administration refers to a drug administration via the human gastrointestinal tract. Enteral administration involves the esophagus, stomach, and small and large intestines (i.e., the gastrointestinal tract). Methods of administration include oral and rectal. Enteral administration may be divided into three different categories, depending on the entrance point into the GI tract: oral (by mouth), gastric (through the stomach), and rectal (from the rectum). (Gastric introduction involves the use of a tube through the nasal passage (NG tube) or a tube in the belly leading directly to the stomach (PEG tube).
- NG tube nasal passage
- PEG tube a tube in the belly leading directly to the stomach
- Rectal administration usually involves rectal suppositories.
- Enteral medications come in various forms, including, e.g., tablets to swallow, chew or dissolve in water; capsules and chewable capsules (with a coating that dissolves in the stomach or bowel to release the medication there), oral soluble films, time-release or sustained-release tablets and capsules (which release the medication gradually), osmotic delivery systems, powders or granules, and liquid medications or syrups.
- oral administration refers to a route of administration where a substance is taken through the mouth. Many medications are taken orally because they are intended to have a systemic effect, reaching different parts of the body via the bloodstream.
- moisture content refers to the quantity of water contained in an oral soluble film described herein.
- the moisture content can encompass bound water and unbound water.
- Water content is expressed as a ratio, which can range from 0 (completely dry) to the value of the soluble film's porosity at saturation. It can be given on a volumetric or mass (gravimetric) basis. Typically, the moisture content will be expressed as a weight percent (e.g., 4 wt. %). Water content can be directly measured using a drying oven.
- LOD loss on drying
- TGA Thermogravimetric Analysis
- IR Moisture Analyzers IR Moisture Analyzers.
- pharmaceutically acceptable refers to those compounds, excipients, active ingredients, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- disintegration refers to a physical process of breaking down a substance into fragments to improve its solubility in a solvent. The process is used predominantly in pharmaceutical and chemical industries. Disintegration occurs when a dosage form breaks up into smaller particles. It usually takes place in two steps; the content breaks up into small granules which then disaggregate. For oral soluble films, this breaking up process of the dosage form usually starts in the oral cavity, where it may be completed depending upon, e.g., the formulation, contact duration, volume of saliva, and whether or not taken with a beverage. If the dosage form passes into the stomach and then into the small intestine, then the process may continue there. Disintegration can usually be observed in the laboratory in a dissolution apparatus. Actual QC disintegration methods, however, use specific pieces of equipment described in USP ⁇ 701>.
- dissolution refers to a process through which solutes dissolve in a solvent. Dissolution is used predominantly in pharmaceutical industries to check how soluble a drug is in the body. Dissolution is a process through which a dosage form dissolves in a solvent to produce a solution. Dissolution requires disintegration of the dosage form to occur first, then drug particles to dissolve. It is the rate (amount of drug and time) at which the drug dissolves. In vivo dissolution of an oral soluble film starts as soon as the drug in the dosage form is wetted with saliva. There are many different dissolution apparatuses used to establish how much drug dissolves and how long this takes. The standard apparatus is also described in USP ⁇ 711>.
- bioavailability refers to a subcategory of absorption and is the fraction (%) of an administered drug that reaches the systemic circulation. Mathematically, bioavailability equals the ratio of comparing the area under the plasma drug concentration curve versus time (AUC) for the extravascular formulation to the AUC for the intravascular formulation. AUC can be utilized because AUC is proportional to the dose that has entered the systemic circulation.
- PK pharmacokinetics
- PD pharmacodynamics
- PK therefore refers to the study of the uptake of drugs by the body, the biotransformation they undergo, the distribution of the drugs and their metabolites in the tissues, and the elimination of the drugs and their metabolites from the body over a period of time.
- Dose Amount of drug administered Dosing interval Time between drug dose administrations.
- C max The peak plasma concentration of a drug after administration.
- T max Time to reach C max .
- C min The lowest (trough) concentration that a drug reaches before the next dose is administered.
- Volume of distribution The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body).
- Absorption half life The time required for the concentration of the drug to double its original value for oral and other extravascular routes.
- Absorption rate The rate at which a drug enters into the body constant for oral and other extravascular routes. Elimination half-life The time required for the concentration of the drug to reach half of its original value.
- Elimination rate The rate at which a drug is removed from constant (K EL ) the body.
- Infusion rate Rate of infusion required to balance elimination.
- Area under the curve The integral of the concentration-time curve (after a single dose or in steady state). Clearance The volume of plasma cleared of the drug per unit time.
- Bioavailability The systemically available fraction of a drug. Fluctuation Peak trough fluctuation within one dosing interval at steady state.
- curing refers to a chemical process that can be used to produce a soluble film (as described herein) from a slurry (also described herein). The process can be carried out by removing solvent (water), by toughening or hardening of polymer material present in the slurry, by cross-linking the polymer chains, etc.
- the term curing can be used to refer to the processes where starting from a liquid or semi-solid solution (e.g., slurry), a solid product (e.g., soluble film) is obtained. Curing can be initiated by heat, radiation, electron beams, or chemical additives. To quote from IUPAC: curing “might or might not require mixing with a chemical curing agent.” IUPAC.
- Mass refers to a measurement of how much matter is in an object. Mass is a combination of the total number of atoms, the density of the atoms, and the type of atoms in an object. Mass is usually measured in grams (which is abbreviated as g) or milligrams (which is abbreviated as mg).
- Density refers to the mass per unit volume of an object (e.g., oral soluble film). Density is calculated by dividing the mass of an object by the volume of the object. The volume of an object can be stated as cubic centimeters or milliliters as both are equivalent.
- tact refers to the tenacity with which the oral soluble film adheres to an accessory (a piece of paper) that has been pressed into contact with the film.
- tensile strength refers to the maximum stress applied to a point at which the oral soluble film specimen breaks. It is calculated by the applied load at rupture divided by the cross-sectional area of oral soluble film, as given in the equation below:
- percent elongation refers to the relative increase in amount in length upon application of stress. When stress is applied on a film sample, it gets stretched. This is referred to as strain. Strain is basically the deformation of film before it gets broken due to stress. It can be measured by using hounsfield universal testing machine. Generally, elongation of the film increases as the plasticizer content increases. It is calculated by the formula:
- tear resistance refers to the resistance which a film offers when some load or force is applied on the film specimen. Specifically, it is the maximum force required to tear the specimen.
- the load mainly applied can be of a very low rate (e.g., 51 mm/min).
- the unit of tear resistance is Newton or pounds-force.
- Young's modulus refers to the measure of stiffness of a soluble film. It is represented as the ratio of applied stress over strain in the region of elastic deformation as follows:
- Hard and brittle strips demonstrate a high tensile strength and Young's modulus with small elongation.
- folding endurance refers to number of times the film can be folded without breaking or without any visible crack. Folding endurance is a measure of the brittleness of a film. The method followed to determine endurance value is that the film specimen is repeatedly folded at the same place until it breaks, or a visible crack is observed. The number of times the film is folded without breaking or without any visible crack is the calculated folding endurance value.
- drug content uniformity refers to the degree of uniformity in the amount of drug substance among dosage units, and unless otherwise specified, is set forth in USP-NF General Chapter ⁇ 905> Uniformity of Dosage Units.
- substances present in the orally soluble film described herein are characterized by the weight percentage amount of substance present therein.
- the substance can be the active pharmaceutical ingredient and/or any one or more of the excipients.
- the weight percentage amount of substance present therein can be based on an anhydrous film (e.g., an orally soluble film containing no significant and appreciable amount of water).
- an anhydrous film e.g., an orally soluble film containing no significant and appreciable amount of water.
- a notable exception is reference to the weight percentage amount of water (moisture) present in the soluble film.
- reference to the weight percentage amount of water (or moisture) contained within the oral soluble film can be based on a hydrated (e.g., 5 ⁇ 1.5 wt. % hydrated) oral soluble film.
- an oral soluble film can be prepared from a slurry, in which an active ingredient (sildenafil citrate) is present in 70.24 mg per 195.10 mg (36.00 wt. %) of an anhydrous oral soluble film. This can be calculated as follows:
- the weight percentage amount of each excipient in the anhydrous oral soluble film can likewise be calculated. In order to arrive at these calculations, the water is not included in the mass of the oral soluble film.
- the active ingredient can be present in 16.8 wt. % of the slurry.
- the water is included in the mass of the slurry.
- the mass of the slurry (10,000 g) is obtained from the amount (mass) of all substances added to form the slurry, including the purified water added (5,328 g). This can be calculated as follows:
- the active ingredient can be present in 70.24 mg per 204.86 mg (34.29 wt. %) of a hydrated oral soluble film. This can be calculated as follows:
- the level of hydration of the hydrated film can be estimated (e.g., a 5% hydrated film). For that hydrated film, the requisite amount of water (e.g., 5 wt. %) is used to obtain the calculated amount of water (mg) in the hydrated film, as well as the calculated weight percentage amounts for each of the substances present in the hydrated film.
- the requisite amount of water e.g., 5 wt. % is used to obtain the calculated amount of water (mg) in the hydrated film, as well as the calculated weight percentage amounts for each of the substances present in the hydrated film.
- particle-size distribution refers to a list of values or a mathematical function that defines the relative amount, typically by mass, of particles present according to size.
- the mass-median-diameter (expressed as, e.g., d10, d50, d90, etc.) refers to the log-normal distribution mass median diameter.
- the MMD is considered to be the average particle diameter by mass.
- the particle size distribution can be obtained by, e.g., laser diffraction, analytical sieving, light scattering, etc.
- Particle size Distribution D10 (or d10) is also written as X10, D(0,1) or X(0,1). It represents the particle diameter corresponding to 10% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D10 is 7.8 um, then 10% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 10%. D10 is a typical point in particle size distribution analysis. D10 is also divided into Dv10, Dw10 and Dn10. Dv10 means volume D10, whereas Dw10 is mass D10 and Dn10 is number D10.
- Particle size Distribution D50 (or d50) is also written as X50, D(0,5) or X(0,5). It represents the particle diameter corresponding to 50% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D50 is 7.8 um, then 50% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 50%. D50 is a typical point in particle size distribution analysis. D50 is also divided into Dv50, Dw50 and Dn50. Dv50 means volume D50, whereas Dw50 is mass D50 and Dn50 is number D50.
- Particle size Distribution D90 (or d90) is also written as X90, D(0,9) or X(0,9). It represents the particle diameter corresponding to 90% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D90 is 7.8 um, then 90% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 90%. D90 is a typical point in particle size distribution analysis. D90 is also divided into Dv90, Dw90 and Dn90. Dv90 means volume D90, whereas Dw90 is mass D90 and Dn90 is number D90.
- the manufacture of oral soluble films can be carried out by various methods such as: (1) casting (e.g., solvent casting or semi-solid casting), (2) extrusion (e.g., hot melt extrusion or solid dispersion), and (3) rolling.
- casting e.g., solvent casting or semi-solid casting
- extrusion e.g., hot melt extrusion or solid dispersion
- the manufacturing process can start with dispensing the excipients, active ingredient and solvent(s) in a defined order, preferably into a temperature-controlled tank and blending them into a slurry, typically using a high shear mixer to achieve a homogenous slurry. Homogeneity of the slurry should be tested by sampling at different locations in the tank and measuring viscosity and solids content. Depending on the properties of the slurry (i.e., bacteriostatic, bactericidal or growth promoting), in-process bioburden testing may be employed. To ensure flexibility of production scheduling, optimal conditions for storing the slurry should be tested.
- the slurry may then be fed into an oven through a coating station, typically using a pump system.
- the slurry may be applied to a liner using a slot die or knife-over-roll coater, at a determined pin gauge.
- the selection of the liner can affect how the solvent (e.g., water) will evaporate and should generally be selected as to mitigate the occurrence of any chemical interaction with the film.
- Relevant parameters when selecting a liner are moisture content of the cast film, the location of the heat source and the directionality and strength of the air flow within the oven. It is generally preferred to “bake” the film rather than “broil” it.
- the liner will preferably be qualified by the FDA, e.g., having its own drug master file (DMF).
- Some oven systems enable the operator to control the height and directionality of the air nozzles and offer modular heat zones (e.g., infrared, progressive temperature increase).
- Oven lengths generally range from 10 ft to 24 ft, or more.
- the film and liner may then be packed as master rolls at the terminal end of the oven and should be stored in a temperature and humidity-controlled environment as oral soluble films tend to be hygroscopic.
- Stability of the intermediate master rolls over time may be established by evaluating API content, moisture levels, physical characteristics, pliability dissolution, microbiology, and tensile strength.
- oral soluble film products are stable at room temperature in an appropriate container closure system.
- additional API and/or occluding layer can be sprayed onto the cast film.
- the film can be 3D printed instead of casting.
- Another step in the production is cutting the master roll into daughter rolls (alternatively referred to as “sitting”) and further into single doses which can be placed into individual pouches or sachets by converting and packaging machines.
- Ink printing of a mark on the film can be carried out.
- the mark can include a logo or indicia, such as the company name and dosage (e.g., “CURR50”—corresponding to Cure Pharmaceutical Holding Corp. (OTC:CURR), and 50 mg sildenafil).
- the ink is preferably pharmaceutically acceptable and will not interfere with the performance characteristics (e.g., disintegration time) of the OSF.
- the API dose of an oral soluble film product is directly informed by the weight of the film.
- Metalized polyester is a suitable primary packaging material for oral soluble film. It can be cost effective and protects the product from moisture and light.
- This pouch material can be child resistant and closure systems can be designed to ensure the product passes child resistant testing, while remaining user friendly for the patient.
- the pouches or sachets can offer larger printable 2D areas which traditional drug product formats do not. This allows the manufacturer to adapt to rapidly evolving labeling and regulatory requirements for information and anti-counterfeiting, such as product serialization.
- the primary package can provide sufficient space to include instructions on how to open the package and use the product, so that patients have a clear understanding of how it works. If desirable, each OSF can be individually packaged.
- One supplier of commercially available primary packaging materials is Bemis Company, Inc. (Neenah, Wis.).
- the manufacturing of oral soluble films can be a continuous but modular process that is suitable to automation.
- the modularity of the process such as master roll holds, allows for finished conversion to be done in the country or region of distribution, which compliments satellite expansion based on regional demand.
- the manufacturing process can have a low carbon footprint, with lower use of water for component preparation, as compared with other dosage forms.
- the sildenafil citrate is present in 36 ⁇ 10 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 9 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 8 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 7 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 6 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 5 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 4 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 3 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 2 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 1 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 0.5 wt. % of the oral soluble film.
- the sildenafil citrate is present in 36 ⁇ 0.25 wt. % of the oral soluble film.
- the sildenafil citrate is present in 34.29 ⁇ 10 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 9 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 8 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 7 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 6 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 4 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sildenafil citrate is present in 34.29 ⁇ 0.25 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 9 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 8 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 7 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 1 mg.
- the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24 ⁇ 0.5 mg.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 25 mg, 50 mg, or 100 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 22.5-27.5 mg of sildenafil, as the free base.
- the sildenafil citrate is present in an amount of up to 0.30 mg/mm 3 .
- the sildenafil citrate is present in an amount of at least 0.20 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.06 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.05 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.04 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.03 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.02 mg/mm 3 .
- the sildenafil citrate is present in an amount of 0.24 ⁇ 0.01 mg/mm 3 .
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 25 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 45-55 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 50 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 50 ⁇ 5 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 90-110 mg of sildenafil, as the free base.
- the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 100 mg of sildenafil, as the free base.
- the oral soluble film includes non-non-micronized sildenafil citrate.
- the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(10) of less than 2 ⁇ m.
- PSD particle size distribution
- the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(50) of less than 5 ⁇ m.
- PSD particle size distribution
- the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(90) of less than 60 ⁇ m.
- PSD particle size distribution
- the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(90) of less than 35 ⁇ m.
- PSD particle size distribution
- the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(10) of less than 2 ⁇ m, Dv(50) of less than 5 ⁇ m, and Dv(90) of less than 35 ⁇ m.
- PSD particle size distribution
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 3 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 2.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 2 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 1.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8 ⁇ 0.5 wt. % of the slurry.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 20 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 15 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 10 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 5 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 2.5 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 1 wt. %.
- the variation of sildenafil citrate between two equally sized unit dosages is less than 0.5 wt. %.
- the binder is present in 30 ⁇ 10 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 9 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 8 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 7 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 6 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 5 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 4 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 3 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 2 wt. % of the oral soluble film.
- the binder is present in 30 ⁇ 1 wt. % of the oral soluble film.
- the binder is present in 28.57 ⁇ 10 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 9 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 8 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 7 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 6 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 4 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the binder is present in 28.57 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 18 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 16 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 14 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 12 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 8 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 7 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the binder is present in 58.53 ⁇ 4 mg.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 3 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 2.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 2 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 1.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the binder is present in 14.1 ⁇ 0.5 wt. % of the slurry.
- the binder includes Kollicoat® Protect.
- the binder includes Kollicoat® Protect, which includes: Kollicoat® IR, polyvinylalcohol, and silicon dioxide.
- the binder includes (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide.
- PVA polyvinyl alcohol
- PVA polyvinyl alcohol
- PEG polyethylene glycol
- the Kollicoat® Protect functions as a binder.
- the Kollicoat® Protect functions as a binder and at least one of a film-coating agent, disintegrating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF and/or elongation, and anti-caking agent.
- the Kollicoat® Protect is present in 30 ⁇ 10 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 9 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 8 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 7 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 6 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 5 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 4 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 3 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 2 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 30 ⁇ 1 wt. % of the oral soluble film.
- the Kollicoat® Protect is present in 28.57 ⁇ 10 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 9 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 8 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 7 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 6 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 4 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the Kollicoat® Protect is present in 28.57 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 18 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 16 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 14 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 12 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 8 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 7 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53 ⁇ 4 mg.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 3 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 2.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 2 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 1.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1 ⁇ 0.5 wt. % of the slurry.
- the filler is present in 5.45 ⁇ 2.5 wt. % of the oral soluble film.
- the filler is present in 5.45 ⁇ 2 wt. % of the oral soluble film.
- the filler is present in 5.45 ⁇ 1.5 wt. % of the oral soluble film.
- the filler is present in 5.19 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 1.25 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 0.75 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the filler is present in 5.19 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the filler is present in 10.63 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the filler is present in 10.63 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the filler is present in 10.63 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the filler is present in 10.63 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the filler is present in 10.63 ⁇ 1 mg.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the filler is present in 2.5 ⁇ 0.1 wt. % of the slurry.
- the filler includes microcrystalline cellulose.
- the microcrystalline cellulose functions as a filler and binder.
- the microcrystalline cellulose functions as a filler and binder, and at least one of an anti-caking agent, emulsifier, bulking agent, and viscosity increasing agent.
- the microcrystalline cellulose is present in 5.45 ⁇ 2.5 wt. % of the oral soluble film.
- the microcrystalline cellulose is present in 5.45 ⁇ 2 wt. % of the oral soluble film.
- the microcrystalline cellulose is present in 5.45 ⁇ 1.5 wt. % of the oral soluble film.
- the microcrystalline cellulose is present in 5.45 ⁇ 1 wt. % of the oral soluble film.
- the microcrystalline cellulose is present in 5.45 ⁇ 0.5 wt. % of the oral soluble film.
- the microcrystalline cellulose is present in 5.19 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the microcrystalline cellulose is present in 5.19 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the microcrystalline cellulose is present in 5.19 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the microcrystalline cellulose is present in 5.19 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the microcrystalline cellulose is present in 5.19 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63 ⁇ 1 mg.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5 ⁇ 0.1 wt. % of the slurry.
- the flavoring agent is present in 6.44 ⁇ 3.5 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 3 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 2.5 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 2 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 1.5 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 1.25 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 1 wt. % of the oral soluble film.
- the flavoring agent is present in 6.44 ⁇ 0.5 wt. % of the oral soluble film.
- the flavoring agent is present in 6.13 ⁇ 3.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 1.25 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the flavoring agent is present in 6.13 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 3.5 mg.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 2.5 mg.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56 ⁇ 1.5 mg.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0 ⁇ 0.1 wt. % of the slurry.
- the flavoring agent includes spearmint flavoring.
- the flavoring agent includes orange flavoring.
- the flavoring agent includes vanilla cream flavoring.
- the flavoring agent includes peppermint flavoring.
- the peppermint flavoring functions as a flavoring agent and at least one of a taste masking agent and permeation enhancer.
- the peppermint flavoring is present in 6.44 ⁇ 3.5 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 3 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 2.5 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 2 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 1.5 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 1.25 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 1 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.44 ⁇ 0.5 wt. % of the oral soluble film.
- the peppermint flavoring is present in 6.13 ⁇ 3.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 1.25 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the peppermint flavoring is present in 6.13 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 3.5 mg.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 2.5 mg.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56 ⁇ 1.5 mg.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0 ⁇ 0.1 wt. % of the slurry.
- the plasticizer is present in 12 ⁇ 4 wt. % of the oral soluble film.
- the plasticizer is present in 12 ⁇ 3.5 wt. % of the oral soluble film.
- the plasticizer is present in 12 ⁇ 2.5 wt. % of the oral soluble film.
- the plasticizer is present in 12 ⁇ 2 wt. % of the oral soluble film.
- the plasticizer is present in 12 ⁇ 1.5 wt. % of the oral soluble film.
- the plasticizer is present in 12 ⁇ 0.5 wt. % of the oral soluble film.
- the plasticizer is present in 11.43 ⁇ 4 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 3.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the plasticizer is present in 11.43 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 12 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 8 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41 ⁇ 2 mg.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6 ⁇ 0.1 wt. % of the slurry.
- the plasticizer includes glycerin.
- the glycerin functions as a plasticizer and at least one of a sweetener, humectant, solvent, thickening agent, and lubricant.
- the glycerin is present in 12 ⁇ 4 wt. % of the oral soluble film.
- the glycerin is present in 12 ⁇ 3.5 wt. % of the oral soluble film.
- the glycerin is present in 12 ⁇ 2.5 wt. % of the oral soluble film.
- the glycerin is present in 12 ⁇ 2 wt. % of the oral soluble film.
- the glycerin is present in 12 ⁇ 1.5 wt. % of the oral soluble film.
- the glycerin is present in 12 ⁇ 0.5 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 4 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 3.5 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 2.5 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 2 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 1.5 wt. % of the oral soluble film.
- the glycerin is present in 11.43 ⁇ 0.5 wt. % of the oral soluble film.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 12 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 8 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the glycerin is present in 23.41 ⁇ 2 mg.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 1.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6 ⁇ 0.25 wt. % of the slurry.
- the sweetening agent is present in 10 ⁇ 4 wt. % of the oral soluble film.
- the sweetening agent is present in 10 ⁇ 3 wt. % of the oral soluble film.
- the sweetening agent is present in 10 ⁇ 2 wt. % of the oral soluble film.
- the sweetening agent is present in 10 ⁇ 1.5 wt. % of the oral soluble film.
- the sweetening agent is present in 10 ⁇ 1 wt. % of the oral soluble film.
- the sweetening agent is present in 10 ⁇ 0.5 wt. % of the oral soluble film.
- the sweetening agent is present in 9.51 ⁇ 4 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent is present in 9.51 ⁇ 3 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent is present in 9.51 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent is present in 9.51 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent is present in 9.51 ⁇ 1 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent is present in 9.51 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5 ⁇ 6 mg.
- the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5 ⁇ 2 mg.
- the sweetening agent includes sucralose and acesulfame potassium (ACE-K).
- the sweetening agent includes sucralose.
- the sweetening agent includes sucralose, present in 6.0 ⁇ 2.5 wt. % of the oral soluble film.
- the sweetening agent includes sucralose, present in 6.0 ⁇ 2 wt. % of the oral soluble film.
- the sweetening agent includes sucralose, present in 6.0 ⁇ 1.5 wt. % of the oral soluble film.
- the sweetening agent includes sucralose, present in 6.0 ⁇ 1.0 wt. % of the oral soluble film.
- the sweetening agent includes sucralose, present in 6.0 ⁇ 0.5 wt. % of the oral soluble film.
- the sweetening agent includes sucralose, present in 5.71 ⁇ 2.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent includes sucralose, present in 5.71 ⁇ 2 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent includes sucralose, present in 5.71 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent includes sucralose, present in 5.71 ⁇ 1.0 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the sweetening agent includes sucralose, present in 5.71 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose and the sucralose is present in 11.7 ⁇ 3.0 mg.
- the oral soluble film is configured as a unit dose and the sucralose is present in 11.7 ⁇ 2.5 mg.
- the oral soluble film is configured as a unit dose and the sucralose is present in 11.7 ⁇ 2.0 mg.
- the oral soluble film is configured as a unit dose and the sucralose is present in 11.7 ⁇ 1.5 mg.
- the oral soluble film is configured as a unit dose and the sucralose is present in 11.7 ⁇ 0.5 mg.
- the sweetening agent includes acesulfame potassium (ACE-K).
- the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00 ⁇ 1.5 wt. % of the oral soluble film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00 ⁇ 1.25 wt. % of the oral soluble film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00 ⁇ 1.0 wt. % of the oral soluble film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00 ⁇ 0.75 wt. % of the oral soluble film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00 ⁇ 0.5 wt. % of the oral soluble film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80 ⁇ 1.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80 ⁇ 1.25 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80 ⁇ 1.0 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80 ⁇ 0.75 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- ACE-K acesulfame potassium
- the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80 ⁇ 0.5 wt. % of the oral soluble film, based on a 5 ⁇ 1.5 wt. % hydrated film.
- ACE-K acesulfame potassium
- the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80 ⁇ 2.5 mg.
- ACE-K acesulfame potassium
- the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80 ⁇ 2.0 mg.
- ACE-K acesulfame potassium
- the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80 ⁇ 1.5 mg.
- ACE-K acesulfame potassium
- the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80 ⁇ 1.0 mg.
- ACE-K acesulfame potassium
- the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80 ⁇ 0.5 mg.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 1.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66 ⁇ 0.1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8 ⁇ 0.75 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8 ⁇ 0.5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8 ⁇ 0.25 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8 ⁇ 0.15 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8 ⁇ 0.1 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.75 wt. % of the slurry.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.5 wt. % of the slurry.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.4 wt. % of the slurry.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.3 wt. % of the slurry.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.2 wt. % of the slurry.
- ACE-K acesulfame potassium
- the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86 ⁇ 0.1 wt. % of the slurry.
- ACE-K acesulfame potassium
- the coloring agent is absent.
- the coloring agent is present.
- the coloring agent is present in 0.01 ⁇ 0.005 wt. % of the oral soluble film.
- the coloring agent is present in 0.01 ⁇ 0.004 wt. % of the oral soluble film.
- the coloring agent is present in 0.01 ⁇ 0.003 wt. % of the oral soluble film.
- the coloring agent is present in 0.01 ⁇ 0.002 wt. % of the oral soluble film.
- the coloring agent is present in 0.01 ⁇ 0.001 wt. % of the oral soluble film.
- the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02 ⁇ 0.007 mg.
- the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02 ⁇ 0.006 mg.
- the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02 ⁇ 0.005 mg.
- the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02 ⁇ 0.004 mg.
- the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02 ⁇ 0.003 mg.
- the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005 ⁇ 0.001 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005 ⁇ 0.0007 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005 ⁇ 0.0005 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005 ⁇ 0.0003 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005 ⁇ 0.0001 wt. % of the slurry.
- the coloring agent includes at least one FD&C color.
- the coloring agent includes FD&C Blue.
- the coloring agent includes FD&C Blue 1.
- the FD&C Blue 1 is present in 0.01 ⁇ 0.005 wt. % of the oral soluble film.
- the FD&C Blue 1 is present in 0.01 ⁇ 0.004 wt. % of the oral soluble film.
- the FD&C Blue 1 is present in 0.01 ⁇ 0.003 wt. % of the oral soluble film.
- the FD&C Blue 1 is present in 0.01 ⁇ 0.002 wt. % of the oral soluble film.
- the FD&C Blue 1 is present in 0.01 ⁇ 0.001 wt. % of the oral soluble film.
- the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02 ⁇ 0.007 mg.
- the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02 ⁇ 0.006 mg.
- the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02 ⁇ 0.005 mg.
- the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02 ⁇ 0.004 mg.
- the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02 ⁇ 0.003 mg.
- the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005 ⁇ 0.001 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005 ⁇ 0.0007 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005 ⁇ 0.0005 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005 ⁇ 0.0003 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005 ⁇ 0.0001 wt. % of the slurry.
- the preservative is present in 0.10 ⁇ 0.06 wt. % of the oral soluble film.
- the preservative is present in 0.10 ⁇ 0.05 wt. % of the oral soluble film.
- the preservative is present in 0.10 ⁇ 0.04 wt. % of the oral soluble film.
- the preservative is present in 0.10 ⁇ 0.03 wt. % of the oral soluble film.
- the preservative is present in 0.10 ⁇ 0.02 wt. % of the oral soluble film.
- the preservative is present in 0.10 ⁇ 0.01 wt. % of the oral soluble film.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.08 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.07 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.06 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.05 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.04 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.03 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.02 mg.
- the oral soluble film is configured as a unit dose and the preservative is present in 0.20 ⁇ 0.01 mg.
- the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05 ⁇ 0.01 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05 ⁇ 0.007 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05 ⁇ 0.005 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05 ⁇ 0.003 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05 ⁇ 0.001 wt. % of the slurry.
- the preservative includes sodium benzoate.
- the sodium benzoate is present in 0.10 ⁇ 0.06 wt. % of the oral soluble film.
- the sodium benzoate is present in 0.10 ⁇ 0.05 wt. % of the oral soluble film.
- the sodium benzoate is present in 0.10 ⁇ 0.04 wt. % of the oral soluble film.
- the sodium benzoate is present in 0.10 ⁇ 0.03 wt. % of the oral soluble film.
- the sodium benzoate is present in 0.10 ⁇ 0.02 wt. % of the oral soluble film.
- the sodium benzoate is present in 0.10 ⁇ 0.01 wt. % of the oral soluble film.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.08 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.07 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.06 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.05 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.04 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.03 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.02 mg.
- the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20 ⁇ 0.01 mg.
- the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05 ⁇ 0.01 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05 ⁇ 0.007 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05 ⁇ 0.005 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05 ⁇ 0.003 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05 ⁇ 0.001 wt. % of the slurry.
- the solvent includes water.
- the water content of the hydrated oral soluble film is 4.5 ⁇ 2 wt. %.
- the water content of the hydrated oral soluble film is 4.5 ⁇ 1.5 wt. %.
- the water content of the hydrated oral soluble film is 4.5 ⁇ 1 wt. %.
- the water content of the hydrated oral soluble film is 4.5 ⁇ 0.5 wt. %.
- the water content of the hydrated oral soluble film is 4.5 ⁇ 0.25 wt. %.
- the water content of the hydrated oral soluble film is 4 ⁇ 2 wt. %.
- the water content of the hydrated oral soluble film is 4 ⁇ 1.5 wt. %.
- the water content of the hydrated oral soluble film is 4 ⁇ 1 wt. %.
- the water content of the hydrated oral soluble film is 4 ⁇ 0.5 wt. %.
- the water content of the hydrated oral soluble film is 4 ⁇ 0.25 wt. %.
- the oral soluble film is configured as a unit dose and the water is present in 9.76 ⁇ 4 mg.
- the oral soluble film is configured as a unit dose and the water is present in 9.76 ⁇ 3 mg.
- the oral soluble film is configured as a unit dose and the water is present in 9.76 ⁇ 2.25 mg.
- the oral soluble film is configured as a unit dose and the water is present in 9.76 ⁇ 2 mg.
- the oral soluble film is configured as a unit dose and the water is present in 9.76 ⁇ 1.5 mg.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 12 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 11 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 10 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 9 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 7 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 5 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 3 wt. % of the slurry.
- the oral soluble film is obtained from a slurry wherein the water is present in 53.3 ⁇ 1 wt. % of the slurry.
- the oral soluble film is essentially free of a saliva stimulating agent, release modifier, adjuvant, fragrant, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant.
- the oral soluble film is essentially free of a saliva stimulating agent.
- the oral soluble film is essentially free of a release modifier.
- the oral soluble film is essentially free of an adjuvant.
- the oral soluble film is essentially free of a fragrant.
- the oral soluble film is essentially free of a surfactant.
- the oral soluble film is essentially free of a pH adjusting agent.
- the oral soluble film is essentially free of a buffering agent.
- the oral soluble film is essentially free of a stabilizer.
- the oral soluble film is essentially free of an antioxidant.
- the oral soluble film further includes at least one of a saliva stimulating agent, release modifier, adjuvant, fragrant, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant.
- the oral soluble film further includes a saliva stimulating agent.
- the oral soluble film further includes a release modifier.
- the oral soluble film further includes an adjuvant.
- the oral soluble film further includes a fragrant.
- the oral soluble film further includes a surfactant.
- the oral soluble film further includes a pH adjusting agent.
- the oral soluble film further includes a buffering agent.
- the oral soluble film further includes a stabilizer.
- the oral soluble film further includes an antioxidant.
- the oral soluble film further includes pharmaceutically acceptable ink.
- the oral soluble film further includes pharmaceutically acceptable ink, used to print a logo or indicia thereon.
- the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.10 wt. % of the oral soluble film.
- the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.05 wt. % of the oral soluble film.
- the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.01 wt. % of the oral soluble film.
- the oral soluble film is an anhydrous film.
- the oral soluble film is a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 1.25 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 1.1 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 1 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 0.85 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 0.75 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 0.5 wt. % hydrated film.
- the oral soluble film is a 5 ⁇ 0.25 wt. % hydrated film.
- the oral soluble film is a 5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose having a mass of 195.1 ⁇ 25 mg.
- the oral soluble film is configured as a unit dose having a mass of 195.1 ⁇ 20 mg.
- the oral soluble film is configured as a unit dose having a mass of 195.1 ⁇ 15 mg.
- the oral soluble film is configured as a unit dose having a mass of 195.1 ⁇ 10 mg.
- the oral soluble film is configured as a unit dose having a mass of 195.1 ⁇ 5 mg.
- the oral soluble film is configured as a unit dose having a mass of 204.9 ⁇ 25 mg, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose having a mass of 204.9 ⁇ 20 mg, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose having a mass of 204.9 ⁇ 15 mg, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose having a mass of 204.9 ⁇ 10 mg, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film is configured as a unit dose having a mass of 204.9 ⁇ 5 mg, based on a 5 ⁇ 1.5 wt. % hydrated film.
- the oral soluble film dissolves within 90 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves within 75 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves within 60 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves within 45 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves within 30 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves within 20 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 5-90 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 10-90 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 15-90 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 5-75 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 10-75 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 15-75 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 5-60 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 10-60 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 15-60 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 20-60 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 5-45 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 10-45 seconds upon contact with an oral mucosal surface.
- the oral soluble film dissolves in 15-45 seconds upon contact with an oral mucosal surface.
- the oral soluble film has a breaking strength of 8-12 N.
- the oral soluble film has a breaking strength of 10 ⁇ 3 N.
- the oral soluble film has a breaking strength of 10 ⁇ 2 N.
- the oral soluble film has a breaking strength of 10 ⁇ 1 N.
- the oral soluble film has an elongation strength of 2-4 mm.
- the oral soluble film has an elongation strength of 3 ⁇ 1 mm.
- the oral soluble film has an elongation strength of 3 ⁇ 0.5 mm.
- the oral soluble film has a pH of 3.8-4.7.
- the oral soluble film has a pH of 4.0-4.5.
- the oral soluble film has a pH of 4.1-4.4.
- the oral soluble film has a density of 0.006-0.009 g/cm 3 .
- the oral soluble film has a density of 0.0065-0.0085 g/cm 3 .
- the oral soluble film has a density of 0.007 ⁇ 0.0012 g/cm 3 .
- the oral soluble film has a density of 0.007 ⁇ 0.1 g/cm 3 .
- the oral soluble film has a density of 0.007 ⁇ 0.0008 g/cm 3 .
- the oral soluble film has a density of 0.007 ⁇ 0.0006 g/cm 3 .
- the oral soluble film has a loss on drying (LOD) of 7 ⁇ 5 wt. %.
- the oral soluble film has a loss on drying (LOD) of 7 ⁇ 4 wt. %.
- the oral soluble film has a loss on drying (LOD) of 7 ⁇ 3 wt. %.
- the oral soluble film has a loss on drying (LOD) of 7 ⁇ 2 wt. %.
- the oral soluble film has a loss on drying (LOD) of 7 ⁇ 1 wt. %.
- the oral soluble film has a loss on drying (LOD) of 5 ⁇ 3 wt. %.
- the oral soluble film has a loss on drying (LOD) of 5 ⁇ 2 wt. %.
- the oral soluble film has a loss on drying (LOD) of 5 ⁇ 1 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 1.5 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 1.25 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 1 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 0.75 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 0.5 wt. %.
- the oral soluble film has a loss on drying (LOD) of 3.5 ⁇ 0.25 wt. %.
- the oral soluble film has a loss on drying (LOD) of less than 5 wt. %.
- the oral soluble film has a loss on drying (LOD) of less than 4 wt. %.
- the oral soluble film has a loss on drying (LOD) of less than 3 wt. %.
- the oral soluble film is formed from a slurry having a density of 0.60-0.90 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.65-0.85 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.725 ⁇ 0.12 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.725 ⁇ 0.10 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.725 ⁇ 0.08 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.725 ⁇ 0.06 g/cm 3 .
- the oral soluble film is formed from a slurry having a density of 0.725 ⁇ 0.05 g/cm 3 .
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 1,500 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 1,250 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 1,000 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 750 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 500 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 250 centipoise (cP).
- oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000 ⁇ 100 centipoise (cP).
- the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 90 wt. % at 5 minutes.
- USP apparatus 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 90 wt. % at 5 minutes.
- the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 95 wt. % release at 5 minutes.
- USP apparatus 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 95 wt. % release at 5 minutes.
- the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 90 wt. % at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- USP apparatus 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 90 wt. % at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 95 wt. % release at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- USP apparatus 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37 ⁇ 0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 95 wt. % release at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- the oral soluble film is mucoadhesive, such that upon oral administration, the oral soluble film adheres to a surface of the oral cavity.
- the oral soluble film is configured as individual unit doses.
- the oral soluble film is configured as a bulk roll.
- the oral soluble film is configured as a self-supporting film-dosage form.
- the oral soluble film is configured as a unit dose.
- the oral soluble film is configured in an unwound form.
- the oral soluble film is configured as a sheet.
- the oral soluble film is cut from a self-supporting film.
- the oral soluble film is configured in a wound form.
- the oral soluble film is configured as a bulk roll.
- the oral soluble film is a monolayer film.
- the oral soluble film is configured as a unit dose having the dimensions 22 ⁇ 3 ⁇ 38 ⁇ 4 ⁇ 0.35 ⁇ 0.06 mm.
- the oral soluble film is configured as a unit dose having the dimensions 22 ⁇ 3 ⁇ 19 ⁇ 2 ⁇ 0.35 ⁇ 0.06 mm.
- the oral soluble film is configured as a unit dose having a width of 22 ⁇ 4 mm.
- the oral soluble film is configured as a unit dose having a width of 22 ⁇ 3 mm.
- the oral soluble film is configured as a unit dose having a width of 22 ⁇ 2 mm.
- the oral soluble film is configured as a unit dose having a width of 22 ⁇ 1 mm.
- the oral soluble film is configured as a unit dose having a width of 22 mm.
- the oral soluble film is configured as a unit dose having a length of 38 ⁇ 5 mm.
- the oral soluble film is configured as a unit dose having a length of 38 ⁇ 4 mm.
- the oral soluble film is configured as a unit dose having a length of 38 ⁇ 3 mm.
- the oral soluble film is configured as a unit dose having a length of 38 ⁇ 2 mm.
- the oral soluble film is configured as a unit dose having a length of 38 ⁇ 1 mm.
- the oral soluble film is configured as a unit dose having a length of 38 mm.
- the oral soluble film is configured as a unit dose having a length of 19 ⁇ 5 mm.
- the oral soluble film is configured as a unit dose having a length of 19 ⁇ 4 mm.
- the oral soluble film is configured as a unit dose having a length of 19 ⁇ 3 mm.
- the oral soluble film is configured as a unit dose having a length of 19 ⁇ 2 mm.
- the oral soluble film is configured as a unit dose having a length of 19 ⁇ 1 mm.
- the oral soluble film is configured as a unit dose having a length of 19 mm.
- the oral soluble film has a thickness of 0.40 ⁇ 0.05 mm.
- the oral soluble film has a thickness of 0.40 ⁇ 0.04 mm.
- the oral soluble film has a thickness of 0.40 ⁇ 0.03 mm.
- the oral soluble film has a thickness of 0.40 ⁇ 0.02 mm.
- the oral soluble film has a thickness of 0.40 ⁇ 0.01 mm.
- the oral soluble film has a thickness of 0.40 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.07 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.06 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.05 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.04 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.03 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.02 mm.
- the oral soluble film has a thickness of 0.35 ⁇ 0.01 mm.
- the oral soluble film has a thickness of 0.35 mm.
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 175 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 150 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 125 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 100 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 75 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 50 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 25 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 10 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 ⁇ 5 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 836 mm.
- the oral soluble film is configured as a unit dose having a surface area of 418 ⁇ 75 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 418 ⁇ 50 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 418 ⁇ 25 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 418 ⁇ 10 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 418 ⁇ 5 mm 2 .
- the oral soluble film is configured as a unit dose having a surface area of 418 mm 2 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 60 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 50 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 40 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 30 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 20 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 10 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 292.6 ⁇ 5 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 30 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 25 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 20 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 15 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 10 mm 3 .
- the oral soluble film is configured as a unit dose having a volume of 143.3 ⁇ 5 mm 3 .
- the oral soluble film exhibits a high stability, such that at least 90 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25 ⁇ 2° C., relative humidity (RH) 60 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- the oral soluble film exhibits a high stability, such that at least 92.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25 ⁇ 2° C., relative humidity (RH) 60 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- the oral soluble film exhibits a high stability, such that at least 95 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25 ⁇ 2° C., relative humidity (RH) 60 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- the oral soluble film exhibits a high stability, such that at least 97.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25 ⁇ 2° C., relative humidity (RH) 60 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- the oral soluble film exhibits a high stability, such that at least 90 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40 ⁇ 2° C., relative humidity (RH) 75 ⁇ 5%, over a period of time of >6 months.
- the oral soluble film exhibits a high stability, such that at least 92.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40 ⁇ 2° C., relative humidity (RH) 75 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- the oral soluble film exhibits a high stability, such that at least 95 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40 ⁇ 2° C., relative humidity (RH) 75 ⁇ 5%, over a period of time of >6 months.
- the oral soluble film exhibits a high stability, such that at least 97.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40 ⁇ 2° C., relative humidity (RH) 75 ⁇ 5%, over a period of time of >6 months.
- RH relative humidity
- oral soluble film e.g., 100 ⁇ 20% absorption of sildenafil citrate.
- sildenafil citrate e.g., Viagra®
- oral soluble film e.g., a tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®)
- administration of the oral soluble film provides 100 ⁇ 15% absorption of sildenafil citrate.
- oral soluble film e.g., a tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®)
- administration of the oral soluble film provides 100 ⁇ 10% absorption of sildenafil citrate.
- oral soluble film results in a lower incidence, severity, and/or duration of adverse reactions, including any one or more of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
- adverse reactions including any one or more of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
- oral soluble film results in a lower incidence, severity, and/or duration of adverse reactions, including each of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
- sildenafil citrate e.g., Viagra®
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes the following:
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean C MAX (ng/mL) of 396.227 ⁇ 79.245.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean C MAX (ng/mL) of 396.227.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC 0 ⁇ t (hr*ng/mL) of 1,426.893 ⁇ 285.379.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC 0 ⁇ t (hr*ng/mL) of 1,426.893.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC 0 ⁇ inf (hr*ng/mL) of 1,524.433 ⁇ 304.889.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC 0 ⁇ inf (hr*ng/mL) of 1,524.433.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T MAX (hr) of 1.088 ⁇ 0.218.
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T MAX (hr) of 1.088.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T 1/2 (hr) of 3.783 ⁇ 0.757.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T 1/2 (hr) of 3.783.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean K EL (1/hr) of 0.211 ⁇ 0.042.
- PK pharmacokinetic
- the oral soluble film upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean K EL (1/hr) of 0.211.
- PK pharmacokinetic
- the active ingredient is selected in an amount, shown below.
- Oral tablets Amount of active having an Active Indication & ingredient in the oral equivalent active
- Ingredient Usage soluble film ingredient Sildenafil Treating ED
- VIAGRA ® citrate to 50 mg of sildenafil (sildenafil citrate) oral tablets
- Sildenafil Treating PAH An amount equivalent RETAVIO ® citrate to 5 mg or 20 mg (sildenafil citrate) of sildenafil oral tablets
- the oral soluble film is rectangular.
- the oral soluble film includes a logo and/or printed indicia located thereon.
- the oral soluble film the oral soluble film includes a logo and/or printed indicia located thereon that indicates the marketing company name, the manufacturing company name, the drug substance name, the drug product name, the strength, the dosage form, the route of administration, and/or the product serialization.
- the oral soluble film includes a logo and/or indicia located thereon, printed with ink.
- the oral soluble film includes a logo and/or indicia located thereon, that is embossed.
- a single dose of the oral soluble film is individually packaged and sealed.
- a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material.
- a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material, wherein the primary packaging material includes multiple layers.
- a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material, wherein the primary packaging material includes multiple layers and wherein at least one layer is manufactured from metalized polyester.
- the primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) identifies a logo and/or includes printed indicia, or (vi) any combination thereof.
- the primary packaging material forms a primary package that protects the oral soluble film from light.
- the primary packaging material forms a primary package that is airtight.
- the primary packaging material forms a primary package that protects the oral soluble film from microbial contamination.
- the primary packaging material forms a primary package that mitigates leachable(s) into the oral soluble film.
- the primary packaging material forms a primary package that is child resistant.
- the primary packaging material forms a primary package that forms a child resistant and closure system.
- the primary packaging material forms a primary package that is a barrier to moisture and vapor.
- the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia.
- the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia instructing the subject how to open the primary package.
- the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia instructing the subject how to use the oral soluble film.
- the primary packaging material forms a primary package that identifies product serialization.
- the primary packaging material forms a primary package that identifies a logo of the marketing company.
- the primary packaging material forms a primary package that identifies a logo of the manufacturing company.
- the primary packaging material forms a primary package that identifies the drug product.
- the primary packaging material forms a primary package that identifies the drug substance.
- the primary packaging material forms a primary package that identifies the strength of the active ingredient.
- the primary packaging material forms a primary package that identifies the route of administration.
- the primary packaging material forms a primary package that identifies the dosage form.
- the primary packaging material forms a primary package that identifies the route of administration.
- the primary packaging material includes at least one of cellophane, polypropylene, nylon, polyester, vinylidene chloride, vinyl chloride, polycarbonate, low-density polyethylene, high-density polyethylene, linear low-density polyethylene, ionomer, polyvinyl alcohol, ethylene/vinyl acetate copolymer, ethylene/acrylic acid copolymer, ethylene/ethyl acrylate copolymer, polystyrene, and aluminum foil.
- the primary packaging material includes metalized polyester.
- a single layer of primary packaging material forms the primary package.
- multiple layers of primary packaging material form the primary package.
- multiple layers of primary packaging material form the primary package, wherein at least one layer includes metalized polyester.
- multiple layers of primary packaging material form the primary package, wherein each layer is independently different from the other layers.
- multiple layers of primary packaging material form the primary package, wherein any one layer is different from the other layers.
- the kit includes an enclosure that contains a single dose of the oral soluble film, individually packaged and sealed with a primary packaging material.
- the kit includes an enclosure that contains (a) a single dose of the oral soluble film, individually packaged and sealed with a primary packaging material, and (b) prescribing information.
- the kit includes an enclosure that contains multiple doses of the oral soluble film, each individually packaged and sealed with a primary packaging material.
- the kit includes an enclosure that contains (a) multiple doses of the oral soluble film, each individually packaged and sealed with a primary packaging material, and (b) prescribing information.
- the enclosure is a box.
- the enclosure is a bag.
- the oral soluble film is administered to treat a disease or disorder ameliorated by sildenafil citrate.
- the oral soluble film is administered to treat erectile dysfunction (ED) in a male subject.
- ED erectile dysfunction
- the oral soluble film is administered to treat antidepressant-induced erectile dysfunction in a male subject.
- the oral soluble film is administered to treat pulmonary arterial hypertension (PAH) in a subject.
- PAH pulmonary arterial hypertension
- the method of administration includes at least one of enteral delivery, transmucosal delivery, sublingual delivery, and buccal delivery, of the sildenafil citrate.
- the method of administration includes enteral delivery of the sildenafil citrate.
- the method of administration includes transmucosal delivery of the sildenafil citrate.
- the method of administration includes sublingual delivery of the sildenafil citrate.
- the method of administration includes buccal delivery of the sildenafil citrate.
- the method of administration includes oral (P.O.) administration of the oral soluble film.
- the oral soluble film is administered to a male subject up to 30 minutes before sexual activity.
- the oral soluble film is administered to a male subject up to 20 minutes before sexual activity.
- the oral soluble film is administered to a male subject up to 15 minutes before sexual activity.
- the oral soluble film is administered to a male subject up to 10 minutes before sexual activity.
- the oral soluble film is placed on the top of the tongue of a subject.
- the oral soluble film is placed against the inside of the cheek of a subject.
- the oral soluble film is placed between the cheek and gums of a subject.
- the oral soluble film is orally administered to a subject in the absence of water or beverage.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present application is a continuation of U.S. patent application Ser. No. 17/236,054, filed on Apr. 4, 2021, which claims the benefit of U.S. provisional patent application No. 63/012,988, filed on Apr. 21, 2020; each of which is incorporated by reference herein in its entirety.
- Sildenafil, sold under the brand name Viagra® among others, is a medication used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It is taken by mouth, or injection into a vein. Sildenafil acts by blocking phosphodiesterase 5 (PDES), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis. It requires sexual arousal, however, to work for ED. It also results in dilation of the blood vessels in the lungs.
- Pfizer originally discovered the medication in 1989 while looking for a treatment for heart-related chest pain. It was approved for medical use in the United States and in the European Union in 1998. In 2017, it was the 217th most commonly prescribed medication in the United States, with more than two million prescriptions. In 2017, it became available as a generic medication after final patents by Pfizer expired. In the United Kingdom, it is available over the counter.
- The primary indication of sildenafil is the treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete sexual intercourse). Its use is now one of the standard treatments for erectile dysfunction, including for men with diabetes mellitus.
- Across multiple dosage forms, drawbacks exist with the use of sildenafil. For example, with Viagra® oral tablets (and generic versions thereof), patients often risk the shame and embarrassment of being seen administering the drug. That is, often times the drug cannot be taken in a discreet manner (within a short window of time), without the sexual partner(s) becoming aware of the need for the treatment of erectile dysfunction by the patient. In addition to the social stigma of erectile dysfunction, the oral tablets are not convenient to carry on the patient's possession, e.g., in a pocket or wallet. While transported by the patient, risks exist with the dosage form inadvertently being crushed and/or contaminated. Many patients also experience difficulties in swallowing oral tablets (e.g., dysphagia), especially in the absence of a liquid beverage. Understandably, the fear of choking can contribute to the level of anxiety with patients, especially within the context and circumstances of a romantic encounter.
- As an alternative to tablets and pills, oral soluble films may be used to deliver active ingredients. The films can be formulated to disintegrate upon oral administration to rapidly (e.g., on the order of seconds) release the active ingredient. Examples of rapidly disintegrating films include films based on hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.
- The following products have been approved by the FDA: BELBUCA® (buprenorphine hydrochloride) buccal film; BUNAVAIL™ (buprenorphine hydrochloride; naloxone hydrochloride) buccal film; SUB OXONE® (buprenorphine hydrochloride; naloxone hydrochloride) sublingual buccal film; SYMPAZAN® (clobazam) oral film; ZUPLENZ® (ondansetron) oral film; EXSERVAN™ (riluzole) oral film; and KYNMOBI™ (apomorphine hydrochloride) sublingual film.
- Significant limitations generally exist with OSFs. First, to date the amount of API (drug loading) included in OSFs has been limited. Typically, the API is dissolved within the film. However, an increase in drug load often leads to an increase in brittleness and longer disintegration times. Second, bitter tasting APIs present challenges when formulating the OSF. The order of addition of the formulation might be sufficient to mask the bitter taste of the API. Alternatively, bitter tasting APIs can be masked before incorporating into the OSF. To enhance the taste, different techniques can be used, but the simplest method includes mixing and co-processing of a bitter tasting API with excipient(s) having a good or pleasant taste (the method is referred to as the obscuration technique, and the excipient can include, e.g., a flavoring agent and/or taste masking agent). Selection of the appropriate flavoring agent or taste masking agent is challenging, as it is not readily apparent which ones will be effective, given a desired (bitter tasting) API and the corresponding remaining excipients. Additionally, the flavoring agent or taste masking agent can inadvertently alter the physical and/or performance characteristics of the OSF, which can regrettably lead to the need to reformulate.
- OSFs containing sildenafil citrate are currently known, and several are commercially available. However, it is currently believed that no OSF containing sildenafil citrate has received approval from the United States Food and Drug Administration (FDA), to be marketed and sold in the United States, for the safe and effective treatment of ED or PAH.
- An aspect of the present invention relates to an oral soluble film for releasing the active ingredient sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) into the oral cavity and delivering, e.g., enterally via ingestion. Another aspect of the present invention relates to an oral soluble film that can be used to administer the active ingredient, at an amount sufficient and effective to (1) obtain a desired result, such as the treatment of the subject, and to (2) obtain a desired level of the active ingredient in the subject (as evidenced by, e.g., plasma levels of the active ingredient). The composition of the oral soluble film includes the active ingredient, in combination with multiple excipients (e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent), present in an amount effective to achieve desired physical and performance characteristics of the oral soluble film, both in vitro and in vivo.
- Across multiple embodiments, the OSF described herein can independently possess one or more advantages relative to other OSFs and/or traditional dosage forms (e.g., tablets and capsules). The one or more advantages can relate to, e.g., physical characteristics and/or performance characteristics of the oral soluble film. For example, in specific embodiments, the OSF can be in the form of a unit dose having a requisite drug load, while having acceptable physical dimensions (e.g., length, width, and thickness), mass, and water content; and while also exhibiting a desired disintegration time and pharmacokinetic (PK) profile. In specific embodiments, the variation of active ingredient between two equally sized unit dosages is relatively small. In specific embodiments, accuracy in the administered dose can be assured from every strip or film. In specific embodiments, the unit dose has a suitable breaking strength, elongation strength, loss on drying (LOD), surface area, and/or density. In specific embodiments, the OSF is flexible, compliant, and not brittle. In specific embodiments, the OSF does not have an unpleasant taste (e.g., the bitter taste of the active ingredient is effectively masked). In specific embodiments, the OSF does not have an unpleasant mouth feel. In specific embodiments, upon administration to the subject, the oral soluble film exhibits a suitable pharmacokinetic (PK) profile that includes, e.g., AUC, Cmax, tmax, and/or t1/2. In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film results in a lower incidence, severity, and/or duration of one or more adverse reactions. In specific embodiments, a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material. In specific embodiments, a single dose of strip can be individually packaged without requiring a secondary container. Individually packaged OSFs are typically more difficult to tamper with, compared to traditional packages for tablets and capsules, such as bottles or foil blister packs. Additionally, many consumers may prefer the convenience to carry individually packaged OSFs. In specific embodiments, the individually packaged OSF can be easily handled, stored, and transported. In further specific embodiments, the primary packaging material forms a primary package that protects the oral soluble film from light, protects the oral soluble film from microbial contamination, is child resistant, is a barrier to moisture and vapor, is airtight, and/or mitigates leachable(s) into the oral soluble film. In specific embodiments, the OSF can easily be titrated. In specific embodiments, the OSF can be discretely administered. In specific embodiments, the OSF can be administered in the absence of water or beverage. This makes the dosage form acceptable among pediatric and geriatric patients, as well as patients with a fear of choking (e.g., those suffering from dysphagia).
- The present invention provides for an oral soluble film that includes: (a) sildenafil citrate, (b) binder, (c) filler, (d) flavoring agent, (e) plasticizer, (f) sweetening agent, (g) preservative, (h) solvent, and (i) optionally coloring agent.
- The present invention provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (i) coloring agent.
- The present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent; (e) plasticizer that includes glycerin; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (g) optionally coloring agent.
- The present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer; (f) sweetening agent; (g) preservative; (h) solvent that includes water; and (i) coloring agent.
- The present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer that includes glycerin; (f) sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) preservative that includes sodium benzoate; (h) solvent that includes water; and (i) optionally coloring agent.
- The present invention also provides for an oral soluble film that includes: (a) sildenafil citrate; (b) binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) filler that includes microcrystalline cellulose; (d) flavoring agent that includes peppermint flavoring; (e) plasticizer that includes glycerin; (f) sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) coloring agent that includes FD&C Blue 1; (h) preservative that includes sodium benzoate; and (i) solvent that includes water.
- The present invention also provides for an oral soluble film that includes: (a) 36±7 wt. % sildenafil citrate; (b) 30±6 wt. % binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) 5.45±1 wt. % filler that includes microcrystalline cellulose; (d) 6.44±1.25 wt. % flavoring agent that includes peppermint flavoring; (e) 12±2.5 wt. % plasticizer that includes glycerin; (f) 10±2 wt. % sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) 0.01±0.002 wt. % coloring agent that includes FD&C Blue 1; and (h) 0.10±0.02 wt. % preservative that includes sodium benzoate.
- The present invention also provides for an oral soluble film configured as a unit dose, wherein the unit dose of the oral soluble film includes: (a) 70.24±7 mg sildenafil citrate; (b) 58.53±12 mg binder that includes: (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide; (c) 10.63±2 mg filler that includes microcrystalline cellulose; (d) 12.56±2.5 mg flavoring agent that includes peppermint flavoring; (e) 23.41±5 mg plasticizer that includes glycerin; (f) 19.5±4 mg sweetening agent that includes sucralose and acesulfame potassium (ACE-K); (g) 0.02±0.004 mg coloring agent that includes FD&C Blue 1; (h) 0.20±0.04 mg preservative that includes sodium benzoate; and (i) 9.76±2.25 mg solvent that includes water.
- The present invention also provides for an oral soluble film that includes: sildenafil citrate, polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, silicon dioxide, microcrystalline cellulose, peppermint flavoring, glycerin, sucralose, acesulfame potassium (ACE-K), FD&C Blue 1, sodium benzoate, and water.
- The present invention also provides for an oral soluble film that includes: 36±7 wt. % sildenafil citrate; 30±6 wt. % in the aggregate of polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and silicon dioxide; 5.45±1 wt. % microcrystalline cellulose; 6.44±1.25 wt. % peppermint flavoring; 12±2.5 wt. % glycerin; 10±2 wt. % in the aggregate sucralose and acesulfame potassium (ACE-K); 0.01±0.002 wt. % FD&C Blue 1; and 0.10±0.02 wt. % sodium benzoate.
- The present invention also provides for an oral soluble film that includes (based on an anhydrous oral soluble film):
-
Amount (w/w) Material/Component Specification 36.00 Sildenafil Citrate USP 30.00 Kollicoat ® Protect: Kollicoat ® IR USP/NF Polyvinylalcohol USP/NF Silicon Dioxide USP/NF 5.45 Microcrystalline Cellulose - NF, Ph. Eur., JP Avicel ® PH-101 6.44 Peppermint Flavor Natural Flavor 12.00 Glycerin USP 6.00 Sucralose NF 4.00 Acesulfame Potassium USP/NF, Ph. Eur., JP 0.01 Blue 1 colorant FDC 0.10 Sodium Benzoate NF TOTAL 100.00 - The present invention also provides for an oral soluble film configured as a unit dose, wherein each unit dose of the oral soluble film includes (based on an anhydrous oral soluble film):
-
Amount per Primary unit (mg) Material/Component Function(s) 70.24 Sildenafil Citrate Active 58.53 Kollicoat ® Protect: Binder Kollicoat ® IR Polyvinylalcohol Silicon Dioxide 10.63 Microcrystalline Cellulose - Filler/Binder Avicel ® PH-101 12.56 Peppermint Flavor Flavor 23.41 Glycerin Plasticizer 11.70 Sucralose Sweetener 7.80 Acesulfame Potassium Sweetener 0.02 FD&C Blue 1 Color 0.20 Sodium Benzoate Preservative TOTAL 195.10 - The present invention also provides for a slurry, suitable for forming an oral soluble film. The slurry includes: 16.8±2 wt. % sildenafil citrate; 14.1±3 wt. % in the aggregate of polyvinyl alcohol (PVA), polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and silicon dioxide; 2.5±0.5 wt. % microcrystalline cellulose; 3.0±0.75 wt. % peppermint flavoring; 5.6±1.25 wt. % glycerin; 4.66±1 wt. % in the aggregate sucralose and acesulfame potassium (ACE-K); 0.005±0.001 wt. % FD&C Blue 1; 0.05±0.01 wt. % sodium benzoate; and 53.3±10 wt. % water.
- The present invention also provides for a single dose of the oral soluble film described herein, that is individually packaged and sealed with a primary packaging material. The primary packaging material includes multiple layers, wherein at least one layer is manufactured from metalized polyester. The primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) is airtight, (vi) mitigates leachable(s) into the oral soluble film, (vii) identifies a logo and/or includes printed indicia, or (viii) any combination thereof.
- The present invention also provides for a kit that includes an enclosure that contains (a) multiple doses of the oral soluble film described herein, each individually packaged and sealed with a primary packaging material, and (b) prescribing information. The primary packaging material includes multiple layers, wherein at least one layer is manufactured from metalized polyester. The primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) is airtight, (vi) mitigates leachable(s) into the oral soluble film, (vii) identifies a logo and/or includes printed indicia, or (viii) any combination thereof.
- The present invention also provides for a method of medical treatment that includes orally administering to a subject in need thereof, the oral soluble film described herein.
- The present invention also provides for a method of treating a disease or disorder ameliorated by sildenafil citrate, the method includes orally administering to a subject in need thereof, the oral soluble film described herein.
- The present invention also provides for a method of treating erectile dysfunction (ED) in a male subject, the method includes orally administering to the male subject in need thereof an oral soluble film described herein.
- The present invention also provides for a method of treating antidepressant-induced erectile dysfunction in a male subject, the method includes orally administering to the male subject in need thereof an oral soluble film described herein.
- The present invention also provides for a method of treating pulmonary arterial hypertension (PAH) in a subject, the method includes orally administering to the subject in need thereof an oral soluble film described herein.
- An aspect of the present invention relates to an oral soluble film for releasing the active ingredient sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) into the oral cavity and delivering, e.g., enterally via ingestion. Another aspect of the present invention relates to an oral soluble film that can be used to administer the active ingredient, at an amount sufficient and effective to (1) obtain a desired result, such as the treatment of the subject, and/or to (2) obtain a desired level of the active ingredient in the subject (as evidenced by, e.g., plasma levels of the active ingredient). The composition of the oral soluble film includes the active ingredient, in combination with multiple excipients (e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and solvent), present in an amount effective to achieve the desired physical and performance characteristics of the oral soluble film, both in vitro and in vivo. This includes, e.g., effectively masking the taste of the active ingredient, which is highly bitter. This is accomplished while employing only those excipients (in amounts) that will be permitted by FDA. This may be further accomplished by obtaining an oral soluble film that is suitable for regulatory approval, as well as improving medication adherence and compliance by the subject. Likewise, this in turn may be accomplished by providing for an oral soluble film having the requisite physical and performance characteristics. These characteristics can include, e.g., the desired and targeted: in vitro disintegration time, in vitro dissolution time, loss on drying (LOD), breaking strength, minimal foreign body sensation, elongation strength, PK parameters (e.g., Cmax, Tmax, t1/2, AUC), mass/weight, thickness, moisture content, density, pH, drug load (content of API), elongation, and/or drug content uniformity (CU).
- The present invention can be more readily understood by reading the following detailed description of the invention and study of the included examples.
- As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
- The terms “comprise,” “comprising,” “include,” “including,” and “includes” when used in this specification and claims are intended to specify the presence of stated substances, features, integers, components, or steps, but they do not preclude the presence or addition of one or more other substances, features, integers, components, steps, or combinations thereof.
- The term “about” modifies the subject values, such that they are within an acceptable error range, as determined by one of ordinary skill in the art, which will depend in part on the limitations of the measurement system.
- The articles “a” and “an” as used herein refers to “one or more” or “at least one,” unless otherwise indicated. That is, reference to any element or component of an embodiment by the indefinite article “a” or “an” does not exclude the possibility that more than one element or component is present.
- The term “excipient” refers to a pharmacologically inactive substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film). An excipient is a substance formulated alongside the active pharmaceutical ingredient (API), and can include agents for stabilizing, bulking/filling, disintegrating, dissolving, flavoring, facilitating drug absorption, reducing viscosity, and/or enhancing solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the API, such as by facilitating powder flowability or non-stick properties, and/or aiding in vitro stability such as prevention or mitigation of degradation of the API over the expected shelf life. The selection of appropriate excipients also depends upon the route of administration and the dosage form, as well as the API and other factors. Pharmaceutical regulations and standards require that all ingredients in drug products, as well as their chemical decomposition products, be identified and shown to be safe. The Federation of International Pharmaceutical Excipients Council (IPEC), a pharmaceutical regulatory non-profit, develops, implements, and promotes global use of appropriate quality, safety, and functionality standards for pharmaceutical excipients and excipient delivery systems.
- Excipients useful in the formulations described herein (e.g., slurry and OSF) include, e.g., binder, filler, preservative, sweetening agent, solvent, co-solvent, plasticizer, flavoring agent, taste masking agent, colorant, anti-caking agent, coating agent, emulsifier, solubilizing agent, lipid, humectant, thickening agent, lubricant, adsorbent, suspending agent, disintegrating agent, permeation enhancer, saliva stimulating agent, release modifier, adjuvant, fragrance, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant. Excipients that can be used in the formulation of oral soluble films are described in, e.g., Lachman, et al., “The Theory and Practice of Industrial Pharmacy,” 4th Edition (2013); Sheskey et al., “Handbook of Pharmaceutical Excipients,” 9th Edition (2020); and Remington, “The Science and Practice of Pharmacy,” 22nd Edition (2015). All excipients used in the formulation of the oral soluble film described herein, in the desired amounts, should preferably be approved by the FDA for use in oral pharmaceutical dosage forms. See, e.g., the FDA Inactive Ingredient Database (IID), https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (accessed Apr. 15, 2021). Additionally, the excipients will preferably be commercially available in acceptable grade, physiologically inert, and physically and chemically stable by themselves, as well as in combination with the desired API.
- Sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate) functions as an active ingredient in the oral soluble film described herein. In specific embodiments, the sildenafil functions as the sole active ingredient. Likewise, one or more excipients used in the pharmaceutical preparation of the oral soluble films described herein can possess a single use or function. In specific embodiments, when present in the oral soluble film described herein, each of sucralose and acesulfame potassium (ACE-K) function as a sweetener. In specific embodiments, when present in the oral soluble film described herein, FD&C Blue 1 functions as a colorant. Additionally, in specific embodiments, when present in the oral soluble film described herein, sodium benzoate functions as a preservative. Without being limited or bound to any particular theory, it is believed that across multiple specific embodiments, these substances provide little or no additional function(s) than those ascribed above.
- In contrast, in specific embodiments, one or more excipients employed in the oral soluble film described herein can have multiple uses or functions. For example, when present in the oral soluble film described herein, Kollicoat® Protect is employed as a binder, but in specific embodiments can further function as an anti-caking agent, disintegrating agent, coating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF, to increase elongation of the OSF, or any combination thereof. When present in the oral soluble film described herein, natural peppermint flavor is employed as a flavoring agent, but in specific embodiments can further function as a taste masking agent, permeation enhancer, or combination thereof. When present in the oral soluble film described herein, glycerin is employed as a plasticizer, but in specific embodiments can further function as a sweetener, humectant, co-solvent, thickening agent, lubricant, or any combination thereof. When present in the oral soluble film described herein, microcrystalline cellulose is employed as a filler, but in specific embodiments can further function as an anti-caking agent, emulsifier, bulking agent, binder, viscosity increasing agent, or any combination thereof.
- In specific embodiments, the present invention provides for an oral soluble film that includes (i) sildenafil citrate, (ii) binder, (iii) filler, (iv) flavoring agent, (v) plasticizer, (vi) sweetener, (vii) coloring agent, and (viii) preservative. It is contemplated that in specific embodiments, one or more excipients can be employed in the oral soluble film, each to effectively serve multiple functions. For example, in specific embodiments, a single excipient (e.g., Kollicoat® Protect) can function as a binder, as well as an anti-caking agent, disintegrating agent, coating agent, taste masking agent, binder, emulsifier, to increase tensile strength of the OSF, and/or to increase elongation of the OSF. In specific embodiments, a single excipient (e.g., Peppermint Flavor) can function as a flavoring agent, as well as a permeation enhancer and/or taste masking agent. In specific embodiments, a single excipient (e.g., glycerin) can function as a plasticizer, as well as a sweetener, humectant, co-solvent, thickening agent, and/or lubricant. Excipients useful in the oral soluble film described herein, having multiple functions, are described, e.g., in Handbook of Pharmaceutical Excipients, Sheskey et al., Eds., 9th Edition, Pharmaceutical Press (2020).
- The OSF may be prepared by first forming a slurry. In forming a slurry, any one or more of the ingredients (including the API) employed can effectively be dissolved or dispersed therein (e.g., in the solvent). This includes, e.g., salts, such as sodium benzoate and acesulfame potassium. This also extends to the drug substance, sildenafil citrate. In doing so, the salt can dissociate into the respective anion and cation; and would therefore no longer necessarily exist in the salt form-benzoic acid, acesulfame free base, and sildenafil free base. However, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the slurry (and resulting oral soluble film) as containing substances in the salt form is otherwise acceptable and appropriate.
- Additionally, in specific embodiments, the inactive ingredient microcrystalline cellulose can be employed in the manufacture of the drug product, oral soluble film. In forming the slurry, the microcrystalline cellulose present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the cellulose would therefore no longer necessarily retain the microcrystalline form. However, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the slurry (and resulting oral soluble film) as containing microcrystalline cellulose (e.g., cellulose in the microcrystalline form) is otherwise acceptable and appropriate.
- Likewise, in specific embodiments, the drug substance sildenafil citrate, having a specified bulk density or particle size distribution (PSD), can be employed in the manufacture of the drug product, oral soluble film. In forming the slurry, the sildenafil citrate present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the sildenafil citrate would therefore no longer necessarily retain the drug substance PSD or bulk density. However, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the slurry (and resulting oral soluble film) as containing the sildenafil citrate having a specified bulk density or PSD (based on the drug substance sildenafil citrate employed) is otherwise acceptable and appropriate.
- Additionally, in specific embodiments, the inactive ingredient microcrystalline cellulose (MCC), having a specified bulk density or particle size distribution (PSD), can be employed in the manufacture of the drug product, oral soluble film. In forming the slurry, the MCC present can effectively be dissolved or dispersed therein (e.g., in the solvent). In doing so, the MCC would therefore no longer necessarily retain the PSD. However, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the slurry (and resulting oral soluble film) as containing the MCC having a specified PSD (based on the MCC employed) is otherwise acceptable and appropriate.
- Reference can therefore be made to the slurry (and the resulting oral soluble film) as containing (or as being manufactured from, or as being formed from) various substances, such as the active ingredient (e.g., sildenafil citrate) and multiple excipients (e.g., binder, filler, flavoring agent, plasticizer, sweetening agent, coloring agent, preservative, and/or solvent). As described herein, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the slurry (and the resulting oral soluble film) as containing the active ingredient and excipients is acceptable and appropriate. This is so, even though those substances may no longer necessarily exist in the same state as when introduced into the slurry, as specifically indicated. Likewise, within the context of the present invention, reference can also be made to the slurry (and the resulting oral soluble film) as being manufactured from (or as being formed from) the active ingredient and excipients, as specifically indicated. It is appreciated that those of skill in the art understand and agree that each of the above characterizations of the slurry (and the resulting oral soluble film) are acceptable and appropriate.
- The term “inactive ingredient” (and equivalent terms such as “inactive component”) refers to a substance that is pharmacologically and biologically inactive. The inactive ingredients are usually called excipients in pharmaceutical contexts.
- The term “slurry” refers to a mixture of solids that is dispersed, suspended, solubilized, and/or dissolved in liquid. Together, the solids and liquid will include those substances used to manufacture the oral soluble film. The solid substances employed in the manufacture of the oral soluble film can essentially be dissolved in the liquid, can essentially be suspended in the liquid, can essentially be dispersed in the liquid, can essentially be solubilized in the liquid, or a combination thereof. An oral soluble film can be formed by curing a cast slurry. The curing can be carried out, e.g., at an elevated temperature, for a period of time. In doing so, a significant amount of the solvent (e.g., water) will be removed. The remaining water will contribute to the moisture content in the oral soluble film (in addition to any moisture from the surrounding environment that is picked up by any hygroscopic polymers employed).
- The term “binder” (and equivalent terms such as “binding agent”) refers to a substance, typically a polymer, used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to hold the ingredients together. Binders ensure that the oral soluble films can be formed with the requisite mechanical strength. The binders also provide the requisite volume to low amount of active present in soluble films. The presence of the binder can also facilitate the formation of the cured film. As such, the binder includes those substances, which when present in the cast slurry and upon curing, will effectively provide for a cured film. In designing of an oral soluble film formulation, consideration should be given to the target product and drug release profile. A primary component of an oral film is the binder, which may be a polymer blend. Selection of the binder may be guided by the desired strength and stability of the oral soluble film, as well as mucoadhesiveness, pliability, dissolution rate, and moisture content. The binder may also be referred to as a “film forming agent,” or more specifically a “film forming polymer” (or equivalent terms, such as “strip-forming polymer” and “mucoadhesive polymer”) when it is a polymer. Polymeric binders (film forming agents) can be natural or a synthetic. Employing a binder can allow for, and promote, the formation of a “film matrix” (also referred to as a polymeric matrix). A film matrix is typically obtained by curing the cast slurry, which contains the binder(s). Examples of binders for use in an OSF described herein include polyacrylic acid (PAA) (alternatively referred to as poly(acrylic acid) or Carbomer®); 1-polyacrylic acid; methyl methacrylate copolymer; carboxyvinyl polymer; polyethylene glycol (PEG) (alternatively referred to as polyethylene oxide or PEO); acacia; agar; alginic acid (alternatively referred to as algin); sodium alginate (Na alginate); calcium carbonate; calcium lactate; carboxymethyl cellulose (CMC) (alternatively referred to as cellulose gum or carboxy methylcellulose or carboxymethylcellulose); carrageenan; cellulose acetate; chitosan; copovidone; starch (e.g., corn starch or pregelatinized starch); cottonseed oil; dextrates; dextrin; dextrose (alternatively referred to as corn sugar and D-glucose); ethylcellulose; (alternatively referred to as ethyl cellulose); gelatin; guar gum; hydroxyethyl cellulose (HEC); hydroxyethyl methyl cellulose (MEMC); hydroxypropyl methylcellulose (HPMC) (alternatively referred to as hydroxypropyl methyl cellulose, hypromellose, or INN) (e.g., Vivapharm® HPMC E3, Methocel™ HPMC K3, Vivapharm® HPMC E5, Vivapharm® HPMC E15, or Methocel™ E15); hydroxypropyl cellulose (HPC); low substituted hydroxypropyl cellulose (L-HPC); hydroxypropyl starch; inulin; lactose; maltodextrin; maltose; methylcellulose (MC) (e.g., Methocel® A15); microcrystalline cellulose (MCC) (e.g., Avicel® PH-101); pectin; poloxamer (e.g., Pluronic®, Kolliphor®, and Synperonic®); polycarbophil; polydextrose; polymethacrylates; polyvinyl alcohol (PVA) (alternatively referred to as poly(vinyl alcohol), polyvinylalcohol or PVOH or PVAI); polyvinylpyrrolidone (PVP) (alternatively referred to as polyvidone or povidone) (e.g., Kollidon® K90, Kollidon® 12 PF, Kollidon® 17 PF, Kollidon® 25 PF, or Kollidon® 30 PF); pullulan; sodium carboxymethylcellulose (CMC-Na) (alternatively referred to as sodium carboxymethyl cellulose) (e.g., Cekol® 30); sucrose; sunflower oil; zein; vinylpyrrolidone-vinyl acetate copolymer (e.g., Kollidon® VA64); polyvinyl acetate/polyvinylpyrrolidone (e.g., Kollidon® SR); polyvinyl alcohol-polyethylene glycol copolymer and polyvinyl alcohol (PVA) (e.g., Kollicoat® Protect); polyvinyl alcohol/polyethylene glycol graft copolymer (e.g., Kollicoat® IR); polyvinyl caprolactampolyvinyl acetate-polyethylene glycol graft co-polymer (e.g., Soluplus®); poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) (e.g., Eudragit® RL100); amino methacrylate copolymer (e.g., Eudragit® E PO); and xanthan gum.
- The term “filler” (and equivalent terms such as “diluent” and “bulking agent”) refers to substances used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to add bulk to the pharmaceutical dosage form, improving the consistency in dose metering and/or making the active ingredient easier for consumer to take. Fillers can also help with the manufacturing and stabilization of these products. Fillers can also bind and stabilize the dosage form. They are employed in the manufacture of an OSF to increase weight/mass and/or to improve content uniformity. Fillers can provide properties such as improved cohesion and/or to promote flow. Examples of fillers for use in an OSF described herein include anhydrous lactose, calcium carbonate, calcium lactate, calcium phosphate (dibasic anhydrous, dibasic dihydrate, or tribasic), calcium silicate, calcium sulfate, cellulose (powdered or silicified microcrystalline), cellulose acetate, corn starch and pregelatinized starch, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glucose, glyceryl palmitostearate, glycine, hydrolyzed starch, lactose, lactose monohydrate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, medium-chain triglycerides, microcrystalline cellulose (MCC), partially pregelatinized starches, plant cellulose, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, pregelatinized starch, sterilizable maize, sucrose, sugar spheres, sulfobutylether β-cyclodextrin, talc, tragacanth, trehalose, and xylitol.
- The term “preservative” refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to prevent or mitigate microbial growth or by undesirable chemical changes. In general, preservation is implemented in two modes, chemical and physical. Examples of preservatives for use in an OSF described herein include ethanol, benzoic acid, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), butylparaben, calcium acetate, calcium chloride, calcium lactate, cetylpyridinium chloride, chlorhexidine, chlorobutanol, citric acid monohydrate, ethylparaben, glycerin, lactic acid, methylparaben, parabens, potassium benzoate, potassium sorbate, propyl gallate, propylene glycol, propylparaben, propylparaben sodium, sodium acetate, sodium benzoate, sodium lactate, sodium propionate, sorbic acid, sulfobutyl ether β-cyclodextrin, edetic acid, xanthan, and xylitol.
- The term “sweetening agent” (and equivalent terms such as “sweetener”) refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to impart a sweet taste like that of sugar. The sweetener can be artificial or naturally occurring. Examples of sweetening agents for use in an OSF described herein include sugar, acesulfame salts (e.g., acesulfame potassium (ACE-K)), alitame, aspartame, dextrose, erythritol, fructose, glycerin, isomalt, lactitol, advantame, monk fruit extract (mogrosides), glucose, galactose, maltitol, maltose, mannitol, monk fruit extract, neohesperidin dihydrochalcone, neotame, saccharin, saccharin salts (e.g., saccharin sodium), sodium cyclamate, sorbitol, stevia, stevioside, rebaudioside A, sucralose, sucrose, tagatose, thaumatin, trehalose, licorice extract, and xylitol.
- The term “solvent” refers to a substance that is used in the pharmaceutical preparation of an oral soluble film, to dissolve the active pharmaceutical ingredient (API) and/or excipients. A solvent can be employed to form a slurry. For most manufacturing methods, solvents improve solubility of the active ingredient within the film forming matrix. Solvents may be chosen based on the active ingredient's solubility therein. Preferred solvents include volatile class 3 residual solvents such as ethanol and acetone and non-volatile solvents such as water. In some embodiments, the solvent is at least one of ethanol and water. Upon curing of a slurry to provide an oral soluble film, a significant portion of the solvent will typically be removed, leaving behind a remaining (or residual) portion of the solvent.
- The term “co-solvent” refers to a substance that is used in the pharmaceutical preparation of an oral soluble film, to assist the solvent in dissolving the active pharmaceutical ingredient (API) and/or excipients, to form a slurry. Examples of co-solvents for use in an OSF described herein include almond oil, castor oil, corn oil, cottonseed oil, ethanol, glycerin, olive oil, polyethylene glycol, polyoxy 35 castor oil, propylene glycol, safflower oil, sesame oil, soybean oil, sunflower oil, and ethanol. Upon curing of a slurry to provide an oral soluble film, a portion of the co-solvent may be removed.
- The term “plasticizer” refers to a substance that, when added to polymer(s), makes the polymer more pliable and softer, enhancing the flexibility and plasticity of the films. They can be added to reduce the glass transition temperature to reduce the risk of thermally destabilizing the active ingredient and/or excipients. The plasticizer is believed to permeate the polymer structure, disrupting intermolecular hydrogen bonding, and permanently lowers intermolecular attractions. Plasticizers can be used to allow initial film forming, to reduce the brittleness, and improve the processability and flexibility of the resulting film, thereby avoiding cracking, e.g., during the curing process. Plasticizers can be used to improve elasticity of the oral soluble film which can be important for manufacturing scale-up. Plasticizers can also play a role when combined with certain polymers in the overall dissolution rate of the film. Examples of plasticizers for use in an OSF described herein include castor oil, glycerin, glycerol monostearate, D, hypromellose phthalate, mannitol, mineral oil and, palmitic acid, polyethylene glycol, polyvinyl acetate phthalate, propylene glycol, pyrrolidone, sorbitol, stearic acid, triacetin, tributyl citrate, triethyl citrate, water, glycerin fatty acid esters, sucrose fatty acid esters, lecithin, enzyme modified lecithin, polysorbates, sorbitan fatty acid esters, maltitol, xylitol, polyethylene glycol (PEG), hydrogenated starch syrup, starch syrup, and glycerol oleate.
- The term “flavoring agent” (and equivalent terms such as “flavoring substance,” “flavor,” “flavoring,” and “flavorant”) refers to a substance used in the pharmaceutical preparation of an oral soluble film, to impart a flavor, e.g., to improve the attractiveness and acceptance by the subject. The basic taste sensations are salty, sweet, bitter, sour, and umami. Flavors may be chosen from natural and synthetic flavorings. An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof. The flavoring agent can be available as a solid (e.g., powder), as a liquid (e.g., oil), or a combination thereof. Additionally, the flavoring agent for use in the OSF can include any one or more of a natural flavoring substance, a nature-identical flavoring substance, and an artificial flavoring substance. Examples of flavoring agents for use in an OSF described herein include allspice, anise, n-butyl lactate, cardamom, cherry, confectioner's sugar, cinnamon, clove, ethyl vanillin, ethylcellulose, eugenol, ginger, gingermint, lemon, lemongrass, levomenthol, lime, malic acid, maltol, menthol, mint, nutmeg, orange, peppermint, phosphoric acid, propionic acid, sodium acetate, sodium lactate, spearmint, tangerine, tartaric acid, thymol, triethyl citrate, vanillin, vanilla cream, watermint, wintergreen, mountain berry, and grape. In specific embodiments, the peppermint flavoring agent can include Natural Peppermint Oil, commercially available from A. M. Todd; Natural Peppermint Flavor 501500 TPK504, commercially available from Firmenich (Anaheim, Calif.); or Natural and Artificial Peppermint, commercially available from Firmenich (Anaheim, Calif.). In specific embodiments, the spearmint flavoring agent can include Spearmint Flavor, Nat & Art, commercially available from FONA (Geneva, Ill.); or Natural Spearmint Flavor, commercially available from Virginia Dare (Brooklyn, N.Y.). In specific embodiments, the orange flavoring agent can include Nat Orange Durarome 860205 TD 1091, commercially available from Firmenich (Anaheim, Calif.); Orange Flavor Nat WONF, commercially available from FONA (Geneva, Ill.); Orange Flavor, Nat & Art, commercially available from FONA (Geneva, Ill.); or Superflex Natural Orange, commercially available from Virginia Dare (Brooklyn, N.Y.). In specific embodiments, the vanilla cream flavoring agent can include Natural Flavor for Cream (NFF Vanilla), commercially available from Virginia Dare (Brooklyn, N.Y.).
- The term “natural flavoring substance” refers to a flavoring substance obtained from plant or animal raw materials, by physical, microbiological, or enzymatic processes. They can be either used in their natural state or processed for human consumption, but cannot contain any nature-identical or artificial flavoring substances.
- The term “nature-identical flavoring substance” refers to a flavoring substance obtained by synthesis or isolated through chemical processes, which is chemically and organoleptically identical to flavoring substances naturally present in products intended for human consumption. They cannot contain any artificial flavoring substances.
- The term “artificial flavoring substance” refers to a flavoring substance that is not identified in a natural product intended for human consumption, whether or not the product is processed. These are typically produced by fractional distillation and additional chemical manipulation of naturally sourced chemicals, crude oil, or coal tar. Although they are chemically different, in sensory characteristics they are the same as natural ones. Most artificial flavors are specific and often complex mixtures of singular naturally occurring flavor compounds combined together to either imitate or enhance a natural flavor. These mixtures are formulated by flavorists to give a food product a unique flavor and to maintain flavor consistency between different product batches or after recipe changes. The list of known artificial flavoring agents includes thousands of molecular compounds, and the flavor chemist (flavorist) can often mix these together to produce many of the common flavors. Many of these artificial flavorants consist of esters, which are often described as being “sweet” or “fruity”.
- The term “taste masking agent” refers to a substance used in the pharmaceutical preparation of an oral soluble film, to mask the unpleasant taste of a substance present in the formulation, to improve the attractiveness and acceptance by the subject. The taste masking agent can specifically refer to a substance used to mask the bitter or unpleasant taste of the active ingredient. Examples of taste masking agents for use in an OSF described herein include alginic acid, erythritol, and glyceryl palmitostearate, and monoammonium glycyrrhizinate (MAG). With the oral soluble films described herein, in addition to masking the taste of any unpleasant or bitter tasting substances (e.g., the active ingredient) present in the oral soluble film, the taste masking agent can optionally also impart a pleasant flavor. In such embodiments, the same substance can serve as both a flavoring agent and as a taste masking agent.
- The term “colorant” (and equivalent terms such as “coloring agent”) refers to substance used in the pharmaceutical preparation of an oral soluble film, to change the color of the slurry and/or oral soluble film. The colorant is a dye, pigment, or substance that imparts color when it is added to a slurry. Colorants work by absorbing varying amounts of light at different wavelengths (or frequencies) of its spectrum, transmitting (if translucent) or reflecting the remaining light in straight lines or scattered. Color consistency can be significant, as it allows easy identification of a medication to the subject. Furthermore, colors often improve the aesthetic look and feel of medications. By increasing these organoleptic properties, a subject is more likely to adhere to their schedule and therapeutic objectives will also have a better outcome for the subject. The colorant can include, e.g., FD&C colors (e.g., FD&C red, FD&C yellow, FD&C blue, FD&C green), D&C colors, or a combination thereof. Examples of colorants for use in an OSF described herein include FD&C Red No. 3, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, FD&C Green No. 3, FD&C Blue No. 1, and FD&C Blue No. 2.
- The term “anti-caking agent” (and equivalent terms such as “anti-tacking agent”) refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film), to prevent or mitigate the occurrence of the formation of lumps (caking) of powdered or granulated materials. Use of the anti-tacking agent can result in the ease of flowability of the solid powders used to form the slurry. Crystalline solids often cake by formation of liquid bridge and subsequent fusion of microcrystals. Amorphous materials can cake by glass transitions and changes in viscosity. Examples of anti-caking agents for use in an OSF described herein include calcium silicate, tribasic calcium phosphate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate, and talc, mannitol, and starch.
- The term “coating agent” refers to a substance that is applied to a solid or powder particle, to sufficiently coat the particle. The thickness of such a coating is usually less than 100 μm. The motivation for coating a particle ranges from improving the stability (light protection, moisture and gas barrier) to increasing the flowability to thereby make it easier to process. Examples of coating agents for use in an OSF described herein include calcium carbonate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carnauba wax, cellulose acetate, (CAP), chitosan, ethylcellulose, fructose, gelatin, glycerin, glyceryl behenate, glyceryl palmitostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, isomalt, glucose, maltitol, maltodextrin, methylcellulose, microcrystalline wax, poloxamer, polydextrose, polyethylene glycol, poly-DL-(lactic acid), polyvinyl acetate phthalate, polyvinyl alcohol, povidone, sucrose, titanium oxide, tributyl citrate, triethyl citrate, vanillin, xylitol, and zein.
- The term “emulsifier” (and equivalent terms such as “emulsifying agent”) refers to a substance capable of forming or promoting an emulsion. In particular reference to the oral soluble films described herein, the emulsifier can promote the separation of phases (e.g., aqueous and lipids), while allowing them to be mixed. Examples of emulsifiers for use in an OSF described herein include acacia, cholesterol, glycerin, glyceryl monostearate, hydroxypropyl cellulose, lecithin, methylcellulose, mineral oil and, monobasic sodium phosphate, monoethanolamine, oleic acid, polyethylene glycol, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polysorbate (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, etc.), propylene glycol, propylene glycol alginate, sodium lauryl sulfate, sorbitan esters, and stearic acid.
- The term “solubilizing agent” (and equivalent terms such as “solubilizer”) refers to a substance used in the pharmaceutical preparation of an oral soluble film, to increase the solubility and/or bioavailability of the API. A solubilizing agent can act as a surfactant and increases the solubility of one agent in another. A substance that would not normally dissolve in a particular solution may be able to dissolve with the use of a solubilizing agent. Examples of solubilizing agents for use in an OSF described herein include cyclodextrins, glycerin monostearate, hydroxpropyl betadex, hypromellose, inulin, lecithin, meglumine, phospholipids, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, povidone, pyrrolidone, sorbitan esters, starch, stearic acid, sulfobutylether β-cyclodextrin, tricaprylin, triolein, and vitamin E polyethylene glycol succinate, N-acetylated amino-acid derivative, ethoxylated sorbitan, mono and diglycerides.
- The term “emulsion” refers to a mixture of two or more liquids that are normally immiscible (unmixable or unblendable) owing to liquid-liquid phase separation. Two liquids can form different types of emulsions. As an example, oil and water can form, first, an oil-in-water emulsion, in which the oil is the dispersed phase, and water is the continuous phase. Second, they can form a water-in-oil emulsion, in which water is the dispersed phase and oil is the continuous phase. Multiple emulsions are also possible, including a “water-in-oil-in-water” emulsion and an “oil-in-water-in-oil” emulsion. Emulsions, being liquids, do not exhibit a static internal structure.
- The droplets dispersed in the continuous phase (sometimes referred to as the “dispersion medium”) are usually assumed to be statistically distributed to produce roughly spherical droplets. When molecules are ordered during liquid-liquid phase separation, they form liquid crystals rather than emulsions. Lipids, used by all living organisms, are one example of molecules able to form either emulsions (e.g.: spherical micelles; Lipoproteins) or liquid crystals (lipid bilayer membranes). The droplets may be amorphous, liquid-crystalline, or any mixture thereof. The diameters of the droplets constituting the dispersed phase usually range from approximately 10 nm to 100 μm; i.e., the droplets may exceed the usual size limits for colloidal particles. An emulsion is termed an oil/water (o/w) emulsion if the dispersed phase is an organic material, and the continuous phase is water or an aqueous solution and is termed water/oil (w/o) if the dispersed phase is water or an aqueous solution and the continuous phase is an organic liquid (an “oil”).
- Two special classes of emulsions—microemulsions and nanoemulsions, with droplet sizes below 100 nm—appear translucent. This property is due to the fact that light waves are scattered by the droplets only if their sizes exceed about one-quarter of the wavelength of the incident light. Since the visible spectrum of light is composed of wavelengths between 390 and 750 nanometers (nm), if the droplet sizes in the emulsion are below about 100 nm, the light can penetrate through the emulsion without being scattered. Due to their similarity in appearance, translucent nanoemulsions and microemulsions are frequently confused. Unlike translucent nanoemulsions, which require specialized equipment to be produced, microemulsions may be spontaneously formed by “solubilizing” oil molecules with a mixture of surfactants, co-surfactants, and co-solvents. The required surfactant concentration in a microemulsion is, however, several times higher than that in a translucent nanoemulsion, and significantly exceeds the concentration of the dispersed phase. Because of many undesirable side-effects caused by surfactants, their presence is often considered disadvantageous or prohibitive in many applications. In addition, the stability of a microemulsion may be compromised by dilution, by heating, or by changing pH levels.
- The term “lipid” refers to a group of naturally occurring molecules that include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, phospholipids, and others. “Lipid” may also refer to ethoxylated fatty alcohols such as oleth-10 and laureth-10 and mixtures of ethoxylated mono and diglycerides such as PEG-16 macadamia glycerides and PEG-10 sunflower glycerides. The compounds are hydrophobic or amphiphilic small molecules. The amphiphilic nature of some lipids allows them to form structures such as vesicles, liposomes, or membranes in an aqueous environment. Biological lipids originate entirely or in part from two distinct types of biochemical subunits or “building-blocks”: ketoacyl and isoprene groups. Using this approach, lipids may be divided into eight categories: fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, and polyketides (derived from condensation of ketoacyl subunits); and sterol lipids and prenol lipids (derived from condensation of isoprene subunits). Although the term lipid is sometimes used as a synonym for fats, fats are a subgroup of lipids called triglycerides. Lipids also encompass molecules such as fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), as well as other sterol-containing metabolites such as cholesterol. Examples of lipids for use in an OSF described herein include almond oil, argan oil, avocado oil, canola oil, cashew oil, castor oil, cocoa butter, coconut oil, colza oil, corn oil, cottonseed oil, grape seed oil, hazelnut oil, hemp oil, hydroxylated lecithin, lecithin, linseed oil, macadamia oil, mango butter, marula oil, mongongo nut oil, olive oil, palm kernel oil, palm oil, peanut oil, pecan oil, perilla oil, pine nut oil, pistachio oil, poppy seed oil, pumpkin seed oil, rice bran oil, safflower oil, sesame oil, Shea butter, soybean oil, sunflower oil, sunflower lecithin, walnut oil, and watermelon seed oil, vitamin E, mono and diglycerides, propylene glycol, polyethylene glycol, Kolliphor® RH, and Kolliphor® EL.
- The term “humectant” refers to a substance used in the pharmaceutical preparation of an oral soluble film, to keep the slurry and/or oral soluble film moist. A humectant attracts and retains the moisture in the air nearby via absorption, drawing the water vapor into or beneath the oral soluble film's surface. This is the opposite use of a hygroscopic material where it is used as a desiccant used to draw moisture away. Humectants can be used in oral soluble films to help solubilize active ingredients, increasing the active ingredients' ability to penetrate a mucosal surface, or its activity time. Examples of humectants for use in an OSF described herein include glycerin, polydextrose, propylene glycol, sodium lactate, sorbitol, trehalose, triacetin, xylitol, sodium chloride, and polyvinylpyrrolidone.
- The term “thickening agent” (and equivalent terms such as “gelling agent” and “viscosity increasing agent”) refers to substances used in the pharmaceutical preparation of oral soluble films, to improve the viscosity and consistency of the slurry before casting. Active ingredient content uniformity is often a requirement for dosage forms, particularly those containing low dose highly potent active ingredients. To uniquely meet this requirement, oral soluble film formulations can contain uniform dispersions of active ingredient throughout the whole manufacturing process. Examples of thickening agents for use in an OSF described herein include acacia, agar, alginic acid, calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, chitosan, cyclomethicone, ethylcellulose, gelatin, glycerin, guar gum, hydrogenated vegetable oil, hydroxyethy cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, locust bean gum, maltodextrin, methylcellulose, pectin, polydextrose, polyethylene glycol, polyvinyl alcohol, potassium chloride, potassium alginate, povidone, propylene glycol alginate, sodium alginate, sodium chloride, starch, sucrose, sulfobutylether β-cyclodextrin, and xanthan gum.
- The term “lubricant” (and equivalent terms such as “glidant”) refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film) to improve processing characteristics. For example, the lubricant can enhance flow of the slurry by reducing interparticulate friction. The lubricant is typically added to a powder to improve its flowability. A lubricant will typically only work at a certain range of concentrations. Above a certain concentration, the lubricant will function to inhibit flowability. Examples of lubricants for use in an OSF described herein include ascorbyl palmitate, calcium palmitate, castor oil, fumed silica (colloidal silicon dioxide), glycerin monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil (e.g., Sterotex®, Lubritab®, and Cutina®), light mineral oil, magnesium stearate, medium-chain triglycerides, mineral oil, palmitic acid, partial fatty acid esters of sugars, polyethylene glycol fatty acid esters, polyethylene glycol fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, 2-ethoxy ethanol, ethyl alcohol, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, starch, sucrose esters, and talc.
- The term “adsorbent” refers to a substance used to prevent or mitigate the occurrence of another substance from undergoing sorption (process in which one substance takes up or holds another, by either absorption or adsorption). Typically, the adsorbent is used to prevent or mitigate another substance from taking up water or moisture. Examples of adsorbents for use in an OSF described herein include aluminum hydroxide, aluminum oxide, aluminum phosphate, attapulgite, bentonite, powdered cellulose, colloidal silicon dioxide, magnesium aluminum silicate, microcrystalline cellulose, pectin, polycarbophil, and talc.
- The term “suspending agent” refers to a substance that helps another substance (e.g., active pharmaceutical ingredient) to stay suspended in the formulation (e.g., slurry) and to prevent or mitigate the occurrence of caking at the bottom of the container. One of the properties of a well-formulated suspension is that it can be easily re-suspended by the use of moderate agitation or blending. Typically, the suspending agent will help other substances to stay suspended in the slurry, prior to the curing. In doing so, the substances are held in the slurry by the suspending agent, and do not settle at the bottom to any appreciable degree. Examples of suspending agents for use in an OSF described herein include acacia, agar, alginic acid, bentonite, calcium stearate, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, powdered cellulose, cellulose (microcrystalline and carboxymethylcellulose sodium), colloidal silicon dioxide, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, kaolin, magnesium aluminum silicate, maltitol solution, medium-chain triglycerides, methylcellulose, microcrystalline cellulose, phospholipids, polycarbophil, polyethylene glycol, polyoxyethylene sorbitan fatty acid esters, potassium alginate, povidone, propylene glycol alginate, sesame oil, sodium alginate, sodium starch glycolate, sorbitan esters, sucrose, tragacanth, vitamin E polyethylene glycol succinate, and xanthan gum.
- The term “disintegrating agent” (and equivalent terms such as “disintegrator” and “disintegrant”) refers to a substance used in the pharmaceutical preparation of oral solid dosage forms (e.g., oral soluble film or orally disintegrating tablet), that helps the dosage form to disintegrate and release the active ingredient on contact with moisture. The disintegrant is employed in the manufacture of an OSF to promote its rapid disintegration or break down into small particles after administration for facilitating rapid dissolution into bodily fluid. Examples of disintegrating agents for use in an OSF described herein include alginic acid, Amberlite™ calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, colloidal silicon dioxide, corn starch and pregelatinized starch, croscarmellose sodium, crospovidone, glycine, guar gum, hydroxypropyl cellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium starch glycolate, pregelatinized starch, and low substituted HPMC.
- The term “permeation enhancer” refers to a substance used in the pharmaceutical preparation of an oral soluble film, to increase the delivery of the active ingredient, when administered in vivo (e.g., orally), resulting in an increased absorption of the active ingredient. The active ingredient can be delivered across the desired body surface, e.g., oral mucosa, such as buccal, sublingual, mucosa, or gingival; or an intestinal surface. Examples of permeation enhancers for use in an OSF described herein include anionic surfactants (e.g., sodium lauryl sulfate, sodium laurate, Laureth-9, sodium dodecyl sulfate (SDS), dioctyl sodium sulfosuccinate), nonionic surfactants (polyoxyethylene-9-lauryl ethe (PLE), Tween® 80, nonylphenoxypolyoxyethylene (NPPOE), polysorbate, sodium glycocholate), cationic surfactants (e.g., cetylpyridinium chloride, chitosan, trimethyl chitosan, poly-L-arginine, L-lysine), fatty acids or derivatives thereof (e.g., oleic acid caprylic acid, mono(di)glycerides, lauric acid, linoleic acid, acylcholines, acylcarnitine, sodium caprate, and oleic acid), and polyols (e.g., propylene glycol, polyethylene glycol, glycerol, or propanediol).
- The term “active pharmaceutical ingredient” or “API” (and equivalent terms such as “active ingredient,” “medicant,” “medicament,” “bioactive,” and “active”) refers to the substance sildenafil (as the free base, or as a pharmaceutically acceptable salt thereof, e.g., sildenafil citrate). The active pharmaceutical ingredient is pharmacologically and biologically active.
- The term “saliva stimulating agent” (and equivalent terms such as “salivary stimulant” and “acidulant”) refers to a substance used to increase the production of saliva, thereby increasing salivary flow rate. Examples of saliva stimulating agents for use in an OSF described herein include organic acids (e.g., ascorbic acid, citric acid, fumaric acid, tartaric acid, and malic acid), parasympathomimetic drugs (e.g., choline esters such as pilocarpine hydrochloride and cholinesterase inhibitors), physostigmine, and other substances (e.g., xylitol, xylitol/sorbitol, and nicotinamide).
- The term “release modifier” refers to a substance used to modify the release of the active ingredient from an oral solid dosage form (e.g., OSF) and/or is used to modify the absorption of the active ingredient when the oral solid dosage form is orally administered to the subject. The drug release can be contrasted to an immediate release (IR), and includes, e.g., an extended release (XR), sustained release (SR), or delayed release (DR).
- The term “adjuvant” refers to a substance used to modify (e.g., increase) the effect or efficacy of the active ingredient present in an oral solid dosage form (e.g., OSF). The adjuvant can be, e.g., a pharmacological agent or immunological agent.
- The term “fragrance” (and equivalent terms such as “fragrant,” “odorant,” or “aroma compound”) refers to a substance used to impart a desired smell, scent, or odor to a formulation (e.g., slurry or OSF).
- The term “surfactant” refers to a substance used to lower the surface tension (or interfacial tension) between two liquids, between a gas and a liquid, or between a liquid and a solid. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, or dispersants. The surfactant can be anionic, cationic, zwitterionic, or non-ionic.
- The term “pH adjusting agent” refers to a substance used to change the pH of an aqueous solution (e.g., slurry). For example, the pH adjusting agent can be an acid, such that when added to an aqueous solution (e.g., slurry), it will decrease the pH. Alternatively, the pH adjusting agent can be a base, such that when added to an aqueous solution (e.g., slurry), it will increase the pH. The base can be an organic base (e.g., sodium bicarbonate), an inorganic base (e.g., sodium hydroxide), or combination thereof. Likewise, the acid can be an inorganic acid (e.g., hydrochloric acid), an organic acid (e.g., citric acid, malic acid, tartaric acid, etc.), or a combination thereof.
- The term “buffering agent” refers to a weak acid or weak base used to maintain the pH (e.g., acidity or basicity) of a solution (e.g., slurry) near a chosen value after the addition of another acid or base. That is, the function of a buffering agent is to prevent or mitigate the occurrence of a rapid change in pH when acids or bases are added to the solution (e.g., slurry). Buffering agents have variable properties—some are more soluble than others; some are acidic while others are basic. The acid can be an organic acid, mineral acid, or combination thereof. Likewise, the base can be an organic base, inorganic base, or combination thereof.
- The term “stabilizer” refers to a substance used to prevent or mitigate the occurrence of degradation of any one of more substances present in a formulation (e.g., the slurry and/or oral soluble film). This would include preventing or mitigating degradation of the active ingredient, as well as any of the inactive ingredients or excipients.
- The term “antioxidant” refers to a substance used to inhibit, prevent, or mitigate the occurrence of oxidation of any one of more substances present in a formulation (e.g., the slurry and/or oral soluble film). This would include inhibiting, preventing, or mitigating oxidation of the active ingredient, as well as any of the inactive ingredients or excipients. Examples of antioxidants for use in an OSF described herein include ascorbic acid (vitamin C), vitamin A, α-tocopherol (vitamin E), beta-carotene, glutathione, ubiquinol (coenzyme Q), and selenium.
- The term “microcrystalline” refers to a crystallized substance containing small crystals, wherein the crystalline lattice is visible only through microscopic examination.
- “Microcrystalline cellulose” or “MCC” is a term used for refined wood pulp. A naturally occurring polymer, it is composed of glucose units connected by a 1-4 beta glycosidic bond. These linear cellulose chains are bundled together as microfibril spiraled together in the walls of plant cell. The term “silicified microcrystalline cellulose” refers to MCC which is silicified. Silicification is the process in which organic matter becomes saturated with silica. When present in the oral soluble film described herein, the microcrystalline cellulose can function as a filler. The microcrystalline cellulose can optionally further function as an anti-caking agent, emulsifier, bulking agent, viscosity increasing agent, binder, or any combination thereof.
- The term “glycerin” refers to the substance having the IUPAC name propane-1,2,3-triol; CAS Number 56-81-5, 8043-29-6, 25618-55-7, 8013-25-0; chemical formula C3H8O3 or CH2OH—CHOH—CH2OH; and molar mass 92.09 g/mol. The glycerin can be glycerin, 99% natural. The “99%” is a designation of purity and the “natural” is a designation that the substance is not synthetically prepared. When present in an oral soluble film described herein, the glycerin can function as a plasticizer. The glycerin can optionally further function as a sweetener, humectant, solvent, thickening agent, lubricant, or any combination thereof.
- The term “copolymer” refers to a polymer derived from more than one species of monomer. The polymerization of monomers into copolymers is called copolymerization. Copolymers obtained by copolymerization of two monomer species are sometimes called bipolymers. Since a copolymer consists of at least two types of constituent units (also structural units), copolymers can be classified based on how these units are arranged along the chain. Linear copolymers consist of a single main chain, and include alternating copolymers, statistical copolymers, and block copolymers. Branched copolymers consist of a single main chain with one or more polymeric side chains, and can be grafted, star shaped or have other architectures. Graft copolymers are a special type of branched copolymer in which the side chains are structurally distinct from the main chain. Typically, the main chain is formed from one type of monomer (A) and branches are formed from another monomer (B), or else the side-chains have constitutional or configurational features that differ from those in the main chain. The individual chains of a graft copolymer may be homopolymers or copolymers. In specific embodiments, the copolymer can be a graft copolymer. In further specific embodiments, the graft copolymer can be polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer. Polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer is present in the product Kollicoat® Protect.
- The term “polyvinyl alcohol” or “PVA” refers to a water-soluble synthetic polymer. It has the chemical formula (C2H4O)x, idealized formula [CH2CH(OH)]n, and CAS No. 9002-89-5. PVA is present in the product Kollicoat® Protect.
- The term “polyethylene glycol” or “PEG” refers to a polyether compound. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), depending on its molecular weight. The structure of PEG is commonly expressed as H—(O—CH2—CH2)n—OH. PEG has the CAS No. 25322-68-3.
- The term “silicon dioxide” (and equivalent terms such as “silica”) refers to an oxide of silicon with the chemical formula SiO2, molar mass 60.08 g/mol, and CAS No. 7631-86-9. Silicon dioxide is present in the product Kollicoat® Protect.
- The term “Kollicoat® Protect” refers to the commercial product containing (i) polyvinyl alcohol (PVA), (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer, and (iii) silicon dioxide. Kollicoat® Protect is a combination of water-soluble Kollicoat® IR and polyvinyl alcohol, wherein the Kollicoat® IR is a polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer. The PEG portion of Kollicoat® IR is PEG 6000. The Kollicoat® products are commercially available from BASF (Florham Park, N.J.). Kollicoat® Protect has the chemical name polyvinyl alcohol-polyethylene glycol copolymer and polyvinyl alcohol (PVA). Kollicoat® Protect has the CAS-Nos: Kollicoat® IR 96734-39-3, Polyvinyl alcohol 9002-89-5, and silicon dioxide 7631-86-9. When present in the oral soluble film described herein, the Kollicoat® Protect can function as a binder (e.g., rapidly dissolving binder). The Kollicoat® Protect can optionally further function as a film-coating agent, disintegrating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF and/or elongation, anti-caking agent, or any combination thereof.
- The term “peppermint” (and equivalent terms such as “Mentha balsamea Wild” and “Mentha×piperita”) refers to a hybrid mint, a cross between watermint and spearmint. Peppermint has a relatively high menthol content. The oil also contains menthone and carboxyl esters, particularly menthyl acetate. Dried peppermint typically has 0.3-0.4 wt. % of volatile oil containing menthol (7-48 wt. %), menthone (20-46 wt. %), menthyl acetate (3-10 wt. %), menthofuran (1-17 wt. %) and 1,8-cineol (3-6 wt. %). Peppermint oil can contain small amounts of many additional compounds including limonene, pulegone, caryophyllene and pinene. Peppermint can also contain terpenoids and flavonoids, such as eriocarpin, hesperidin, and kaempferol 7-O-rutinoside. The peppermint can be available as dried peppermint (e.g., spray dried peppermint powder) or as a liquid (e.g., peppermint oil). When present as a spray dried powder, the peppermint can include a combination of peppermint oil and carrier (e.g., 25 wt. % peppermint oil and 75 wt. % carrier). The peppermint can include, e.g., the product Natural Peppermint Flavor, which is commercially available as Product No. 501500 TPK0504 from Firmenich Inc. (Anaheim, Calif.); the product Natural Peppermint Oil, commercially available from A. M. Todd; or the product Natural and Artificial Peppermint, commercially available from Firmenich (Anaheim, Calif.). When present in the oral soluble film described herein, the peppermint can function as a flavoring agent. The peppermint can optionally further function as a taste masking agent, permeation enhancer, or a combination thereof.
- The term “sildenafil” refers to the compound having the name 5-{2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; CAS No. 139755-83-2, molecular formula C22H30N6O4S, and molar mass 474.5764 g/mol. The structural formula is provided below.
- Sildenafil is described in standard references such as, e.g., The Physician's Desk Reference, 2018 Edition; The Merck Index, 15th Edition (2013); and United States Pharmacopeia (USP) (2018). Together with a pharmaceutically acceptable counter-ion, sildenafil is also available as a pharmaceutically acceptable salt, e.g., the citrate salt (CAS No. 171599-83-0, molecular formula .C6H8O7). The sildenafil citrate present in the oral soluble film described herein functions as an active ingredient (e.g., the sole active ingredient). In specific embodiments, the oral soluble film (drug product) can be manufactured from sildenafil citrate (drug substance) having a desired bulk density and/or particle size distribution (PSD). In specific embodiments, the oral soluble film (drug product) can be manufactured from sildenafil citrate (drug substance) having a desired physical form (e.g., amorphous, or crystalline), hydrate, or solvate thereof. Sildenafil citrate is commercially available from, e.g., MSN Organics Private Ltd. (Telangana, India); Amoli Organics Pvt. Ltd. (Milan, Italy); Azico Biophore India Pvt. Ltd. (Hyderabad, India); Raks Pharma Pvt. Ltd. (Andhra Pradesh, India); and SMS Pharmaceuticals Ltd. (Hyderabad, India).
- The term “sodium benzoate” refers to the substance which has the chemical formula C6H5COONa; CAS No. 532-32-1; and molar mass 144.105 g/mol. When present in the oral soluble film described herein, the sodium benzoate can function as a preservative.
- The term “FD&C Blue 1” refers to a synthetic organic compound used primarily as a blue colorant for processed foods, medications, dietary supplements, and cosmetics. It has the IUPAC name disodium; 2-[[4-[ethyl-[(3-sulfonatophenyl)methyl]amino]phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]benzenesulfonate. It is classified as a triarylmethane dye and is known under various names, such as FD&C Blue No. 1 or Acid Blue 9. It is denoted by E number E133 and has a color index of 42090. It has the appearance of a blue powder and is soluble in water and glycerol, with a maximum absorption at about 628 nanometers. It is one of the oldest FDA-approved color additives and is generally considered nontoxic and safe. When present in the oral soluble film described herein, the FD&C Blue 1 can function as a colorant.
- The term “acesulfame potassium” or “ACE-K” refers to a calorie-free sugar substitute (artificial sweetener) having the IUPAC name potassium 6-methyl-2,2-dioxo-2H-1,2λ6,3-oxathiazin-4-olate. In the European Union, it is known under the E number (additive code) E950. In chemical structure, acesulfame potassium is the potassium salt of 6-methyl-1,2,3-oxathiazine-4(3H)-one 2,2-dioxide. It is a white crystalline powder with molecular formula C4H4KNO4S and a molecular weight of 201.24 g/mol. When present in the oral soluble film described herein, the ACE-K can function as a sweetener.
- The term “sucralose” refers to an artificial sweetener and sugar substitute. In the European Union, it is also known under the E number E955. Sucralose has the IUPAC name 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside; CAS No. 56038-13-2; chemical formula C12H19Cl3O8; and molar mass 397.64 g/mol. When present in the oral soluble film described herein, the sucralose can function as a sweetener.
- The term “oral soluble film” or “OSF” (and the equivalent terms such as “soluble film,” “orodispersible film,” “oral thin film,” “OTF,” “oral film,” “edible film,” “mucoadhesive film,” “mucoadhesive oral film,” “MOF,” “oral disintegrating film,” “oral dissolvable film,” “ODF,” etc.) refers to a soluble film specifically configured for oral administration. The term also includes “buccal film” (oral soluble film intended to be placed in the buccal space) and “sublingual film” (oral soluble film intended to be placed under the tongue). The oral soluble film is self-supporting, or in other words, is able to maintain its integrity and structure in the absence of a separate support. Oral soluble films are composed of pharmaceutically acceptable ingredients that are edible or ingestible. The oral soluble film can be configured for multi- or unidirectional release. OSFs can be similar in size and shape to a postage stamp, and are designed for oral administration, with the user placing the strip on the tongue (enteric), under the tongue (sublingual), through the oral mucosa (mucosal), against the inside of the cheek (buccal), or on the gums (gingival). Aside from the enteric route, these drug delivery options allow the medication to bypass the first pass metabolism thereby making the medication more bioavailable. As the film dissolves, the drug can enter the blood stream enterically, mucosally, buccally, gingivally, and/or sublingually. As such, the oral soluble film is prepared using hydrophilic polymers that can dissolve on the tongue or buccal cavity, delivering the drug to the systemic circulation via dissolution when contact with liquid is made. Oral film drug delivery accordingly uses a dissolving film to administer drugs via absorption in the mouth (buccally, sublingually, or gingivally) and/or via the small intestines (enterically). Especially for drugs which are metabolized extensively by the first-pass effect, oral films described herein can provide a faster-acting and better absorption profile. The oral soluble film can be shaped as being circular, round, oval, elliptical, or polygonal (e.g., triangular, square, or rectangular). Additionally, the OSF can optionally include a logo and/or indicia located thereon. The logo and/or indicia can identify, e.g., the marketing company name, manufacturing company name, drug substance name, drug product name, strength, dosage form, route of administration, and/or product serialization. Such logo and/or indicia can be printed thereon, e.g., with pharmaceutically acceptable ink, or can be embossed.
- The term “anhydrous film” refers to an oral soluble film containing no significant or appreciable amount of water. As such, reference to the weight percentage amount of water (moisture) present in an anhydrous film is essentially zero. Within the context of the present invention, it is appreciated that those of skill in the art understand and agree that an oral soluble film will likely include at least trace amounts of water—as the complete removal of the water during the curing phase is unlikely. And that the oral soluble film may pick up moisture during the packaging, shipment, and/or storage. However, with the exception of the solvent water, substances (e.g., excipients and API) present in the orally soluble film described herein can be characterized by the weight percentage amount, based on an anhydrous film. As such, within the context of the present invention, it is appreciated that those of skill in the art understand and agree that reference to the oral soluble film as being anhydrous, at least for purposes of expressing the weight percentage amount of the excipients and/or API (with the notable exception of the solvent water) is otherwise acceptable and appropriate.
- The term “hydrated film” refers to an oral soluble film containing a significant and appreciable amount of water. The amount of water present in a hydrated film can be measured (e.g., loss on drying).
- The term “unit dosage” (and equivalent terms such as “unit dose” and “unit dosage form”) refers to an oral soluble film sized to the appropriate dimension, such that the individual film contains a desired amount of active ingredient to be administered to a subject for an intended use. Prior to sizing to the appropriate dimension (thereby providing the unit dosage form), the soluble film can exist, e.g., in either the unwound form (e.g., sheet) or in the wound form (e.g., bulk roll).
- The term “drug substance” refers to the unformulated API (active pharmaceutical ingredient). The API has the therapeutic effect in the body as opposed to the excipients, which assist with the delivery of the API. The chemical purity and physical state (crystal form, salt form, etc.) can influence the quality and performance of a drug substance. This is especially important for water insoluble drugs.
- The term “drug product” refers to the formulated drug substance with excipients. The drug product is typically the final marketed dosage form of the drug substance, for example a tablet, capsule, or oral soluble film (OSF). A drug substance, because of multiple factors (sensitivity, stability, etc.) is often mixed with other components before being released for use in the market. The drug substance together with the added ingredients (excipients) is known as drug product. The drug substance together with these added agents is called the drug product and within its packaging is called the “finished product.”
- The term “drug load” (and equivalent terms such as “load of active ingredient”) refers to the amount of active pharmaceutical ingredient present in the oral soluble film. For example, in specific embodiments the oral soluble film can have a high drug load, such that the active pharmaceutical ingredient is present in a relatively high amount (e.g., above 30 wt. %) of the oral soluble film. The drug load is expressed as
-
- The term “binder load” (and equivalent terms such as “load of binder”) refers to the amount of binder (e.g., Kollicoat® Protect and MCC) present in the oral soluble film. In specific embodiments, the oral soluble film can have a high binder load, such that the binders are present, in the aggregate, in a relatively high amount (e.g., at least 25 wt. % of the oral soluble film). In further specific embodiments, the oral soluble film can have a high binder load, such that the Kollicoat® binders are present, in the aggregate, in a relatively high amount (e.g., at least 30 wt. % of the oral soluble film).
- The term “weight ratio” refers to the weight ratio of two items. For example, the weight ratio of binder to API can be expressed as
-
- In specific embodiments, the weight ratio of binder to API is 83±10%. In further specific embodiments, the weight ratio of binder to API is 83±5%.
- The term “CL/F” refers to the apparent total clearance of drug from plasma after oral administration. It is measured in units of volume/time (mL/min) or in units of volume/time/kg (mL/min/kg).
- The term “Tmax” refers to time of maximum plasma concentration and is the time to reach maximum (peak) plasma concentration following drug administration. It is measured in units of time (hours).
- The term “t1/2” refers to elimination half-life and is time to reach elimination half-life (to be used in one or non-compartmental model). It is measured in units of time (hours).
- The term “treating” (and equivalent terms such as “treat,” “treated,” and “treatment”) of a subject includes the administration of an active pharmaceutical ingredient (API), or a unit dosage form containing the same (e.g., oral soluble film), to a subject with the purpose of preventing, mitigating, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of the disease or disorder. The disease or disorder can be, e.g., erectile dysfunction (ED), antidepressant-induced erectile dysfunction (ED), or pulmonary arterial hypertension (PAH).
- The term “erectile dysfunction” or “ED” (and the equivalent term “impotence”) refers to the type of sexual dysfunction in which the penis fails to become or stay erect during sexual activity. It is the most common sexual problem in men. Through its connection to self-image and to problems in sexual relationships, erectile dysfunction can cause psychological harm. ED is characterized by the regular or repeated inability to achieve or maintain an erection of sufficient rigidity to accomplish sexual activity. ED often has an impact on the emotional well-being of both men and their partner(s). Many men do not seek treatment due to feelings of embarrassment. It is believed that about 75% of diagnosed cases of ED go untreated.
- The term “kit” refers to a system for delivering an oral soluble film as described herein, from one location to another. Such delivery systems can include enclosures that allow for the storage, transport, and/or delivery of an oral soluble film as described herein and any accompanying materials. The enclosure can be, e.g., a box or a bag. The accompanying materials can include, e.g., label, reference material, prescribing information, supporting material, or a combination thereof. For example, the kit can include a single dose of the oral soluble film described herein, that is individually packaged and sealed with a primary packaging material. Alternatively, the kit can include multiple doses of the oral soluble film described herein, each of which is individually packaged and sealed with a primary packaging material. Additionally, the kit can include an enclosure containing (i) multiple doses of the oral soluble film described herein, each individually packaged and sealed with a primary packaging material, and (ii) prescribing information. The primary packaging material can include at least one of metalized polyester, cellophane, polypropylene, nylon, polyester, vinylidene chloride, vinyl chloride, polycarbonate, low-density polyethylene, high-density polyethylene, linear low-density polyethylene, ionomer, polyvinyl alcohol, ethylene/vinyl acetate copolymer, ethylene/acrylic acid copolymer, ethylene/ethyl acrylate copolymer, polystyrene, and aluminum foil. The primary packaging material can include a single layer of material, or can include multiple layers of material (wherein each layer can independently include the same or different material as the other layers). The primary packaging material forms a primary package that can (i) protect the oral soluble film from light, (ii) protect the oral soluble film from microbial contamination, (iii) be child resistant, (iv) be a barrier to moisture and vapor, (v) mitigate leachable into the oral soluble film, (vi) identifies a logo and/or includes printed indicia, or (vii) any combination thereof. The logo and/or printed indicia can identify, e.g., the marketing company name, manufacturing company name, drug substance name, drug product name, strength, dosage form, route of administration, and/or product serialization.
- The term “prescribing information” (and the equivalent terms “product information,” “product labeling,” “package insert,” or “PI”) refers to information relevant to the drug product, that is generally drafted by the drug company and such information is approved by the FDA. It includes the details and directions healthcare providers need to prescribe the drug product properly. It is also the basis for how the drug company can advertise its drug product. The prescribing information includes such details about the drug product as: its chemical description; how it works; how it interacts with other drugs, supplements, foods, and beverages; what condition(s) or disease(s) it treats; who should not use the drug product; serious side effects, even if they occur rarely; commonly occurring side effects, even if they are not serious; and effects on specific groups of patients, such as children, pregnant women, or older adults and how to use it in these populations. Sometimes, the drug company drafts prescription drug information designed for patients that the FDA approves. These are often called “Patient Package Inserts,” “Patient Product Information,” or “PPIs.”
- The term “drug company” refers to the one or more companies that (i) markets the drug product (or retains ownership rights to the same), (ii) manufactures the drug product (or retains ownership rights to the same), and/or (iii) is the NDA applicant holder. As such, the drug company can be a single company or can include separate, multiple companies.
- The term “subject” refers to living organisms such as humans, dogs, cats, and other mammals. Administration of the active ingredient included in the oral soluble film described herein can be carried out at dosages and for periods of time effective for the treatment of the subject. In some embodiments, the subject is a human. Within the context of treating PAH, the human subject can be a male or female, and can further be an adult, adolescent, child, toddler, or infant. Within the context of treating ED, the human subject can be a post-pubescent male, typically at least 18 years old.
- The term “transmucosal” refers to any route of administration via a mucosal membrane or mucosal surface. Examples include, but are not limited to, buccal, sublingual, nasal, vaginal, and rectal.
- The term “buccal administration” refers to a topical route of administration by which a drug held or applied in the buccal area (in the cheek) diffuses through the oral mucosa (tissues which line the mouth) and enters directly into the bloodstream. Buccal administration may provide better bioavailability of some drugs and a more rapid onset of action compared to oral administration because the medication does not pass through the digestive system and thereby avoids first pass metabolism. In multiple instances, buccal administration has been found to avoid liver and GI toxicities.
- The term “buccal space” (also termed the buccinator space) refers to a fascial space of the head and neck (sometimes also termed fascial tissue spaces or tissue spaces). It is a potential space in the cheek, and is paired on each side. The buccal space is superficial to the buccinator muscle and deep to the platysma muscle and the skin. The buccal space is part of the subcutaneous space, which is continuous from head to toe.
- The term “oral mucosa” refers to the mucous membrane lining the inside of the mouth and consists of stratified squamous epithelium termed oral epithelium and an underlying connective tissue termed lamina propria. Oral mucosa can be divided into three main categories based on function and histology: (1) Masticatory mucosa, keratinized stratified squamous epithelium, found on the dorsum of the tongue, hard palate and attached gingiva; (2) Lining mucosa, nonkeratinized stratified squamous epithelium, found almost everywhere else in the oral cavity, including the: (a) Buccal mucosa refers to the inside lining of the cheeks and floor of the mouth and is part of the lining mucosa; (b) Labial mucosa refers to the inside lining of the lips and is part of the lining mucosa; and (c) Alveolar mucosa refers to the lining between the buccal and labial mucosae. It is a brighter red, smooth and shiny with many blood vessels, and is not connected to underlying tissue by rete pegs; and (3) Specialized mucosa, specifically in the regions of the taste buds on lingual papillae on the dorsal surface of the tongue that contains nerve endings for general sensory reception and taste perception.
- The term “sublingual administration,” from the Latin for “under the tongue,” refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue. When a drug comes in contact with the mucous membrane beneath the tongue, it is absorbed. Because the connective tissue beneath the epithelium contains a profusion of capillaries, the substance then diffuses into them and enters the venous circulation. In contrast, substances absorbed in the intestines are subject to first-pass metabolism in the liver before entering the general circulation. Sublingual administration has certain advantages over oral administration. Being more direct, it is often faster, and it ensures that the substance will risk degradation only by salivary enzymes before entering the bloodstream, whereas orally administered drugs must survive passage through the hostile environment of the gastrointestinal tract, which risks degrading them, by either stomach acid or bile, or by enzymes such as monoamine oxidase (MAO). Furthermore, after absorption from the gastrointestinal tract, such drugs must pass to the liver, where they may be extensively altered; this is known as the first pass effect of drug metabolism. Due to the digestive activity of the stomach and intestines, the oral route is unsuitable for certain substances.
- The term “gingival administration” refers to the pharmacological route of administration by which substances diffuse into the blood through tissues in the gums. The gums or gingiva (plural: gingivae), consist of the mucosal tissue that lies over the mandible and maxilla inside the mouth.
- The term “enteral administration” refers to a drug administration via the human gastrointestinal tract. Enteral administration involves the esophagus, stomach, and small and large intestines (i.e., the gastrointestinal tract). Methods of administration include oral and rectal. Enteral administration may be divided into three different categories, depending on the entrance point into the GI tract: oral (by mouth), gastric (through the stomach), and rectal (from the rectum). (Gastric introduction involves the use of a tube through the nasal passage (NG tube) or a tube in the belly leading directly to the stomach (PEG tube). Rectal administration usually involves rectal suppositories.) Enteral medications come in various forms, including, e.g., tablets to swallow, chew or dissolve in water; capsules and chewable capsules (with a coating that dissolves in the stomach or bowel to release the medication there), oral soluble films, time-release or sustained-release tablets and capsules (which release the medication gradually), osmotic delivery systems, powders or granules, and liquid medications or syrups.
- The term “oral administration” or “PO” refers to a route of administration where a substance is taken through the mouth. Many medications are taken orally because they are intended to have a systemic effect, reaching different parts of the body via the bloodstream.
- The term “moisture content” (and equivalent terms such as “water content”) refers to the quantity of water contained in an oral soluble film described herein. The moisture content can encompass bound water and unbound water. Water content is expressed as a ratio, which can range from 0 (completely dry) to the value of the soluble film's porosity at saturation. It can be given on a volumetric or mass (gravimetric) basis. Typically, the moisture content will be expressed as a weight percent (e.g., 4 wt. %). Water content can be directly measured using a drying oven. Other methods that determine water content of a sample include chemical titrations (for example the Karl Fischer titration), determining mass loss on heating (perhaps in the presence of an inert gas), or after freeze drying. The Dean-Stark method is also commonly used. Unless specified otherwise, the loss on drying (LOD) method can be employed to calculate the moisture content of a soluble film described herein.
- The term “loss on drying” or “LOD” refers to the loss of weight expressed as percentage w/w resulting from water and/or volatile matter that can be driven off under specified conditions from an object (e.g., oral soluble film). In this technique, a sample of material (e.g., oral soluble film) is weighed, heated in an oven for an appropriate period, cooled in the dry atmosphere of a desiccator, and then reweighed. The difference in weight is the loss on drying (LOD). For example, the oral soluble film can have a loss on drying (LOD) of 5±2 wt. %. Methods employed include Thermogravimetric Analysis (TGA) and IR Moisture Analyzers.
- The term “pharmaceutically acceptable” refers to those compounds, excipients, active ingredients, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- The term “disintegration” refers to a physical process of breaking down a substance into fragments to improve its solubility in a solvent. The process is used predominantly in pharmaceutical and chemical industries. Disintegration occurs when a dosage form breaks up into smaller particles. It usually takes place in two steps; the content breaks up into small granules which then disaggregate. For oral soluble films, this breaking up process of the dosage form usually starts in the oral cavity, where it may be completed depending upon, e.g., the formulation, contact duration, volume of saliva, and whether or not taken with a beverage. If the dosage form passes into the stomach and then into the small intestine, then the process may continue there. Disintegration can usually be observed in the laboratory in a dissolution apparatus. Actual QC disintegration methods, however, use specific pieces of equipment described in USP <701>.
- The term “dissolution” refers to a process through which solutes dissolve in a solvent. Dissolution is used predominantly in pharmaceutical industries to check how soluble a drug is in the body. Dissolution is a process through which a dosage form dissolves in a solvent to produce a solution. Dissolution requires disintegration of the dosage form to occur first, then drug particles to dissolve. It is the rate (amount of drug and time) at which the drug dissolves. In vivo dissolution of an oral soluble film starts as soon as the drug in the dosage form is wetted with saliva. There are many different dissolution apparatuses used to establish how much drug dissolves and how long this takes. The standard apparatus is also described in USP <711>.
- The term “bioavailability” refers to a subcategory of absorption and is the fraction (%) of an administered drug that reaches the systemic circulation. Mathematically, bioavailability equals the ratio of comparing the area under the plasma drug concentration curve versus time (AUC) for the extravascular formulation to the AUC for the intravascular formulation. AUC can be utilized because AUC is proportional to the dose that has entered the systemic circulation.
- The term “pharmacokinetics,” sometimes abbreviated as “PK” refers to a branch of pharmacology dedicated to determining the fate of substances administered to a living organism. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is the study of how an organism affects a drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.
- PK therefore refers to the study of the uptake of drugs by the body, the biotransformation they undergo, the distribution of the drugs and their metabolites in the tissues, and the elimination of the drugs and their metabolites from the body over a period of time.
- The following are commonly measured pharmacokinetic metrics:
-
-
Characteristic Description Dose Amount of drug administered. Dosing interval Time between drug dose administrations. Cmax The peak plasma concentration of a drug after administration. Tmax Time to reach Cmax. Cmin The lowest (trough) concentration that a drug reaches before the next dose is administered. Volume of distribution The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body). Concentration Amount of drug in a given volume of plasma. Absorption half life The time required for the concentration of the drug to double its original value for oral and other extravascular routes. Absorption rate The rate at which a drug enters into the body constant for oral and other extravascular routes. Elimination half-life The time required for the concentration of the drug to reach half of its original value. Elimination rate The rate at which a drug is removed from constant (KEL) the body. Infusion rate Rate of infusion required to balance elimination. Area under the curve The integral of the concentration-time curve (after a single dose or in steady state). Clearance The volume of plasma cleared of the drug per unit time. Bioavailability The systemically available fraction of a drug. Fluctuation Peak trough fluctuation within one dosing interval at steady state. - The term “curing” refers to a chemical process that can be used to produce a soluble film (as described herein) from a slurry (also described herein). The process can be carried out by removing solvent (water), by toughening or hardening of polymer material present in the slurry, by cross-linking the polymer chains, etc. The term curing can be used to refer to the processes where starting from a liquid or semi-solid solution (e.g., slurry), a solid product (e.g., soluble film) is obtained. Curing can be initiated by heat, radiation, electron beams, or chemical additives. To quote from IUPAC: curing “might or might not require mixing with a chemical curing agent.” IUPAC. Compendium of Chemical Terminology, 2nd ed. (the “Gold Book”). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). Online version (2019-) created by S. J. Chalk. ISBN 0-9678550-9-8. https://doi.org/10.1351/goldbook. Thus, two broad classes are (i) curing induced by chemical additives (also called curing agents, hardeners) and (ii) curing in the absence of additives. An intermediate case involves a mixture of resin and additives that requires external stimulus (light, heat, radiation) to induce curing.
- The term “mass” refers to a measurement of how much matter is in an object. Mass is a combination of the total number of atoms, the density of the atoms, and the type of atoms in an object. Mass is usually measured in grams (which is abbreviated as g) or milligrams (which is abbreviated as mg).
- The term “density” refers to the mass per unit volume of an object (e.g., oral soluble film). Density is calculated by dividing the mass of an object by the volume of the object. The volume of an object can be stated as cubic centimeters or milliliters as both are equivalent.
- The term “tack” refers to the tenacity with which the oral soluble film adheres to an accessory (a piece of paper) that has been pressed into contact with the film.
- The term “tensile strength” refers to the maximum stress applied to a point at which the oral soluble film specimen breaks. It is calculated by the applied load at rupture divided by the cross-sectional area of oral soluble film, as given in the equation below:
-
Tensile strength=Load at failure×100/Film thickness×Film width - The term “percent elongation” refers to the relative increase in amount in length upon application of stress. When stress is applied on a film sample, it gets stretched. This is referred to as strain. Strain is basically the deformation of film before it gets broken due to stress. It can be measured by using hounsfield universal testing machine. Generally, elongation of the film increases as the plasticizer content increases. It is calculated by the formula:
-
% Elongation=Increase in length of film×100/Initial length of film - The term “tear resistance” refers to the resistance which a film offers when some load or force is applied on the film specimen. Specifically, it is the maximum force required to tear the specimen. The load mainly applied can be of a very low rate (e.g., 51 mm/min). The unit of tear resistance is Newton or pounds-force.
- The term “Young's modulus” (and equivalent terms such as “elastic modulus”) refers to the measure of stiffness of a soluble film. It is represented as the ratio of applied stress over strain in the region of elastic deformation as follows:
-
Young's modulus=Slope×100/Film thickness×Cross head speed - Hard and brittle strips demonstrate a high tensile strength and Young's modulus with small elongation.
- The term “folding endurance” refers to number of times the film can be folded without breaking or without any visible crack. Folding endurance is a measure of the brittleness of a film. The method followed to determine endurance value is that the film specimen is repeatedly folded at the same place until it breaks, or a visible crack is observed. The number of times the film is folded without breaking or without any visible crack is the calculated folding endurance value.
- The term “drug content uniformity” (and equivalent terms such as “uniformity of dosage unit” or “CU”) refers to the degree of uniformity in the amount of drug substance among dosage units, and unless otherwise specified, is set forth in USP-NF General Chapter<905> Uniformity of Dosage Units.
- Across multiple embodiments, substances present in the orally soluble film described herein are characterized by the weight percentage amount of substance present therein. The substance can be the active pharmaceutical ingredient and/or any one or more of the excipients. The weight percentage amount of substance present therein can be based on an anhydrous film (e.g., an orally soluble film containing no significant and appreciable amount of water). A notable exception is reference to the weight percentage amount of water (moisture) present in the soluble film. Specifically, because an anhydrous film contains no water, reference to the weight percentage amount of water (or moisture) contained within the oral soluble film can be based on a hydrated (e.g., 5±1.5 wt. % hydrated) oral soluble film. By way of illustration, reference is made to the product illustrated in the table below. In one embodiment, an oral soluble film can be prepared from a slurry, in which an active ingredient (sildenafil citrate) is present in 70.24 mg per 195.10 mg (36.00 wt. %) of an anhydrous oral soluble film. This can be calculated as follows:
-
- The weight percentage amount of each excipient in the anhydrous oral soluble film can likewise be calculated. In order to arrive at these calculations, the water is not included in the mass of the oral soluble film.
- In another embodiment, the active ingredient (sildenafil citrate) can be present in 16.8 wt. % of the slurry. In arriving at this calculation, the water is included in the mass of the slurry. The mass of the slurry (10,000 g) is obtained from the amount (mass) of all substances added to form the slurry, including the purified water added (5,328 g). This can be calculated as follows:
-
- Likewise, the active ingredient (sildenafil citrate) can be present in 70.24 mg per 204.86 mg (34.29 wt. %) of a hydrated oral soluble film. This can be calculated as follows:
-
- The level of hydration of the hydrated film can be estimated (e.g., a 5% hydrated film). For that hydrated film, the requisite amount of water (e.g., 5 wt. %) is used to obtain the calculated amount of water (mg) in the hydrated film, as well as the calculated weight percentage amounts for each of the substances present in the hydrated film.
-
FORMULATION 1.01 ORAL SOLUBLE FILM Amount Amount SLURRY in 5% in 5% Quantity Amount Amount in Amount in hydrated hydrated dispensed in slurry anhydrous anhydrous film film Substance (g) (wt. %) film (wt. %) film (mg) (wt. %) (mg) Sildenafil Citrate 1678.6 16.8 36.00 70.24 34.29 70.24 Kollicoat ® Protect 1406.3 14.1 30.00 58.53 28.57 58.53 Microcrystalline 252.1 2.5 5.45 10.63 5.19 10.63 Cellulose - Avicel ® PH-101 Natural Peppermint 299.9 3.0 6.44 12.56 6.13 12.56 Flavor Glycerin, 99.7% pure 558.5 5.6 12.00 23.41 11.43 23.41 Sucralose 280.0 2.8 6.00 11.70 5.71 11.70 Acesulfame 186.0 1.86 4.00 7.80 3.80 7.80 Potassium FD&C Blue 1 0.5 0.005 0.01 0.02 0.01 0.02 Sodium Benzoate 5.0 0.05 0.10 0.20 0.10 0.20 Water 5328 53.3 NA NA 5.00 9.76 TOTAL 10000.0 100 100 195.10 100 204.86 - The term “particle-size distribution” or “PSD” refers to a list of values or a mathematical function that defines the relative amount, typically by mass, of particles present according to size. For example, the mass-median-diameter (MMD) (expressed as, e.g., d10, d50, d90, etc.) refers to the log-normal distribution mass median diameter. The MMD is considered to be the average particle diameter by mass. The particle size distribution can be obtained by, e.g., laser diffraction, analytical sieving, light scattering, etc.
- Particle size Distribution D10 (or d10) is also written as X10, D(0,1) or X(0,1). It represents the particle diameter corresponding to 10% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D10 is 7.8 um, then 10% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 10%. D10 is a typical point in particle size distribution analysis. D10 is also divided into Dv10, Dw10 and Dn10. Dv10 means volume D10, whereas Dw10 is mass D10 and Dn10 is number D10.
- Particle size Distribution D50 (or d50) is also written as X50, D(0,5) or X(0,5). It represents the particle diameter corresponding to 50% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D50 is 7.8 um, then 50% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 50%. D50 is a typical point in particle size distribution analysis. D50 is also divided into Dv50, Dw50 and Dn50. Dv50 means volume D50, whereas Dw50 is mass D50 and Dn50 is number D50.
- Particle size Distribution D90 (or d90) is also written as X90, D(0,9) or X(0,9). It represents the particle diameter corresponding to 90% cumulative (from 0 to 100%) undersize particle size distribution. In other words, if particle size D90 is 7.8 um, then 90% of the particles in the tested sample are smaller than 7.8 micrometer, or the percentage of particles smaller than 7.8 micrometer is 90%. D90 is a typical point in particle size distribution analysis. D90 is also divided into Dv90, Dw90 and Dn90. Dv90 means volume D90, whereas Dw90 is mass D90 and Dn90 is number D90.
- The manufacture of oral soluble films can be carried out by various methods such as: (1) casting (e.g., solvent casting or semi-solid casting), (2) extrusion (e.g., hot melt extrusion or solid dispersion), and (3) rolling. These methods of manufacturing oral soluble films are generally well-known to the skilled artisans. See, e.g., “Manufacturing Techniques of Orally Dissolving Films,” Pharmaceutical Technology, Volume 35, Issue 1 (Jan. 2, 2011); “Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms,” Vikas Anand Saharan, pp. 318-356 (39) (2017); A short review on “A novel approach in oral fast dissolving drug delivery system and their patents,” M. N. Siddiqui, G. Garg, P. K. Sharma, Adv. Biol. Res., 5 (2011), pp. 291-303; “Orally disintegrating films: A modern expansion in drug delivery system,” Ifran et al., Saudi Pharmaceutical Journal, Volume 24, Issue 5, pp. 537-546 (September 2016); “Development and characterization of pharmacokinetic parameters of fast-dissolving films containing levocetirizine,” D. R. Choudhary, V. A. Patel, U. K. Chhalotiya, H. V. Patel, A. J. Kundawala; Sci. Pharm., 80 (2012), pp. 779-787; “Orally disintegrating preparations: recent advancement in formulation and technology,” R. R. Thakur, D. S. Rathore, S. Narwal; J. Drug Deliv. Therap., 2 (3) (2012), pp. 87-96; “Development of innovative orally fast disintegrating film dosage forms: a review,” B. P. Panda, N. S. Dey, M. E. B. Rao; Int. J. Pharm. Sci. Nanotechnol., 5 (2012), pp. 1666-1674.
- Several methods for manufacturing an oral soluble film may be pursued, but the most common is solvent casting. Using this method, the manufacturing process can start with dispensing the excipients, active ingredient and solvent(s) in a defined order, preferably into a temperature-controlled tank and blending them into a slurry, typically using a high shear mixer to achieve a homogenous slurry. Homogeneity of the slurry should be tested by sampling at different locations in the tank and measuring viscosity and solids content. Depending on the properties of the slurry (i.e., bacteriostatic, bactericidal or growth promoting), in-process bioburden testing may be employed. To ensure flexibility of production scheduling, optimal conditions for storing the slurry should be tested.
- The slurry may then be fed into an oven through a coating station, typically using a pump system. The slurry may be applied to a liner using a slot die or knife-over-roll coater, at a determined pin gauge. The selection of the liner can affect how the solvent (e.g., water) will evaporate and should generally be selected as to mitigate the occurrence of any chemical interaction with the film. Relevant parameters when selecting a liner are moisture content of the cast film, the location of the heat source and the directionality and strength of the air flow within the oven. It is generally preferred to “bake” the film rather than “broil” it. Additionally, the liner will preferably be qualified by the FDA, e.g., having its own drug master file (DMF).
- Casting parameters—oven temperature, pin gauge and belt speed—required to meet product specifications at the terminal end of the oven, are generally optimized to achieve the fastest belt speed for highest throughput and cost efficiencies. Some oven systems enable the operator to control the height and directionality of the air nozzles and offer modular heat zones (e.g., infrared, progressive temperature increase). Oven lengths generally range from 10 ft to 24 ft, or more. The film and liner may then be packed as master rolls at the terminal end of the oven and should be stored in a temperature and humidity-controlled environment as oral soluble films tend to be hygroscopic. Stability of the intermediate master rolls over time may be established by evaluating API content, moisture levels, physical characteristics, pliability dissolution, microbiology, and tensile strength. Typically, oral soluble film products are stable at room temperature in an appropriate container closure system. Of note, there is currently no official method or monograph in the US Pharmacopeia for evaluating oral soluble film properties such as disintegration, dissolution or mucoadhesion. Additionally, at the end of casting, additional API and/or occluding layer can be sprayed onto the cast film. Alternatively, the film can be 3D printed instead of casting.
- Another step in the production is cutting the master roll into daughter rolls (alternatively referred to as “sitting”) and further into single doses which can be placed into individual pouches or sachets by converting and packaging machines. Ink printing of a mark on the film can be carried out. The mark can include a logo or indicia, such as the company name and dosage (e.g., “CURR50”—corresponding to Cure Pharmaceutical Holding Corp. (OTC:CURR), and 50 mg sildenafil). The ink is preferably pharmaceutically acceptable and will not interfere with the performance characteristics (e.g., disintegration time) of the OSF. The API dose of an oral soluble film product is directly informed by the weight of the film. It is therefore critical to control the weight of each film product that is packaged. The size to which each individual film should cut must be determined during process development to ensure the product meets its the target weight and API load. A significant advantage with this dosage form is the ease in which multiple stock keeping units (SKUs) can be produced, by simply modifying the size or mass of the film.
- Metalized polyester is a suitable primary packaging material for oral soluble film. It can be cost effective and protects the product from moisture and light. This pouch material can be child resistant and closure systems can be designed to ensure the product passes child resistant testing, while remaining user friendly for the patient. The pouches or sachets can offer larger printable 2D areas which traditional drug product formats do not. This allows the manufacturer to adapt to rapidly evolving labeling and regulatory requirements for information and anti-counterfeiting, such as product serialization. Furthermore, the primary package can provide sufficient space to include instructions on how to open the package and use the product, so that patients have a clear understanding of how it works. If desirable, each OSF can be individually packaged. One supplier of commercially available primary packaging materials is Bemis Company, Inc. (Neenah, Wis.).
- The manufacturing of oral soluble films can be a continuous but modular process that is suitable to automation. The modularity of the process, such as master roll holds, allows for finished conversion to be done in the country or region of distribution, which compliments satellite expansion based on regional demand. The manufacturing process can have a low carbon footprint, with lower use of water for component preparation, as compared with other dosage forms.
- The specific embodiments describing the ranges and values provided below are for illustration purposes only, and do not otherwise limit the scope of the disclosed subject matter, as defined by the claims.
- In specific embodiments, the sildenafil citrate is present in 36±10 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±9 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±8 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±7 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±6 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±5 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±4 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±3 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±2 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±1 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±0.5 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 36±0.25 wt. % of the oral soluble film.
- In specific embodiments, the sildenafil citrate is present in 34.29±10 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±9 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±8 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±7 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±6 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±4 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sildenafil citrate is present in 34.29±0.25 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±9 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±8 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±7 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±1 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sildenafil citrate is present in 70.24±0.5 mg.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 25 mg, 50 mg, or 100 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 22.5-27.5 mg of sildenafil, as the free base.
- In specific embodiments, the sildenafil citrate is present in an amount of up to 0.30 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of at least 0.20 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.06 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.05 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.04 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.03 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.02 mg/mm3.
- In specific embodiments, the sildenafil citrate is present in an amount of 0.24±0.01 mg/mm3.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 25 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 45-55 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 50 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 50±5 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 90-110 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film is in the form of a unit dose and the sildenafil citrate is present in an amount equivalent to 100 mg of sildenafil, as the free base.
- In specific embodiments, the oral soluble film includes non-non-micronized sildenafil citrate.
- In specific embodiments, the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(10) of less than 2 μm.
- In specific embodiments, the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(50) of less than 5 μm.
- In specific embodiments, the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(90) of less than 60 μm.
- In specific embodiments, the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(90) of less than 35 μm.
- In specific embodiments, the oral soluble film is manufactured from non-micronized sildenafil citrate having the following particle size distribution (PSD): Dv(10) of less than 2 μm, Dv(50) of less than 5 μm, and Dv(90) of less than 35 μm.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±3 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±2.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±2 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±1.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sildenafil citrate is present in 16.8±0.5 wt. % of the slurry.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 20 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 15 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 10 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 5 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 2.5 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 1 wt. %.
- In specific embodiments, the variation of sildenafil citrate between two equally sized unit dosages is less than 0.5 wt. %.
- In specific embodiments, the binder is present in 30±10 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±9 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±8 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±7 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±6 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±5 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±4 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±3 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±2 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 30±1 wt. % of the oral soluble film.
- In specific embodiments, the binder is present in 28.57±10 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±9 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±8 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±7 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±6 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±4 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the binder is present in 28.57±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±18 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±16 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±14 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±12 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±8 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±7 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the binder is present in 58.53±4 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±3 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±2.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±2 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±1.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the binder is present in 14.1±0.5 wt. % of the slurry.
- In specific embodiments, the binder includes Kollicoat® Protect.
- In specific embodiments, the binder includes Kollicoat® Protect, which includes: Kollicoat® IR, polyvinylalcohol, and silicon dioxide.
- In specific embodiments, the binder includes (i) polyvinyl alcohol (PVA); (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and (iii) silicon dioxide.
- In specific embodiments, the Kollicoat® Protect functions as a binder.
- In specific embodiments, the Kollicoat® Protect functions as a binder and at least one of a film-coating agent, disintegrating agent, taste masking agent, emulsifier, to increase tensile strength of the OSF and/or elongation, and anti-caking agent.
- In specific embodiments, the Kollicoat® Protect is present in 30±10 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±9 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±8 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±7 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±6 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±5 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±4 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±3 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±2 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 30±1 wt. % of the oral soluble film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±10 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±9 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±8 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±7 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±6 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±4 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the Kollicoat® Protect is present in 28.57±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±18 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±16 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±14 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±12 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±8 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±7 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the Kollicoat® Protect is present in 58.53±4 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±3 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±2.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±2 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±1.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the Kollicoat® Protect is present in 14.1±0.5 wt. % of the slurry.
- In specific embodiments, the filler is present in 5.45±2.5 wt. % of the oral soluble film.
- In specific embodiments, the filler is present in 5.45±2 wt. % of the oral soluble film.
- In specific embodiments, the filler is present in 5.45±1.5 wt. % of the oral soluble film.
- In specific embodiments, the filler is present in 5.19±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±1.25 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±0.75 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the filler is present in 5.19±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the filler is present in 10.63±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the filler is present in 10.63±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the filler is present in 10.63±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the filler is present in 10.63±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the filler is present in 10.63±1 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the filler is present in 2.5±0.1 wt. % of the slurry.
- In specific embodiments, the filler includes microcrystalline cellulose.
- In specific embodiments, the microcrystalline cellulose functions as a filler and binder.
- In specific embodiments, the microcrystalline cellulose functions as a filler and binder, and at least one of an anti-caking agent, emulsifier, bulking agent, and viscosity increasing agent.
- In specific embodiments, the microcrystalline cellulose is present in 5.45±2.5 wt. % of the oral soluble film.
- In specific embodiments, the microcrystalline cellulose is present in 5.45±2 wt. % of the oral soluble film.
- In specific embodiments, the microcrystalline cellulose is present in 5.45±1.5 wt. % of the oral soluble film.
- In specific embodiments, the microcrystalline cellulose is present in 5.45±1 wt. % of the oral soluble film.
- In specific embodiments, the microcrystalline cellulose is present in 5.45±0.5 wt. % of the oral soluble film.
- In specific embodiments, the microcrystalline cellulose is present in 5.19±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the microcrystalline cellulose is present in 5.19±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the microcrystalline cellulose is present in 5.19±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the microcrystalline cellulose is present in 5.19±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the microcrystalline cellulose is present in 5.19±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the microcrystalline cellulose is present in 10.63±1 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the microcrystalline cellulose is present in 2.5±0.1 wt. % of the slurry.
- In specific embodiments, the flavoring agent is present in 6.44±3.5 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±3 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±2.5 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±2 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±1.5 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±1.25 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±1 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.44±0.5 wt. % of the oral soluble film.
- In specific embodiments, the flavoring agent is present in 6.13±3.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±1.25 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the flavoring agent is present in 6.13±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±3.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±2.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the flavoring agent is present in 12.56±1.5 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the flavoring agent is present in 3.0±0.1 wt. % of the slurry.
- In specific embodiments, the flavoring agent includes spearmint flavoring.
- In specific embodiments, the flavoring agent includes orange flavoring.
- In specific embodiments, the flavoring agent includes vanilla cream flavoring.
- In specific embodiments, the flavoring agent includes peppermint flavoring.
- In specific embodiments, the peppermint flavoring functions as a flavoring agent and at least one of a taste masking agent and permeation enhancer.
- In specific embodiments, the peppermint flavoring is present in 6.44±3.5 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±3 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±2.5 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±2 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±1.5 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±1.25 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±1 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.44±0.5 wt. % of the oral soluble film.
- In specific embodiments, the peppermint flavoring is present in 6.13±3.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±1.25 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the peppermint flavoring is present in 6.13±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±3.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±2.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the peppermint flavoring is present in 12.56±1.5 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the peppermint flavoring is present in 3.0±0.1 wt. % of the slurry.
- In specific embodiments, the plasticizer is present in 12±4 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 12±3.5 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 12±2.5 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 12±2 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 12±1.5 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 12±0.5 wt. % of the oral soluble film.
- In specific embodiments, the plasticizer is present in 11.43±4 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±3.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the plasticizer is present in 11.43±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±12 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±8 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the plasticizer is present in 23.41±2 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the plasticizer is present in 5.6±0.1 wt. % of the slurry.
- In specific embodiments, the plasticizer includes glycerin.
- In specific embodiments, the glycerin functions as a plasticizer and at least one of a sweetener, humectant, solvent, thickening agent, and lubricant.
- In specific embodiments, the glycerin is present in 12±4 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 12±3.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 12±2.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 12±2 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 12±1.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 12±0.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±4 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±3.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±2.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±2 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±1.5 wt. % of the oral soluble film.
- In specific embodiments, the glycerin is present in 11.43±0.5 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±12 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±8 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the glycerin is present in 23.41±2 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±1.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the glycerin is present in 5.6±0.25 wt. % of the slurry.
- In specific embodiments, the sweetening agent is present in 10±4 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 10±3 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 10±2 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 10±1.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 10±1 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 10±0.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent is present in 9.51±4 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent is present in 9.51±3 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent is present in 9.51±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent is present in 9.51±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent is present in 9.51±1 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent is present in 9.51±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5±6 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sweetening agent is present in 19.5±2 mg.
- In specific embodiments, the sweetening agent includes sucralose and acesulfame potassium (ACE-K).
- In specific embodiments, the sweetening agent includes sucralose.
- In specific embodiments, the sweetening agent includes sucralose, present in 6.0±2.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes sucralose, present in 6.0±2 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes sucralose, present in 6.0±1.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes sucralose, present in 6.0±1.0 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes sucralose, present in 6.0±0.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes sucralose, present in 5.71±2.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes sucralose, present in 5.71±2 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes sucralose, present in 5.71±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes sucralose, present in 5.71±1.0 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes sucralose, present in 5.71±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sucralose is present in 11.7±3.0 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sucralose is present in 11.7±2.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sucralose is present in 11.7±2.0 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sucralose is present in 11.7±1.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sucralose is present in 11.7±0.5 mg.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K).
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00±1.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00±1.25 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00±1.0 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00±0.75 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 4.00±0.5 wt. % of the oral soluble film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80±1.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80±1.25 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80±1.0 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80±0.75 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the sweetening agent includes acesulfame potassium (ACE-K), present in 3.80±0.5 wt. % of the oral soluble film, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80±2.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80±2.0 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80±1.5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80±1.0 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the acesulfame potassium (ACE-K) is present in 7.80±0.5 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±1.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sweetening agent is present in 4.66±0.1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8±0.25 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8±0.15 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein sucralose is present in 2.8±0.1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.75 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.4 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.3 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.2 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein acesulfame potassium (ACE-K) is present in 1.86±0.1 wt. % of the slurry.
- In specific embodiments, the coloring agent is absent.
- In specific embodiments, the coloring agent is present.
- In specific embodiments, the coloring agent is present in 0.01±0.005 wt. % of the oral soluble film.
- In specific embodiments, the coloring agent is present in 0.01±0.004 wt. % of the oral soluble film.
- In specific embodiments, the coloring agent is present in 0.01±0.003 wt. % of the oral soluble film.
- In specific embodiments, the coloring agent is present in 0.01±0.002 wt. % of the oral soluble film.
- In specific embodiments, the coloring agent is present in 0.01±0.001 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02±0.007 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02±0.006 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02±0.005 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02±0.004 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the coloring agent is present in 0.02±0.003 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005±0.001 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005±0.0007 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005±0.0005 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005±0.0003 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the coloring agent is present in 0.005±0.0001 wt. % of the slurry.
- In specific embodiments, the coloring agent includes at least one FD&C color.
- In specific embodiments, the coloring agent includes FD&C Blue.
- In specific embodiments, the coloring agent includes FD&C Blue 1.
- In specific embodiments, the FD&C Blue 1 is present in 0.01±0.005 wt. % of the oral soluble film.
- In specific embodiments, the FD&C Blue 1 is present in 0.01±0.004 wt. % of the oral soluble film.
- In specific embodiments, the FD&C Blue 1 is present in 0.01±0.003 wt. % of the oral soluble film.
- In specific embodiments, the FD&C Blue 1 is present in 0.01±0.002 wt. % of the oral soluble film.
- In specific embodiments, the FD&C Blue 1 is present in 0.01±0.001 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02±0.007 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02±0.006 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02±0.005 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02±0.004 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the FD&C Blue 1 is present in 0.02±0.003 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005±0.001 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005±0.0007 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005±0.0005 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005±0.0003 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the FD&C Blue 1 is present in 0.005±0.0001 wt. % of the slurry.
- In specific embodiments, the preservative is present in 0.10±0.06 wt. % of the oral soluble film.
- In specific embodiments, the preservative is present in 0.10±0.05 wt. % of the oral soluble film.
- In specific embodiments, the preservative is present in 0.10±0.04 wt. % of the oral soluble film.
- In specific embodiments, the preservative is present in 0.10±0.03 wt. % of the oral soluble film.
- In specific embodiments, the preservative is present in 0.10±0.02 wt. % of the oral soluble film.
- In specific embodiments, the preservative is present in 0.10±0.01 wt. % of the oral soluble film. In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.08 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.07 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.06 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.05 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.04 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.03 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.02 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the preservative is present in 0.20±0.01 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05±0.01 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05±0.007 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05±0.005 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05±0.003 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the preservative is present in 0.05±0.001 wt. % of the slurry.
- In specific embodiments, the preservative includes sodium benzoate.
- In specific embodiments, the sodium benzoate is present in 0.10±0.06 wt. % of the oral soluble film.
- In specific embodiments, the sodium benzoate is present in 0.10±0.05 wt. % of the oral soluble film.
- In specific embodiments, the sodium benzoate is present in 0.10±0.04 wt. % of the oral soluble film.
- In specific embodiments, the sodium benzoate is present in 0.10±0.03 wt. % of the oral soluble film.
- In specific embodiments, the sodium benzoate is present in 0.10±0.02 wt. % of the oral soluble film.
- In specific embodiments, the sodium benzoate is present in 0.10±0.01 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.08 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.07 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.06 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.05 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.04 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.03 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.02 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the sodium benzoate is present in 0.20±0.01 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05±0.01 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05±0.007 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05±0.005 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05±0.003 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the sodium benzoate is present in 0.05±0.001 wt. % of the slurry.
- In specific embodiments, the solvent includes water.
- In specific embodiments, the water content of the hydrated oral soluble film is 4.5±2 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4.5±1.5 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4.5±1 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4.5±0.5 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4.5±0.25 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4±2 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4±1.5 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4±1 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4±0.5 wt. %.
- In specific embodiments, the water content of the hydrated oral soluble film is 4±0.25 wt. %.
- In specific embodiments, the oral soluble film is configured as a unit dose and the water is present in 9.76±4 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the water is present in 9.76±3 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the water is present in 9.76±2.25 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the water is present in 9.76±2 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose and the water is present in 9.76±1.5 mg.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±12 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±11 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±10 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±9 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±7 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±5 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±3 wt. % of the slurry.
- In specific embodiments, the oral soluble film is obtained from a slurry wherein the water is present in 53.3±1 wt. % of the slurry.
- In specific embodiments, the oral soluble film is essentially free of a saliva stimulating agent, release modifier, adjuvant, fragrant, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant.
- In specific embodiments, the oral soluble film is essentially free of a saliva stimulating agent.
- In specific embodiments, the oral soluble film is essentially free of a release modifier.
- In specific embodiments, the oral soluble film is essentially free of an adjuvant.
- In specific embodiments, the oral soluble film is essentially free of a fragrant.
- In specific embodiments, the oral soluble film is essentially free of a surfactant.
- In specific embodiments, the oral soluble film is essentially free of a pH adjusting agent.
- In specific embodiments, the oral soluble film is essentially free of a buffering agent.
- In specific embodiments, the oral soluble film is essentially free of a stabilizer.
- In specific embodiments, the oral soluble film is essentially free of an antioxidant.
- In specific embodiments, the oral soluble film further includes at least one of a saliva stimulating agent, release modifier, adjuvant, fragrant, surfactant, pH adjusting agent, buffering agent, stabilizer, and antioxidant.
- In specific embodiments, the oral soluble film further includes a saliva stimulating agent.
- In specific embodiments, the oral soluble film further includes a release modifier.
- In specific embodiments, the oral soluble film further includes an adjuvant.
- In specific embodiments, the oral soluble film further includes a fragrant.
- In specific embodiments, the oral soluble film further includes a surfactant.
- In specific embodiments, the oral soluble film further includes a pH adjusting agent.
- In specific embodiments, the oral soluble film further includes a buffering agent.
- In specific embodiments, the oral soluble film further includes a stabilizer.
- In specific embodiments, the oral soluble film further includes an antioxidant.
- In specific embodiments, the oral soluble film further includes pharmaceutically acceptable ink.
- In specific embodiments, the oral soluble film further includes pharmaceutically acceptable ink, used to print a logo or indicia thereon.
- In specific embodiments, the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.10 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.05 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film further includes pharmaceutically acceptable ink, present in up to 0.01 wt. % of the oral soluble film.
- In specific embodiments, the oral soluble film is an anhydrous film.
- In specific embodiments, the oral soluble film is a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±1.25 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±1.1 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±1 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±0.85 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±0.75 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±0.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5±0.25 wt. % hydrated film.
- In specific embodiments, the oral soluble film is a 5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 195.1±25 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 195.1±20 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 195.1±15 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 195.1±10 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 195.1±5 mg.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 204.9±25 mg, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 204.9±20 mg, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 204.9±15 mg, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 204.9±10 mg, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film is configured as a unit dose having a mass of 204.9±5 mg, based on a 5±1.5 wt. % hydrated film.
- In specific embodiments, the oral soluble film dissolves within 90 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves within 75 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves within 60 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves within 45 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves within 30 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves within 20 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 5-90 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 10-90 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 15-90 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 5-75 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 10-75 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 15-75 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 5-60 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 10-60 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 15-60 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 20-60 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 5-45 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 10-45 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film dissolves in 15-45 seconds upon contact with an oral mucosal surface.
- In specific embodiments, the oral soluble film has a breaking strength of 8-12 N.
- In specific embodiments, the oral soluble film has a breaking strength of 10±3 N.
- In specific embodiments, the oral soluble film has a breaking strength of 10±2 N.
- In specific embodiments, the oral soluble film has a breaking strength of 10±1 N.
- In specific embodiments, the oral soluble film has an elongation strength of 2-4 mm.
- In specific embodiments, the oral soluble film has an elongation strength of 3±1 mm.
- In specific embodiments, the oral soluble film has an elongation strength of 3±0.5 mm.
- In specific embodiments, the oral soluble film has a pH of 3.8-4.7.
- In specific embodiments, the oral soluble film has a pH of 4.0-4.5.
- In specific embodiments, the oral soluble film has a pH of 4.1-4.4.
- In specific embodiments, the oral soluble film has a density of 0.006-0.009 g/cm3.
- In specific embodiments, the oral soluble film has a density of 0.0065-0.0085 g/cm3.
- In specific embodiments, the oral soluble film has a density of 0.007±0.0012 g/cm3.
- In specific embodiments, the oral soluble film has a density of 0.007±0.1 g/cm3.
- In specific embodiments, the oral soluble film has a density of 0.007±0.0008 g/cm3.
- In specific embodiments, the oral soluble film has a density of 0.007±0.0006 g/cm3.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 7±5 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 7±4 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 7±3 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 7±2 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 7±1 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 5±3 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 5±2 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 5±1 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±1.5 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±1.25 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±1 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±0.75 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±0.5 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of 3.5±0.25 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of less than 5 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of less than 4 wt. %.
- In specific embodiments, the oral soluble film has a loss on drying (LOD) of less than 3 wt. %.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.60-0.90 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.65-0.85 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.725±0.12 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.725±0.10 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.725±0.08 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.725±0.06 g/cm3.
- In specific embodiments, the oral soluble film is formed from a slurry having a density of 0.725±0.05 g/cm3.
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±1,500 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±1,250 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±1,000 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±750 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±500 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±250 centipoise (cP).
- In specific embodiments, oral soluble film is formed from a slurry having a viscosity at 22-30° Celsius of 6,000±100 centipoise (cP).
- In specific embodiments, the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37±0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 90 wt. % at 5 minutes.
- In specific embodiments, the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37±0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of at least 95 wt. % release at 5 minutes.
- In specific embodiments, the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37±0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 90 wt. % at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- In specific embodiments, the oral soluble film has a dissolution (USP apparatus: 1 (basket); media: 0.01 N HCl; volume: 900-ml; temperature: 37±0.5° C.; RPM: 100; sampling: 5, 10, 15, 30, 45, 60 min) of (i) at least 95 wt. % release at 5 minutes and (ii) 100 wt. % release at 10 minutes.
- In specific embodiments, the oral soluble film is mucoadhesive, such that upon oral administration, the oral soluble film adheres to a surface of the oral cavity.
- In specific embodiments, the oral soluble film is configured as individual unit doses.
- In specific embodiments, the oral soluble film is configured as a bulk roll.
- In specific embodiments, the oral soluble film is configured as a self-supporting film-dosage form.
- In specific embodiments, the oral soluble film is configured as a unit dose.
- In specific embodiments, the oral soluble film is configured in an unwound form.
- In specific embodiments, the oral soluble film is configured as a sheet.
- In specific embodiments, the oral soluble film is cut from a self-supporting film.
- In specific embodiments, the oral soluble film is configured in a wound form.
- In specific embodiments, the oral soluble film is configured as a bulk roll.
- In specific embodiments, the oral soluble film is a monolayer film.
- In specific embodiments, the oral soluble film is configured as a unit dose having the dimensions 22±3×38±4×0.35±0.06 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having the dimensions 22±3×19±2×0.35±0.06 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a width of 22±4 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a width of 22±3 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a width of 22±2 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a width of 22±1 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a width of 22 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38±5 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38±4 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38±3 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38±2 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38±1 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 38 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19±5 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19±4 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19±3 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19±2 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19±1 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a length of 19 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40±0.05 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40±0.04 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40±0.03 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40±0.02 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40±0.01 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.40 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.07 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.06 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.05 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.04 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.03 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.02 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35±0.01 mm.
- In specific embodiments, the oral soluble film has a thickness of 0.35 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±175 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±150 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±125 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±100 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±75 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±50 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±25 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±10 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836±5 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 836 mm.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418±75 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418±50 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418±25 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418±10 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418±5 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a surface area of 418 mm2.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±60 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±50 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±40 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±30 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±20 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±10 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 292.6±5 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±30 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±25 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±20 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±15 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±10 mm3.
- In specific embodiments, the oral soluble film is configured as a unit dose having a volume of 143.3±5 mm3.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 90 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25±2° C., relative humidity (RH) 60±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 92.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25±2° C., relative humidity (RH) 60±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 95 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25±2° C., relative humidity (RH) 60±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 97.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under stability conditions of 25±2° C., relative humidity (RH) 60±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 90 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40±2° C., relative humidity (RH) 75±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 92.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40±2° C., relative humidity (RH) 75±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 95 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40±2° C., relative humidity (RH) 75±5%, over a period of time of >6 months.
- In specific embodiments, the oral soluble film exhibits a high stability, such that at least 97.5 wt. % of the sildenafil citrate remains in the oral dissolvable film, under accelerated stability conditions of 40±2° C., relative humidity (RH) 75±5%, over a period of time of >6 months.
- In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film provides 100±20% absorption of sildenafil citrate.
- In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film provides 100±15% absorption of sildenafil citrate.
- In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film provides 100±10% absorption of sildenafil citrate.
- In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film results in a lower incidence, severity, and/or duration of adverse reactions, including any one or more of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
- In specific embodiments, relative to an oral tablet having an equivalent amount of sildenafil citrate (e.g., Viagra®), administration of the oral soluble film results in a lower incidence, severity, and/or duration of adverse reactions, including each of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes the following:
-
Amount of sildenafil citrate equivalent PK parameter to 50 mg of sildenafil CMAX (ng/mL) 396.227 ± 105.035 AUC0→t (hr*ng/mL) 1,426.893 ± 520.565 AUC0→inf (hr*ng/mL) 1,524.433 ± 592.798 TMAX (hr) 1.088 ± 0.466 T1/2 (hr) 3.783 ± 1.769 KEL (1/hr) 0.211 ± 0.068 - In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean CMAX (ng/mL) of 396.227±79.245.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean CMAX (ng/mL) of 396.227.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC0→t (hr*ng/mL) of 1,426.893±285.379.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC0→t (hr*ng/mL) of 1,426.893.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC0→inf (hr*ng/mL) of 1,524.433±304.889.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean AUC0→inf (hr*ng/mL) of 1,524.433.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean TMAX (hr) of 1.088±0.218.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean TMAX (hr) of 1.088.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T1/2 (hr) of 3.783±0.757.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean T1/2 (hr) of 3.783.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean KEL (1/hr) of 0.211±0.042.
- In specific embodiments, upon administration under fasted conditions with water, the oral soluble film (containing an amount of sildenafil citrate equivalent to 50 mg of sildenafil) exhibits a single-dose administration pharmacokinetic (PK) profile that includes a mean KEL (1/hr) of 0.211.
- In specific embodiments, the active ingredient is selected in an amount, shown below.
-
Oral tablets Amount of active having an Active Indication & ingredient in the oral equivalent active Ingredient Usage soluble film ingredient Sildenafil Treating ED An amount equivalent VIAGRA ® citrate to 50 mg of sildenafil (sildenafil citrate) oral tablets Sildenafil Treating PAH An amount equivalent RETAVIO ® citrate to 5 mg or 20 mg (sildenafil citrate) of sildenafil oral tablets - In specific embodiments, the oral soluble film is rectangular.
- In specific embodiments, the oral soluble film includes a logo and/or printed indicia located thereon.
- In specific embodiments, the oral soluble film the oral soluble film includes a logo and/or printed indicia located thereon that indicates the marketing company name, the manufacturing company name, the drug substance name, the drug product name, the strength, the dosage form, the route of administration, and/or the product serialization.
- In specific embodiments, the oral soluble film includes a logo and/or indicia located thereon, printed with ink.
- In specific embodiments, the oral soluble film includes a logo and/or indicia located thereon, that is embossed.
- In specific embodiments, a single dose of the oral soluble film is individually packaged and sealed.
- In specific embodiments, a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material.
- In specific embodiments, a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material, wherein the primary packaging material includes multiple layers.
- In specific embodiments, a single dose of the oral soluble film is individually packaged and sealed with a primary packaging material, wherein the primary packaging material includes multiple layers and wherein at least one layer is manufactured from metalized polyester.
- In specific embodiments, the primary packaging material forms a primary package that (i) protects the oral soluble film from light, (ii) protects the oral soluble film from microbial contamination, (iii) is child resistant, (iv) is a barrier to moisture and vapor, (v) identifies a logo and/or includes printed indicia, or (vi) any combination thereof.
- In specific embodiments, the primary packaging material forms a primary package that protects the oral soluble film from light.
- In specific embodiments, the primary packaging material forms a primary package that is airtight.
- In specific embodiments, the primary packaging material forms a primary package that protects the oral soluble film from microbial contamination.
- In specific embodiments, the primary packaging material forms a primary package that mitigates leachable(s) into the oral soluble film.
- In specific embodiments, the primary packaging material forms a primary package that is child resistant.
- In specific embodiments, the primary packaging material forms a primary package that forms a child resistant and closure system.
- In specific embodiments, the primary packaging material forms a primary package that is a barrier to moisture and vapor.
- In specific embodiments, the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia.
- In specific embodiments, the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia instructing the subject how to open the primary package.
- In specific embodiments, the primary packaging material forms a primary package that identifies a logo and/or includes printed indicia instructing the subject how to use the oral soluble film.
- In specific embodiments, the primary packaging material forms a primary package that identifies product serialization.
- In specific embodiments, the primary packaging material forms a primary package that identifies a logo of the marketing company.
- In specific embodiments, the primary packaging material forms a primary package that identifies a logo of the manufacturing company.
- In specific embodiments, the primary packaging material forms a primary package that identifies the drug product.
- In specific embodiments, the primary packaging material forms a primary package that identifies the drug substance.
- In specific embodiments, the primary packaging material forms a primary package that identifies the strength of the active ingredient.
- In specific embodiments, the primary packaging material forms a primary package that identifies the route of administration.
- In specific embodiments, the primary packaging material forms a primary package that identifies the dosage form.
- In specific embodiments, the primary packaging material forms a primary package that identifies the route of administration.
- In specific embodiments, the primary packaging material includes at least one of cellophane, polypropylene, nylon, polyester, vinylidene chloride, vinyl chloride, polycarbonate, low-density polyethylene, high-density polyethylene, linear low-density polyethylene, ionomer, polyvinyl alcohol, ethylene/vinyl acetate copolymer, ethylene/acrylic acid copolymer, ethylene/ethyl acrylate copolymer, polystyrene, and aluminum foil.
- In specific embodiments, the primary packaging material includes metalized polyester.
- In specific embodiments, a single layer of primary packaging material forms the primary package.
- In specific embodiments, multiple layers of primary packaging material form the primary package.
- In specific embodiments, multiple layers of primary packaging material form the primary package, wherein at least one layer includes metalized polyester.
- In specific embodiments, multiple layers of primary packaging material form the primary package, wherein each layer is independently different from the other layers.
- In specific embodiments, multiple layers of primary packaging material form the primary package, wherein any one layer is different from the other layers.
- In specific embodiments, the kit includes an enclosure that contains a single dose of the oral soluble film, individually packaged and sealed with a primary packaging material.
- In specific embodiments, the kit includes an enclosure that contains (a) a single dose of the oral soluble film, individually packaged and sealed with a primary packaging material, and (b) prescribing information.
- In specific embodiments, the kit includes an enclosure that contains multiple doses of the oral soluble film, each individually packaged and sealed with a primary packaging material.
- In specific embodiments, the kit includes an enclosure that contains (a) multiple doses of the oral soluble film, each individually packaged and sealed with a primary packaging material, and (b) prescribing information.
- In specific embodiments, the enclosure is a box.
- In specific embodiments, the enclosure is a bag.
- In specific embodiments, the oral soluble film is administered to treat a disease or disorder ameliorated by sildenafil citrate.
- In specific embodiments, the oral soluble film is administered to treat erectile dysfunction (ED) in a male subject.
- In specific embodiments, the oral soluble film is administered to treat antidepressant-induced erectile dysfunction in a male subject.
- In specific embodiments, the oral soluble film is administered to treat pulmonary arterial hypertension (PAH) in a subject.
- In specific embodiments, the method of administration includes at least one of enteral delivery, transmucosal delivery, sublingual delivery, and buccal delivery, of the sildenafil citrate.
- In specific embodiments, the method of administration includes enteral delivery of the sildenafil citrate.
- In specific embodiments, the method of administration includes transmucosal delivery of the sildenafil citrate.
- In specific embodiments, the method of administration includes sublingual delivery of the sildenafil citrate.
- In specific embodiments, the method of administration includes buccal delivery of the sildenafil citrate.
- In specific embodiments, the method of administration includes oral (P.O.) administration of the oral soluble film.
- In specific embodiments, the oral soluble film is administered to a male subject up to 30 minutes before sexual activity.
- In specific embodiments, the oral soluble film is administered to a male subject up to 20 minutes before sexual activity.
- In specific embodiments, the oral soluble film is administered to a male subject up to 15 minutes before sexual activity.
- In specific embodiments, the oral soluble film is administered to a male subject up to 10 minutes before sexual activity.
- In specific embodiments, the oral soluble film is placed on the top of the tongue of a subject.
- In specific embodiments, the oral soluble film is placed against the inside of the cheek of a subject.
- In specific embodiments, the oral soluble film is placed between the cheek and gums of a subject.
- In specific embodiments, the oral soluble film is orally administered to a subject in the absence of water or beverage.
- In specific embodiments, the oral soluble film is orally administered to a subject with water or beverage.
- In specific embodiments, the subject is a male.
- In specific embodiments, the subject is a male that is at least 18 years old.
- In specific embodiments, the oral soluble film is orally administered to treat erectile dysfunction, and the male subject achieves an erection in 25 minutes.
- In specific embodiments, the oral soluble film is orally administered to treat erectile dysfunction (ED), and the male subject achieves an erection in 12-70 minutes.
- In specific embodiments, the oral soluble film is administered sublingually, to treat erectile dysfunction (ED), the male subject achieves an erection in 15 minutes, and the erection lasting for 40 minutes.
- In specific embodiments, up to two oral soluble films are administered per dose.
- In specific embodiments, 1-2 oral soluble films are administered per dose.
- In specific embodiments, two oral soluble films are administered per dose.
- In specific embodiments, one and a half oral soluble films are administered per dose.
- In specific embodiments, one oral soluble film is administered per dose.
- In specific embodiments, a portion of an oral soluble film is administered per dose.
- In specific embodiments, one-half of an oral soluble film is administered per dose.
- In specific embodiments, the maximum recommended dosing frequency is twice per day.
- In specific embodiments, the maximum recommended dosing frequency is once per day.
- Specific enumerated embodiments <1> to <47> provided below are for illustration purposes only, and do not otherwise limit the scope of the disclosed subject matter, as defined by the claims. These enumerated embodiments encompass all combinations, sub-combinations, and multiply referenced (e.g., multiply dependent) combinations described therein.
- <Embodiment 1> An oral soluble film that includes:
- (a) sildenafil citrate;
- (b) binder that includes:
-
- (i) polyvinyl alcohol (PVA);
- (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and
- (iii) silicon dioxide;
- (c) filler that includes microcrystalline cellulose (MCC);
- (d) flavoring agent that includes peppermint flavoring;
- (e) plasticizer that includes glycerin;
- (f) sweetening agent that includes sucralose and acesulfame potassium (ACE-K);
- (g) coloring agent that includes FD&C Blue 1;
- (h) preservative that includes sodium benzoate; and
- (i) solvent that includes water.
- <Embodiment 2> The oral soluble film of embodiment <1>, configured as a unit dose having a mass of 200±20 mg.
<Embodiment 3> The oral soluble film of any one of embodiments <1> to <2>, having a thickness of 0.35±0.06 mm.
<Embodiment 4> The oral soluble film of any one of embodiments <1> to <3>, having a water content of 4±1.5 wt. %.
<Embodiment 5> The oral soluble film of any one of embodiments <1> to <4>, configured as a unit dose which dissolves within 60 seconds upon contact with an oral mucosal surface.
<Embodiment 6> The oral soluble film of any one of embodiments <1> to <5>, wherein the sildenafil citrate is present in 36±7 wt. % of the oral soluble film.
<Embodiment 7> The oral soluble film of any one of embodiments <1> to <6>, configured as a unit dose and wherein the sildenafil citrate is present in 70.24±7 mg.
<Embodiment 8> The oral soluble film of any one of embodiments <1> to <7>, wherein the binder is present in 30±6 wt. % of the oral soluble film.
<Embodiment 9> The oral soluble film of any one of embodiments <1> to <8>, configured as a unit dose and wherein the binder is present in 58.53±12 mg.
<Embodiment 10> The oral soluble film of any one of embodiments <1> to <9>, wherein the filler is present in 5.45±1 wt. % of the oral soluble film.
<Embodiment 11> The oral soluble film of any one of embodiments <1> to <10>, configured as a unit dose and wherein the filler is present in 10.63±2 mg.
<Embodiment 12> The oral soluble film of any one of embodiments <1> to <11>, wherein the flavoring agent is present in 6.44±1.25 wt. % of the oral soluble film.
<Embodiment 13> The oral soluble film of any one of embodiments <1> to <12>, configured as a unit dose and wherein the flavoring agent is present in 12.56±2.5 mg.
<Embodiment 14> The oral soluble film of any one of embodiments <1> to <13>, wherein the flavoring agent includes natural peppermint flavor.
<Embodiment 15> The oral soluble film of any one of embodiments <1> to <14>, wherein the plasticizer is present in 12±2.5 wt. % of the oral soluble film.
<Embodiment 16> The oral soluble film of any one of embodiments <1> to <15>, configured as a unit dose and wherein the plasticizer is present in 23.41±5 mg.
<Embodiment 17> The oral soluble film of any one of embodiments <1> to <16>, wherein the sweetening agent is present in 10±2 wt. % of the oral soluble film.
<Embodiment 18> The oral soluble film of any one of embodiments <1> to <17>, configured as a unit dose and wherein the sweetening agent is present in 19.5±4 mg.
<Embodiment 19> The oral soluble film of any one of embodiments <1> to <18>, wherein the coloring agent is present in 0.01±0.002 wt. % of the oral soluble film.
<Embodiment 20> The oral soluble film of any one of embodiments <1> to <19>, configured as a unit dose and wherein the coloring agent is present in 0.02±0.004 mg.
<Embodiment 21> The oral soluble film of any one of embodiments <1> to <20>, wherein the preservative is present in 0.10±0.02 wt. % of the oral soluble film.
<Embodiment 22> The oral soluble film of any one of embodiments <1> to <21>, configured as a unit dose and wherein the preservative is present in 0.20±0.04 mg.
<Embodiment 23> An oral soluble film that includes: - (a) 36±7 wt. % sildenafil citrate;
- (b) 30±6 wt. % binder that includes:
-
- (i) polyvinyl alcohol (PVA);
- (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and
- (iii) silicon dioxide;
- (c) 5.45±1 wt. % filler that includes microcrystalline cellulose (MCC);
- (d) 6.44±1.25 wt. % flavoring agent that includes peppermint flavoring;
- (e) 12±2.5 wt. % plasticizer that includes glycerin;
- (f) 10±2 wt. % sweetening agent that includes sucralose and acesulfame potassium (ACE-K);
- (g) 0.01±0.002 wt. % coloring agent that includes FD&C Blue 1; and
- (h) 0.10±0.02 wt. % preservative that includes sodium benzoate.
- <Embodiment 24> An oral soluble film that includes:
- (a) 70.24±7 mg sildenafil citrate;
- (b) 58.53±12 mg binder that includes:
-
- (i) polyvinyl alcohol (PVA);
- (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and
- (iii) silicon dioxide;
- (c) 10.63±2 mg filler that includes microcrystalline cellulose (MCC);
- (d) 12.56±2.5 mg flavoring agent that includes peppermint flavoring;
- (e) 23.41±5 mg plasticizer that includes glycerin;
- (f) 19.5±4 mg sweetening agent that includes sucralose and acesulfame potassium (ACE-K);
- (g) 0.02±0.004 mg coloring agent that includes FD&C Blue 1;
- (h) 0.20±0.04 mg preservative that includes sodium benzoate; and
- (i) 9.76±2.25 mg water;
- wherein,
- the oral soluble film is configured as a unit dose;
- the oral soluble film has a mass of 205±20 mg;
- the oral soluble film has a thickness of 0.35±0.06 mm; and
- upon contact with an oral mucosal surface, the oral soluble film dissolves within 60 seconds.
- <Embodiment 25> The oral soluble film of embodiment <24>, having a mass of 205±15 mg and dissolves within 45 seconds upon contact with an oral mucosal surface.
<Embodiment 26> An oral soluble film that includes: - (a) 70.24±7 mg sildenafil citrate;
- (b) 58.53±12 mg binder that includes:
-
- (i) polyvinyl alcohol (PVA);
- (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and
- (iii) silicon dioxide;
- (c) 10.63±2 mg filler that includes microcrystalline cellulose (MCC);
- (d) 12.56±2.5 mg flavoring agent that includes peppermint flavoring;
- (e) 23.41±5 mg plasticizer that includes glycerin;
- (f) 19.5±4 mg sweetening agent that includes sucralose and acesulfame potassium (ACE-K);
- (g) 0.02±0.004 mg coloring agent that includes FD&C Blue 1;
- (h) 0.20±0.04 mg preservative that includes sodium benzoate; and
- (i) 9.76±2.25 mg water;
- wherein,
- the oral soluble film is configured as a unit dose.
- <Embodiment 27> An oral soluble film that includes:
- (a) 70.24±7 mg sildenafil citrate;
- (b) 58.53±11.7 mg in the aggregate of:
-
- (i) polyvinyl alcohol (PVA);
- (ii) polyvinyl alcohol (PVA)-polyethylene glycol (PEG) graft copolymer; and
- (iii) silicon dioxide;
- (c) 10.63±2 mg microcrystalline cellulose (MCC);
- (d) 12.56±2.5 mg peppermint flavoring;
- (e) 23.41±5 mg glycerin;
- (f) 11.7±3 mg sucralose
- (g) 7.8±2.5 mg acesulfame potassium (ACE-K);
- (h) 0.02±0.004 mg FD&C Blue 1;
- (i) 0.20±0.04 mg sodium benzoate; and
- (j) 9.76±2.25 mg water;
- wherein,
- the oral soluble film is configured as a unit dose;
- the oral soluble film has a mass of 204.9±20 mg;
- the oral soluble film has a thickness of 0.35±0.06 mm; and
- upon contact with an oral mucosal surface, the oral soluble film dissolves within 60 seconds.
- <Embodiment 28> A method of treating erectile dysfunction (ED) in a male subject, the method includes orally administering the oral soluble film of any one of embodiments <1> to <27> to a male subject in need thereof.
<Embodiment 29> The method of embodiment <28>, wherein the oral administration includes at least one of enteral delivery of sildenafil, transmucosal delivery of sildenafil, sublingual delivery of sildenafil, and buccal delivery of sildenafil; wherein the sildenafil delivered is the free base or as the citrate salt.
<Embodiment 30> The method of any one of embodiments <28> to <29>, wherein the oral soluble film is administered to a male subject 1 hour before sexual activity.
<Embodiment 31> The method of any one of embodiments <28> to <29>, wherein the oral soluble film is administered to a male subject up to 20 minutes before sexual activity.
<Embodiment 32> The method of any one of embodiments <28> to <29>, wherein the oral soluble film is administered to a male subject 30 minutes to 4 hours before sexual activity.
<Embodiment 33> The method of any one of embodiments <28> to <32>, wherein the oral soluble film is placed on a mucosal surface within the oral cavity of the male subject.
<Embodiment 34> The method of any one of embodiments <28> to <33>, wherein the oral soluble film is placed on the top of the tongue of the male subject.
<Embodiment 35> The method of any one of embodiments <28> to <33>, wherein the oral soluble film is placed against the inside of the cheek of the male subject.
<Embodiment 36> The method of any one of embodiments <28> to <33>, wherein the oral soluble film is placed between the cheek and gums of the male subject.
<Embodiment 37> The method of any one of embodiments <28> to <36>, wherein the oral soluble film is orally administered to the male subject in the absence of water or beverage.
<Embodiment 38> The method of any one of embodiments <28> to <36>, wherein the oral soluble film is orally administered to the male subject with water or beverage.
<Embodiment 39> The method of any one of embodiments <28> to <38>, wherein the male subject achieves an erection within 25 minutes after the oral soluble film is orally administered.
<Embodiment 40> The method of any one of embodiments <28> to <38>, wherein the male subject achieves an erection in 12-70 minutes after the oral soluble film is orally administered.
<Embodiment 41> The method of any one of embodiments <28> to <38>, wherein the oral soluble film is administered sublingually, the male subject achieves an erection within 15 minutes, and the erection lasts for at least 30 minutes.
<Embodiment 42> The method of any one of embodiments <28> to <41>, wherein relative to VIAGRA® oral tablets having an equivalent amount of sildenafil citrate, administration of the oral soluble film results in a lower incidence, severity, and/or duration of adverse reactions, including at least one of headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
<Embodiment 43> The method of any one of embodiments <28> to <42>, wherein upon administration under fasted conditions with water, the oral soluble film exhibits a single-dose administration pharmacokinetic (PK) profile that includes: -
Amount of sildenafil citrate PK parameter equivalent to 50 mg of sildenafil CMAX (ng/mL) 396.227 ± 105.035 AUC0→t (hr*ng/mL) 1,426.893 ± 520.565 AUC0→inf (hr*ng/mL) 1,524.433 ± 592.798 TMAX (hr) 1.088 ± 0.466 T1/2 (hr) 3.783 ± 1.769 KEL (1/hr) 0.211 ± 0.068
<Embodiment 44> The method of any one of embodiments <28> to <42>, wherein upon administration under fasted conditions with no water, the oral soluble film exhibits a single-dose administration pharmacokinetic (PK) profile that includes: -
Amount of sildenafil citrate PK parameter equivalent to 50 mg of sildenafil CMAX (ng/mL) 396.227 ± 105.035 AUC0→t (hr*ng/mL) 1,426.893 ± 520.565 AUC0→inf (hr*ng/mL) 1,524.433 ± 592.798 TMAX (hr) 1.088 ± 0.466 T1/2 (hr) 3.783 ± 1.769 KEL (1/hr) 0.211 ± 0.068
<Embodiment 45> The method of any one of embodiments <28> to <44>, wherein up to two oral soluble films are administered per dose.
<Embodiment 46> The method of any one of embodiments <28> to <44>, having a maximum dosing frequency of once per day.
<Embodiment 47> The method of any one of embodiments <28> to <44>, wherein the male subject is at least 18 years old. - All publications, patents, and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
- The following examples are set forth to further illustrate the presently disclosed subject matter (e.g., oral soluble films, methods of using the same, and methods of preparing the same). The below examples, however, should not be construed as limiting in any manner the present invention, as set forth in the claims.
-
-
FORMULATION 1.01 SLURRY ORAL SOLUBLE FILM Quantity Amount in Amount in Amount in Amount in 5% Amount in 5% dispensed slurry anhydrous film anhydrous film hydrated film hydrated film Substance (g) (wt. %) (wt. %) (mg) (wt. %) (mg) Sildenafil Citrate 1,678.6 16.8 36.00 70.24 34.29 70.24 Kollicoat ® Protect 1,406.3 14.1 30.00 58.53 28.57 58.53 Microcrystalline 252.1 2.5 5.45 10.63 5.19 10.63 Cellulose - Avicel ® PH-101 Peppermint Flavor 299.9 3.0 6.44 12.56 6.13 12.56 Glycerin, 99.7% 558.5 5.6 12.00 23.41 11.43 23.41 pure Sucralose 280.0 2.8 6.00 11.70 5.71 11.70 Acesulfame 186.0 1.86 4.00 7.80 3.80 7.80 Potassium (ACE-K) FD&C Blue 1 0.5 0.005 0.01 0.02 0.01 0.02 Sodium Benzoate 5.0 0.05 0.10 0.20 0.10 0.20 Water 5328 53.3 NA NA 5.00 9.76 TOTAL 10,000.0 100 100 195.10 100 204.86 FORMULATION 1.02 Film weight (anhydrous): 209.6 mg; Film weight (10% hydrated): 233 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 47.83 1100 10.04 23.40 Glycerin 7.83 180 13.49 31.44 Natural Orange 4.17 96 7.20 16.77 Vanilla cream 1.04 24 1.80 4.19 Sucralose 2.61 60 4.50 10.48 Acesulfame Potassium 1.30 30 2.25 5.24 (ACE-K) Microcrystalline Cellulose 1.57 36 2.70 6.29 Kollicoat ® Protect 12.13 279 20.92 48.73 HPMC 2910, 15-18 mPa-s 4.04 93 6.97 16.24 Sildenafil Citrate 17.48 402 30.14 70.22 FD&C Red 40 0.00 FD&C Yellow 5 0.00 FORMULATION 1.03 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.5882 240 10.09 21.90 Glycerin 1.3235 4.5 4.05 8.78 Honey 2.6471 9 8.09 17.56 Polysorbate 80 1.1765 4 3.60 7.80 Peppermint 2.0588 7 6.29 13.66 Sucralose 1.4706 5 4.50 9.76 ACE-K 0.7353 2.5 2.25 4.88 Pectin 7.2794 24.75 22.25 48.29 HPMC 2.1294 7.24 6.51 14.13 Sildenafil Citrate 10.5882 36 32.37 70.24 FD&C Blue 1 0.0029 0.01 0.01 0.02 FORMULATION 1.04 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.5882 240 10.09 21.9 Glycerin 3.9706 13.5 12.14 26.34 Polysorbate 80 1.1765 4 3.60 7.80 Peppermint 2.0588 7 6.29 13.66 Sucralose 1.4706 5 4.50 9.76 ACE-K 0.7353 2.5 2.25 4.88 Pectin 7.2500 24.65 22.16 48.09 HPMC 2.1294 7.24 6.51 14.13 Sildenafil Citrate 10.5882 36 32.37 70.24 FD&C Blue 1 0.0029 0.01 0.01 0.02 Na Benzoate 0.0294 0.1 0.09 0.20 FORMULATION 1.05 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.59 240 10.09 21.90 Glycerin 2.94 10 8.99 19.51 Polysorbate 80 2.65 9 8.09 17.56 Menthol 0.46 1.55 1.39 3.02 Peppermint 0.13 0.45 0.40 0.88 Vanilla Cream 0.59 2 1.80 3.90 Sucralose 1.76 6 5.39 11.71 ACE-K 0.88 3 2.70 5.85 Cekol ® 30 7.25 24.65 22.16 48.09 HPMC 2.13 7.24 6.51 14.13 Sildenafil Citrate 10.59 36 32.37 70.24 FD&C Blue 1 0.00 0.01 0.01 0.02 Na Benzoate 0.03 0.1 0.09 0.20 FORMULATION 1.06 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.59 240 10.09 21.90 Glycerin 3.24 11 9.89 21.46 Polysorbate 80 2.65 9 8.09 17.56 Menthol 0.43 1.45 1.30 2.83 Spearmint 0.32 1.1 0.99 2.15 Peppermint 0.13 0.45 0.40 0.88 Sucralose 1.76 6 5.39 11.71 ACE-K 0.88 3 2.70 5.85 Cekol ® 30 7.25 24.65 22.16 48.09 HPMC 2.13 7.24 6.51 14.13 Sildenafil Citrate 10.59 36 32.37 70.24 FD&C Blue 1 0.003 0.01 0.01 0.02 Na Benzoate 0.03 0.1 0.09 0.20 FORMULATION 1.07 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.59 240 10.09 21.90 Glycerin 2.94 10 8.99 19.51 Polysorbate 80 3.53 12 10.79 23.41 Orange 1.76 6 5.39 11.71 Vanilla Cream 0.76 2.59 2.33 5.05 Sucralose 2.06 7 6.29 13.66 ACE-K 0.88 3 2.70 5.85 Cekol ® 30 5.29 18 16.18 35.12 HPMC 1.56 5.3 4.77 10.34 Sildenafil Citrate 10.59 36 32.37 70.24 FD&C Blue 1 0.003 0.01 0.01 0.02 Na Benzoate 0.03 0.1 0.09 0.20 FORMULATION 1.08 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.59 240 10.09 21.9 Glycerin 3.50 11.91 10.71 23.24 Polysorbate 80 2.60 8.84 7.95 17.25 NaOH 0.18 0.6 0.54 1.17 Peppermint 1.72 5.84 5.25 11.39 Sucralose 2.06 7 6.29 13.66 ACE-K 1.18 4 3.60 7.80 Cekol ® 30 5.59 19 17.08 37.07 HPMC 1.97 6.7 6.02 13.07 Sildenafil Citrate 10.59 36 32.37 70.24 FD&C Blue 1 0.003 0.01 0.01 0.02 Na Benzoate 0.03 0.1 0.09 0.20 FORMULATION 1.09 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Quantity Amount in Amount in Slurry dispensed 10% hydrated 10% hydrated Material (wt. %) (g) film (wt. %) film (mg) Water 70.59 240 10.09 21.90 Glycerin 3.53 12 10.79 23.41 NaOH 0.18 0.6 0.54 1.17 Mint 1.72 5.84 5.25 11.39 Sucralose 1.76 6 5.39 11.71 ACE-K 1.18 4 3.60 7.80 Kollicoat ® protect 8.82 30 26.97 58.53 MCC 1.60 5.45 4.90 10.63 Sildenafil Citrate 10.59 36 32.37 70.24 FD&C Blue 1 0.003 0.01 0.01 0.02 Na Benzoate 0.03 0.1 0.09 0.20 FORMULATION 1.10 Film weight (anhydrous): 195.1 mg; Film weight (10% hydrated): 217 mg SLURRY ORAL SOLUBLE FILM Amount in Amount in Amount in Amount in Slurry anhydrous 10% hydrated 10% hydrated Material (wt. %) film (wt.%) film (wt. %) film (mg) Water 54.79 0 10 21.68 Sildenafil citrate 16.27 36.00 32.40 70.24 Kollicoat ® protect 13.56 30.00 27.00 58.53 MCC 2.46 5.45 4.91 10.64 Spray mint flavoring 2.64 6.44 5.80 12.57 Glycerin 5.42 12.00 10.80 23.41 Sucralose 2.71 6.00 5.40 11.71 ACE-K 1.81 4.00 3.60 7.80 FD&C Blue 1 0.01 0.01 0.01 0.02 Na Benzoate 0.05 0.10 0.09 0.20 - Physical properties and performance characteristics for the oral soluble film of Formulation 1.01 (Example 1) include:
-
- The anhydrous film weight is 195.1±5 milligrams (mg).
- The 5 wt. % hydrated film weight is 204.9±5 mg.
- The breaking strength of the film is 8-12 Newtons (N).
- The elongation strength of the film is 2-4 millimeters (mm).
- The pH of the film is 4.0-4.5.
- The disintegration time of the film is ˜1 minute or less.
- The Loss on Drying (LOD) of the film is 4±3 wt. %.
- The thickness of the film is 0.35±0.06 mm.
- The viscosity of the slurry at 20-30° Celsius is 6,000±1,000 centipoise (cP).
- Load of the active (sildenafil citrate) is 34.2% (in the 5% hydrated film) or 36% (in the anhydrous film).
-
Description of Measurement, Protocol (USP Physical or Performance Characteristic No.), and Equipment Mass/weight of drug product Gravimetric using calibrated scales Thickness of drug product Calipers Moisture content of drug product USP <921> Gravimetric, mass loss on drying using a calibrated IR balance Dissolution time of drug product in USP <711> solution Drug release from the dosage form using USP apparatus 1 (basket) Microbiology USP <60>, USP <61>, and USP <62> Disintegration time of drug product in USP <701> mouth Done In-Vitro, approximately 30 sec. to break apart, full disintegration at about 1 min 40 sec. Density of intermediate drug product Gravimetric using weight/volume of a 22 × 38 mm film Loss on drying (LOD) of drug product USP <921> Same as above for moisture content Breaking strength of drug product Performed via Texture Analyzer, measures the forced required to break the film Elongation strength of drug product Performed via Texture Analyzer, measures the distanced traveled before breaking the film pH of drug product Performed via 3-point calibrated pH meter Viscosity of the slurry Tested using a viscometer with rotor 7 speed 100 rpm Drug Assay USP <621> HPLC used to measure the amount of API in the slurry (±5%) and the finished good, OSF (±10%) Drug content uniformity of drug product USP <905> Measure the total drug content of 10 individual films which must pass with an Acceptance Value (AV) of less than 15 Particle-size distribution of sildenafil D(90) <60 μm, obtained from the API supplier, citrate (drug substance) CoA Impurities and Related Substances USP <1086> Chromatography method to detect, characterize and quantify potential impurities and related substances from the drug product. - The oral soluble film of Formulation 1.01 (Example 1) was manufactured as described below.
- 3.1 Dispensing
- Dispense the following raw materials in its given amounts in separate containers.
-
Theoretical Ingredient % w/w (g) Thatch Water 53.30% 5,327.6 Sildenafil Citrate 16.79% 1,678.6 Kollicoat ® Protect 14.08% 1,406.3 Avicel ® PH-101 Microcrystalline 2.53% 252.1 Cellulose Natural Peppermint Flavor 3.00% 299.9 Glycerin 99.7% 5.59% 558.5 Sucralose 2.80% 280.0 Ace-K 1.86% 186.0 FD&C Blue #1 Powder 0.005% 0.5 Sodium Benzoate Powder 0.05% 5.0 Total 100.00% 10,000.00 - 3.2 Blending, Method A
-
- 3.2.1 Add water into a mixing container. To this container, add the glycerin and mix for approximately 10 minutes.
- 3.2.2 Weigh and add the following powders together, in the following order:
- 1. Kollicoat® Protect
- 2. Sildenafil Citrate
- 3. Sucralose
- 4. Ace-K
- 5. Sodium Benzoate
- 6. Microcrystalline Cellulose
- 7. Peppermint
- 8. FD&C Blue
- 3.3 Blending, Method B
-
- 3.3.1 Add water into a mixing container and begin mixing.
- 3.3.2 Weigh and add the following excipients and add into water container, in the following order:
- 1. Sildenafil Citrate
- 2. Glycerin
- 3. Sucralose
- 4. Ace-K
- 5. Sodium Benzoate
- 6. FD&C Blue #1
- 7. Microcrystalline Cellulose
- 8. Kollicoat® Protect
- 9. Peppermint
- 3.3.3 Check the temperature, density, and viscosity of the blend against target. Continue mixing and add water if needed.
- 3.3.4 Once blend is finished, take sample for % solids by IR and LOD analysis.
- 3.4 Curing
- Cure the slurry on the oven.
-
- 3.4.1 Set the oven with the following parameters.
-
Parameter Pin Gauge Oven Temperature Line Speed Knife web size -
- 3.4.2 Begin curing process once oven achieved desired temperature.
- 3.4.3 Start rewinder at desired line speed.
- 3.4.4 Slowly pour slurry into the extruder.
- 3.4.5 Record measurements as needed.
- 3.4.6 Stored the results in a temperature and humidity-controlled environment in appropriated bags.
- 3.5 Converting
-
- 3.5.1 Load a bulk roll onto the machine and input the relevant setting for speed, shape, and weight.
- 3.5.2 Load the primary packaging material and input the relevant setting for example strength of seal.
- 3.5.3 Preform in process checks as necessary to ensure the finished product meet desired specifications.
- A bioavailability study (under fasting conditions, with water) in healthy adult human male subjects (n=18) was conducted, to compare the sildenafil citrate oral soluble film (EQ 50 mg base) of Formulation 1.01 (Example 1), with that of Viagra® oral tablets (EQ 50 mg base), post single oral administration. Each subject was given water (40 ml) with the sample.
Primary parameters (Cmax, AUC0→t, and AUC0→inf) as well as secondary parameters (Tmax T1/2, and Kel) were measured.
The table below provides the results of the study. -
-
PK Parameter Sample (Reference or Test) Mean Std. Dev. CMAX (ng/mL) Viagra ® oral tablets (EQ 50 mg base) 405.717 136.894 Sildenafil citrate oral soluble film (EQ 50 mg base) 396.227 105.035 AUC0→t Viagra ® oral tablets (EQ 50 mg base) 1,237.489 339.650 (hr*ng/mL) Sildenafil citrate oral soluble film (EQ 50 mg base) 1,426.893 520.565 AUC0→inf Viagra ® oral tablets (EQ 50 mg base) 1,330.010 364.587 (hr*ng/mL) Sildenafil citrate oral soluble film (EQ 50 mg base) 1,524.433 592.798 TMAX (hr) Viagra ® oral tablets (EQ 50 mg base) 1.083 0.636 Sildenafil citrate oral soluble film (EQ 50 mg base) 1.088 0.466 T1/2 (hr) Viagra ® oral tablets (EQ 50 mg base) 4.577 2.771 Sildenafil citrate oral soluble film (EQ 50 mg base) 3.783 1.769 KEL (1/hr) Viagra ® oral tablets (EQ 50 mg base) 0.188 0.074 Sildenafil citrate oral soluble film (EQ 50 mg base) 0.211 0.068
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/488,610 US20220023198A1 (en) | 2020-04-21 | 2021-09-29 | Oral soluble film containing sildenafil citrate |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063012988P | 2020-04-21 | 2020-04-21 | |
US17/236,054 US11179331B1 (en) | 2020-04-21 | 2021-04-21 | Oral soluble film containing sildenafil citrate |
US17/488,610 US20220023198A1 (en) | 2020-04-21 | 2021-09-29 | Oral soluble film containing sildenafil citrate |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/236,054 Continuation US11179331B1 (en) | 2020-04-21 | 2021-04-21 | Oral soluble film containing sildenafil citrate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220023198A1 true US20220023198A1 (en) | 2022-01-27 |
Family
ID=78703602
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/236,054 Active US11179331B1 (en) | 2020-04-21 | 2021-04-21 | Oral soluble film containing sildenafil citrate |
US17/488,610 Pending US20220023198A1 (en) | 2020-04-21 | 2021-09-29 | Oral soluble film containing sildenafil citrate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/236,054 Active US11179331B1 (en) | 2020-04-21 | 2021-04-21 | Oral soluble film containing sildenafil citrate |
Country Status (1)
Country | Link |
---|---|
US (2) | US11179331B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114557981A (en) * | 2022-03-02 | 2022-05-31 | 山东新时代药业有限公司 | Montelukast oral cavity dissolving film agent and preparation process thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116617193B (en) * | 2023-07-10 | 2024-01-30 | 北京丰科睿泰医药科技有限公司 | Pirenpananel oral film-dissolving agent |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4343860A1 (en) | 1993-12-22 | 1995-06-29 | Fritz Hakemann | Door leaf for a thermally insulated compartment, in particular a refrigerator compartment of a refrigerator |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
AU2001273545A1 (en) | 2000-07-19 | 2002-01-30 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
IN192750B (en) | 2000-12-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
US20060110478A1 (en) | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US20030118653A1 (en) | 2001-07-06 | 2003-06-26 | Lavipharm Laboratories Inc. | Quick dissolving oral mucosal drug delivery device with moisture barrier coating |
US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US20140070440A1 (en) | 2001-10-12 | 2014-03-13 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US20130220526A1 (en) | 2001-10-12 | 2013-08-29 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
US20160206639A9 (en) | 2001-10-12 | 2016-07-21 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US20030194420A1 (en) | 2002-04-11 | 2003-10-16 | Richard Holl | Process for loading a drug delivery device |
WO2004087111A1 (en) | 2003-04-04 | 2004-10-14 | Ranbaxy Laboratories Limited | Oral taste masked pharmaceutical compositions |
JP2007502823A (en) | 2003-08-15 | 2007-02-15 | キューエルティー・ユーエスエイ・インコーポレーテッド | Adhesive and bioerodible transmucosal drug delivery systems |
EP1968539A2 (en) | 2005-12-13 | 2008-09-17 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US20070196494A1 (en) | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
WO2008008120A1 (en) | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
ES2577390T3 (en) | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Transmucosal administration devices with greater uptake |
US20080026040A1 (en) | 2006-07-31 | 2008-01-31 | Isaac Farr | Active agent-releasing dosage forms |
HUE038022T4 (en) | 2006-10-02 | 2023-02-28 | Spepharm Ag | Non-mucoadhesive film dosage forms |
WO2008140459A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
WO2008140460A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
US20080286343A1 (en) | 2007-05-16 | 2008-11-20 | Dzenana Cengic | Solid form |
US20080311162A1 (en) | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
KR101903781B1 (en) * | 2007-06-06 | 2018-11-13 | 바스프 에스이 | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
CN101686942B (en) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
US20090047350A1 (en) | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Perforated water soluble polymer based edible films |
US20090047330A1 (en) | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Oral fast dissolving films for erectile dysfunction bioactive agents |
KR100905027B1 (en) | 2007-10-03 | 2009-06-30 | (주)씨엘팜 | Edible Film |
WO2009045022A2 (en) | 2007-10-03 | 2009-04-09 | C.L. Pharm | Edible film |
MX2010004265A (en) | 2007-10-19 | 2010-07-28 | Innozen Inc | Composition for administering an active ingredient and method for making and using the same. |
WO2009074995A1 (en) | 2007-12-10 | 2009-06-18 | Ajanta Pharma Limited | Taste masked chewable compositions of sildenafil citrate |
WO2010044736A1 (en) | 2008-10-14 | 2010-04-22 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
US20100184722A1 (en) | 2008-12-19 | 2010-07-22 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
PL2952191T3 (en) | 2009-06-12 | 2019-02-28 | Sunovion Pharmaceuticals Inc. | Sublingual apomorphine |
US20120128740A1 (en) | 2009-06-19 | 2012-05-24 | Filipcsei Genoveva | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010150930A1 (en) | 2009-06-25 | 2010-12-29 | (주)벡스코아 | Fast dissolving film for oral administration which prevents unpleasant taste effectively |
KR101074271B1 (en) | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | Fast dissolving oral dosage form containing steviosides as a taste masking agent |
US9095577B2 (en) | 2009-07-13 | 2015-08-04 | Monosol Rx, Llc | Stabilized amine-containing actives in oral film compositions |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
EP2377526A1 (en) | 2010-03-23 | 2011-10-19 | BioAlliance Pharma | Fast dissolving drug delivery systems |
US20110237563A1 (en) | 2010-03-23 | 2011-09-29 | Dominique Costantini | Fast dissolving drug delivery systems |
RU2560693C2 (en) | 2010-03-23 | 2015-08-20 | Апр Эпплайд Фарма Рисерч, С.А. | Rapidly dissolving medication-releasing systems |
EP2566467A1 (en) | 2010-05-07 | 2013-03-13 | Hexal Aktiengesellschaft | Mucosal film containing two sugar substitutes |
DE102010049708A1 (en) | 2010-10-28 | 2012-05-03 | Hexal Ag | Oral pharmaceutical film formulation for bitter-tasting drugs |
DE102010049706A1 (en) | 2010-10-28 | 2012-05-03 | Hexal Ag | Production of orodispersible films |
WO2012083269A1 (en) | 2010-12-16 | 2012-06-21 | Cynapsus Therapeutics, Inc. | Sublingual films |
AU2012214939B2 (en) | 2011-02-11 | 2016-11-17 | Ctc Bio, Inc. | Sildenafil-free base-containing film preparation and method for producing same |
KR101077468B1 (en) | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | Stable orodispersible film formulation |
CA2845634C (en) | 2011-08-18 | 2021-07-13 | Biodelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
EP3108876A1 (en) | 2011-10-13 | 2016-12-28 | Jaleva Pharmaceuticals LLC | Methods and compositions for rapid transbuccal delivery of active agents |
KR101188594B1 (en) | 2011-12-06 | 2012-10-08 | (주)씨엘팜 | Bitter taste masked oral thin film formulation of sildenafil citrate |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
WO2013121663A1 (en) | 2012-02-14 | 2013-08-22 | 救急薬品工業株式会社 | Intraorally dissolving film preparation |
CN104168895B (en) | 2012-02-28 | 2020-02-21 | 首尔制药株式会社 | Bitter taste-masking high-content fast-dissolving film comprising sildenafil as active ingredient |
WO2014027975A2 (en) | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Novel orally administered pharmaceutical formulations |
US20170143623A1 (en) | 2012-09-28 | 2017-05-25 | Pharmafilm S.R.L. | Orodispersible films having quick dissolution times for therapeutic and food use |
WO2014137189A1 (en) | 2013-03-07 | 2014-09-12 | 에스케이케미칼주식회사 | Oral dispersible film containing high drug content and manufacturing method therefor |
US20140335153A1 (en) | 2013-05-09 | 2014-11-13 | Cure Pharmaceutical Corporation | Thin film with high load of active ingredient |
EP3003285B1 (en) | 2013-06-03 | 2022-02-16 | McNeil AB | Solid pharmaceutical dosage form for release of at least two active pharmaceutical ingredients in the oral cavity |
KR101516875B1 (en) | 2013-08-21 | 2015-04-30 | (주)우신메딕스 | The oral disintegration film formulation of sildenafil citrate having improved dispersion, and manufacturing thereof |
KR101407922B1 (en) | 2013-11-14 | 2014-06-17 | 주식회사 서울제약 | Porous Orally Disintegrating Film comprising pharmacologically active substance and Precess For Producing thereof |
US20170100327A1 (en) | 2014-05-30 | 2017-04-13 | Cure Pharmaceutical Corporation | Pharmaceutical composition with ionically crosslinked polymer encapsulation of active ingredient |
CA2969466A1 (en) | 2014-12-09 | 2016-06-16 | Monosolrx Llc | Linear polysaccharide based film products |
EP3368084A4 (en) | 2015-10-29 | 2019-07-03 | Solubest Ltd | Pharmaceutical compositions for transmucosal delivery |
US20190336453A1 (en) | 2017-01-04 | 2019-11-07 | BonAyu Lifesciences Private Limited | Oral dispersible film composition |
-
2021
- 2021-04-21 US US17/236,054 patent/US11179331B1/en active Active
- 2021-09-29 US US17/488,610 patent/US20220023198A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114557981A (en) * | 2022-03-02 | 2022-05-31 | 山东新时代药业有限公司 | Montelukast oral cavity dissolving film agent and preparation process thereof |
Also Published As
Publication number | Publication date |
---|---|
US11179331B1 (en) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nagaraju et al. | Comprehensive review on oral disintegrating films | |
JP6294479B2 (en) | Oral dispersible film | |
US10092651B2 (en) | High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient | |
Nibha et al. | An overview on: Sublingual route for systemic drug delivery | |
ES2881710T3 (en) | Pharmaceutical formulation | |
US11179331B1 (en) | Oral soluble film containing sildenafil citrate | |
Singh et al. | Fast dissolving drug delivery systems: formulation, preparation techniques and evaluation | |
KR20090020561A (en) | Film-coated solid dosage forms | |
EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
WO2003084511A1 (en) | Palatable chewable tablet | |
Ghorwade | Formulation and evaluation of montelukast sodium fast dissolving films | |
US20210322306A1 (en) | Oral dissolvable film with high load of polymeric binder | |
Renuka et al. | Recent update on oral films: a bench to market potential | |
Roshan et al. | Orodispersible tablets: a compendious review | |
Garsuch | Preparation and characterization of fast-dissolving oral films for pediatric use | |
US20110257159A1 (en) | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same | |
Kulkarni et al. | A systematic review on oral drug delivery as a fast dissolving film to improve therapeutic effectiveness | |
US20220047504A1 (en) | Oral dissolvable film with pores extending therethrough | |
EP2370062A1 (en) | Formulations for systemic buccal delivery comprising s- adenosylmethionine, their preparation and use | |
US11857557B2 (en) | Oral dissolvable film containing vitamin D3 | |
Gupta et al. | An overview of novel techniques employed in mouth dissolving drug delivery system | |
WO2023067620A1 (en) | Orally disintegrating pharmaceutical compositions of rivaroxaban | |
Gupta et al. | An overview of mouth dissolving films: Formulation aspects | |
JP2012031164A (en) | Film-shaped preparation | |
Khan et al. | Fast Dissolving Oral Film: A Modern Development In Drug Delivery System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: CURE PHARMACEUTICAL CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ESPINOZA, MARIBEL;GIGI, VERED;REEL/FRAME:059884/0918 Effective date: 20220510 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: TF TECH VENTURES, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CURE PHARMACEUTICAL CORPORATION;REEL/FRAME:060598/0016 Effective date: 20220722 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: TF TECH VENTURES, INC., FLORIDA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:CURE PHARMACEUTICAL CORPORATION;REEL/FRAME:064256/0361 Effective date: 20220722 |
|
AS | Assignment |
Owner name: CURE PHARMACEUTICAL, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:TF TECH VENTURES, INC.;REEL/FRAME:064286/0450 Effective date: 20221122 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |